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ABSTRACT
Regulatory T cells (Tregs) are an essential subtype of immune cells that controls self-tolerance,
inflammatory responses, and tissue homeostasis. In tumor immunity, Treg cells are involved in
tumor development and progression by inhibiting antitumor immunity. Therapeutically targeting
Treg cells in inflammation-related diseases and cancers will therefore require the identification of
context-specific mechanisms that guide their functions. The AMP-activated protein kinase (AMPK)
functions as a master sensor and modulator of cellular energy and redox homeostasis, both of
which are vital to various immune cells including Tregs. However, whether and how AMPK plays
its roles in Tregs was unknown. My dissertation aims to elucidate the contributions of AMPK in
the regulation of Tregs function in different mouse disease status.
In the first part of this dissertation, I established the essential roles of AMPK in the regulation
of immune homeostasis from AMPKα1 global knock-out mice. By using both bone marrow
transplantation and the adoptive Treg transfer experiment, I discovered that both Treg dysfunction
and the autoimmune diseases occurred in AMPKα1 global knock-out mice. By using Treg-specific
AMPKα1 knock-out mice, I further uncovered the indispensable roles of AMPK in the regulation
of Treg functions, as the Treg-specific AMPKα1 knock-out mice develops autoimmune disease in
livers. Mechanistically, I found that AMPK regulates normal functions of Treg by maintaining the
protein stability of Foxp3, a critical transcriptional factor of Tregs.
In the second part, I studied the roles of AMPK in Tregs in tumor growth and metastasis. Tregspecific AMPKα1 knock-out mice exhibited delayed tumor progression and enhanced antitumor T
cell immunity. Further experiments showed that AMPKα1 maintains the functional integrity of Treg
cells and prevents interferon-γ production in tumor-infiltrating Tregs cells, indicating that AMPK
promotes tumor growth by maintaining high levels of Foxp3 in infiltrating Tregs in tumor tissues.
Mechanistically, AMPKα1 maintains the protein stability of FOXP3 in Tregs cells by
downregulating the expression of E3 ligase CHIP (STUB1). Our results suggest that selective
inhibition of AMPK in Tregs cells might be an effective anti-tumor therapy.

In the third part of the dissertation, I interrogated the role of AMPK in Tregs senescence and
aging, as a decline of AMPK has been widely described in aged animals and humans. Compared
to non-senescent Tregs, senescent Tregs showed fewer protective effects on arterial inflammation
and atherosclerosis development. Treg-specific AMPKα1 knock-out mice displayed accelerated
Treg senescence and arterial inflammation. Hypercholesterolemia, an established risk factor of
cardiovascular diseases, promoted Treg senescence, resulting in the formation of plasticity Tregs
with uncontrolled production of interferon-γ and impaired suppressive function. Selective
activation of AMPK in Tregs restrained Treg senescence, downregulated the levels of reactive
oxygen species (ROS) in aortic walls, and suppressed high fat diets-induced atherosclerosis in
mice in vivo. Taken together, my results demonstrates that AMPK activation in Tregs might be a
valid target for treating aging related diseases including atherosclerosis.
In conclusion, in this dissertation I have established essential roles of AMPK in maintaining
Tregs functions and deregulated AMPK with consequent Tregs dysfunctions plays causative roles
in the initiations and progressions of autoimmune liver diseases, cancer, and atherosclerosisrelated cardiovascular diseases.
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immunity, Senescence, Atherosclerosis
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1 INTRODUCTION
Cell constantly needs to adjust its metabolism to meet the energy demands via an
availability of nutrients (Von Bertalanffy, 1950). A series of specialized biochemical processes
have been evolved to extract, reuse and store chemical energy in the form of ATP. When the
cellular ATP levels decrease, cells need to lower energy consumption or restore energy supply,
such as activating energy supply pathway or turning over of energetic content. The
serine/threonine kinase adenosine monophosphate (AMP)-activated protein kinase (AMPK)
is the primary cellular energy sensor through cellular adenosine triphosphate (ATP) levels that
evolved across all eukaryotic organisms.(Hardie et al., 2012). In response to low energy supply,
AMPK is activated by an allosteric mechanism through binding with AMP or ADP(Hardie et al.,
2012). Once activated, AMPK regulates a network of downstream substrates toward increased
catabolism and decreased anabolism. In addition to regulating cellular metabolism, AMPK is
also activated in response to oxidant stress, caloric restriction and exercise, etc., maintaining
organismal metabolism (Handschin, 2016).
1.1 The Structure of AMPK
AMP-activated protein kinase (AMPK) is a highly conserved heterotrimeric serine/threonineprotein kinase composed of α, β, and γ subunits. The α-subunit contains the catalytic kinase
domain and a critical residue (Thr172) phosphorylated by upstream kinases. The β subunit
contains a carbohydrate-binding module (CBM) that allows the interactions of AMPK with
glycogen and an αγ binding domain at the C terminus (Hudson et al., 2003). A myristylation
site at the N terminus of the β subunit facilitates AMPK target to cellular membranes(Hudson
et al., 2003). The γ subunit contains four cystathionine β-synthase repeats (CBS) that allow
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AMPK to bind to nucleotide and acquire the ability to sense the cell's energy state(Xiao et al.,
2007). In mammals, each subunit is encoded by different isoforms; the α subunit contains α1
and α2 isoforms, which are encoded by Prkaa1 and Prkaa2 (Stapleton et al., 1996); the β
subunit has β1 and β2 isoforms, encoded by Prkab1 and Prkab2 (Thornton et al., 1998); the
γ subunit has three isoforms, γ1, γ2, and γ3, encoded by Prkag1, Prkag2, and Prkag3(Cheung
et al., 2000). Each AMPK contains one α, one β, and one γ leading to 12 possible AMPK
complexes(Ross et al., 2016). In vivo, the expression of each isoform varies across tissues
and cells, affecting the activation of AMPK in response to different stress stimuli(Rajamohan
et al., 2016).
Multiple studies have shown that the crystal structure of AMPK is essential for its activation.
The regulatory subunit-interacting motifs (RIMs) of the α subunit create a conformational link
between the α subunit and γ subunit CBS domains, which is essential for nucleotide binding
and AMPK activation (Yan et al., 2018). Another important feature of the AMPK structure is
the allosteric drug and metabolite (ADaM), which is located at the interface of α subunit kinase
domain (KD) and the β subunit CBM. This site has been identified as the primary location for
binding a host of small-molecule activators of AMPK (Ngoei et al., 2018). This site has
attracted considerable interest for its capacity for mediating the activation of AMPK by
synthetic ligands such as A-769662(Cool et al., 2006) and compound 991(Xiao et al., 2013).
In addition, a recent study showed that the interaction of long-chain fatty acid (LCFA) CoA
esters with this site is also capable of stimulating AMPK activation (Pinkosky et al., 2020).
Multiple pre-clinical programs have targeted this motif to develop pan-AMPK activators as
potential metabolic therapies for type 2 diabetes(Steneberg et al., 2018).
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1.2 Regulation of AMPK
1.2.1 Regulation of AMPK by AMP/ATP Ratios
Under cellular stress, AMPK can be activated in response to decreased ATP production and
increased ATP consumption. The increased AMP level bound to the γ subunit promoted the
activity of AMPK through three mechanisms (Hawley et al., 2003; Hawley et al., 1995). Firstly,
AMP has been shown to promote the phosphorylation of Thr172 by directly stimulating the
upstream kinase activity of AMPK, such as LKB1 and CAMMK2(Fujiwara et al., 2016; Woods
et al., 2003). The tumor suppressor LKB1 and the calcium-sensitive kinase CAMKK2 are the
primary two upstream kinases for AMPK activity.

LKB1 is responsible for most AMPK

activation under mitochondrial insults and low-energy conditions(Shackelford and Shaw,
2009). However, AMPK can also be active in response to calcium flux by CAMKK2. Studies of
LKB1 null cells indicate that CAMKK2 can maintain some AMPK activity independently of
LKB1(Fogarty et al., 2010). Secondly, AMP prevents the dephosphorylation of Thr172 and
caused allosteric activation of AMPK already phosphorylated on Thr172 to enhance AMPK
activity (Davies et al., 1995; Suter et al., 2006). Lastly, AMP can activate AMPK by both
allosteric activation and enhancing net phosphorylation. AMP can cause over 10-fold allosteric
activation even at lower concentrations than ATP. And the allosteric activation by AMP can
increase pACC under conditions in which there is no change in Thr172 phosphorylation
(Gowans et al., 2013).
A variety of physiological conditions lead to the activation of AMPK, including mitochondrial
inhibition, nutrient starvation and exercise, through modulating the AMP/ATP ratio(Herzig and
Shaw, 2018). In addition, several small molecule activators of AMPK, such as A-769662,
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compounds 991, PF-739 and MK-8722, have been developed to activate AMPK independently
of nucleotide levels.
1.2.2 Regulation of AMPK by Reactive Oxygen Species (ROS)
ROS are plenty of free radicals and chemically reactive molecules which are most generated
from oxygen molecule. The function of ROS can be both beneficial and detrimental, which is
closely related to cell survival. Excessive production of ROS, usually termed oxidative stress,
can lead to numerous diseases such as diabetes, cancer, neurodegenerative disease, and
cardiovascular disease (CVD)(Brieger et al., 2012). Recent study has also demonstrated
excess production of ROS provokes energy stress by disrupting the TCA cycle and
mitochondrial function, which strongly activates AMPK(Zhao et al., 2017). The activity of
AMPK was increased in a dose-dependent manner under hydrogen peroxide (H2O2) treatment,
which was associated with an increased AMP-to-ATP ratio(Hinchy et al., 2018). However,
overexpression AMPKγ2 R531G， an AMP-insensitive AMPK complex, can prevent H2O2
induced AMPK activation(Hawley et al., 2010). These data suggest that activation of AMPK
by H2O2 may not target AMPK itself, but through changes to ADP, AMP, and ATP.
In addition, study showed that ROS can induce direct S-glutathionylation of AMPKα subunit
at Cys299 and Cys304, which contributes to AMPK activation without affecting the ATP-toAMP/ADP ratios(Zmijewski et al., 2010). However, the replacement of cysteine residues with
insensitive alanine residues does not affect H2O2-induced AMPK activation(Hinchy et al.,
2018).
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1.2.3 Regulation of AMPK by Reactive Nitrogen Species (RNS)
Both Nitric oxide (NO) and its derivative RNS have also been implicated in AMPK activation.
NO is produced by nitric oxide synthase (NOS) from L-arginine in cells. The interaction
between NO and superoxide will generate peroxynitrite which reacts with other molecules to
produce RNS, including dinitrogen trioxide, nitrogen dioxide, and other types of chemically
reactive molecules.
In cultured endothelial cells (ECs), NO endogenously activates AMPK via elevating Ca2+
levels through activating soluble guanylyl cyclase(Zhang et al., 2008). Treat ECs with
chemically synthesized peroxynitrite acutely and significantly increased phosphorylation of
AMPK and its downstream target ACC without affecting cellular AMP level(Zou et al., 2003).
Inhibition of NOS or overexpression of SOD prevent hypoxia-reoxygenation (H/R) induced
AMPK activation in cultured bovine aortic endothelial cells (BAECs), suggesting a required
role of peroxynitrite in H/R induced AMPK activation(Zou et al., 2003).
These effects of NO and RNS on AMPK activation is probably related to their role in
suppressing mitochondrial ATP production. NO can react with complex I and cytochrome c
oxidase, modulating physiologically the mitochondrial respiratory or OXPHOS efficiency(Sarti
et al., 2012). RNS can induce cysteine S-nitrosylation or tyrosine nitration in almost all the
complexes of mitochondrial ETC(Almeida et al., 2005).
1.3 The Functions of AMPK
Once activated, AMPK can phosphorylate downstream molecules to promote energy
conservation via inhibiting anabolic processes that consume ATP and stimulating catabolic
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pathways to generate ATP(Ma et al., 2017).
1.3.1 Inhibition of Anabolic Pathways
Acetyl-CoA Carboxylase (ACC) is a well-known AMPK substrate that blocks the oxidation
of fatty acids and promotes synthesis (Kahn et al., 2005). Phosphorylation of ACC by AMPK
inhibits its activity, promoting lipid oxidation and blocking de novo lipogenesis (Davies et al.,
1990). Additionally, activation of AMPK inhibits phosphorylation of HMG-CoA reductase
(HMGCR), which catalyzes the rate-limiting step of cholesterol synthesis(Carling et al., 1987).
The essential role of AMPK in regulating lipid and sterol synthesis has significant implications
in the treatment of diseases associated with excess fatty acid production, such as nonalcoholic
fatty liver disease (NAFLD)(Smith et al., 2016).Under long-term conditions of reduced energy,
AMPK maintains cellular energy by inhibiting gluconeogenesis. AMPK phosphorylates class
IIa HDACs (HDAC4, 5, and 7) and prevents nucleus translocation resulting in decreased
gluconeogenesis and increased glycogen storage(Mihaylova et al., 2011).
AMPK can also regulate energy consumption via modulation of mTOR, a master regulator
of cell growth and protein translation. AMPK inhibits mTORC1 via phosphorylation and
activation of the negative mTORC1 regulator TSC2 (Inoki et al., 2003), whereas
phosphorylation and inhibition of the mTORC1 subunit RAPTOR(Gwinn et al., 2008). In
response to energy-shortage conditions, increased AMPK activity leads to a decrease in
mTOR activity, leading to decreased cell growth and protein synthesis to maintain or restore
the cell's energy balance. Therefore, activation of AMPK limits ATP consumption by inhibiting
anabolic glucose, lipid, and protein synthesis pathways under energy stress.
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1.3.2 Activation of Catabolic Pathways
In addition to inhibiting anabolic pathways, AMPK also stimulates glucose utilization,
mobilization of lipid stores, and turnover of macromolecules by autophagy to replenish ATP
stores. AMPK stimulates glucose utilization via phosphorylating several downstream targets
involved in glucose uptake, including TXNIP(Wu et al., 2013), TBC1D1(Chavez et al., 2008),
and PLD1(Kim et al., 2010). For lipid mobilization, AMPK can stimulate lipases to release free
fatty acids for β-oxidation and this process is dependent on the phosphorylation of ACC at Ser
79 and Ser 221 (Fullerton et al., 2013).
Growing evidence has shown that AMPK regulates various aspects of autophagy machinery
to replenish nutrient stores during energy stress. Regulation of autophagy by AMPK through
two independent mechanisms: the inhibition of mTOR signaling and directly phosphorylation
of ULK1. ULK1 is an essential kinase for autophagy induction, whose activation
phosphorylates several proteins involved in the execution of autophagy(Egan et al., 2015).
AMPK has been shown to phosphorylates ULK1 on at least four residues: Ser467, Ser555,
Thr574, and Ser637, and the phosphorylation of ULK1 by AMPK is essential for autophagy
and cell survival during starvation and metabolic stress(Kim et al., 2011). Once activated, both
AMPK and ULK1 can direct phosphorylate downstream PI3K-related VPS34 and the subunit
Beclin1, a part of the autophagy initiation complex(Egan et al., 2015; Kim et al., 2013).
Additionally, AMPK and ULK1 have also been reported to phosphorylate another rate-limiting
autophagy protein, ATG9, to modulate autophagosome formation (Weerasekara et al., 2014).
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1.3.3 AMPK Regulates Mitochondria Biogenesis
Mitochondrial biogenesis occurs in response to increased energy expenditure to produce
more ATP. AMPK has been shown to participate in the process of mitochondria biogenesis.
Mice with a dominant-negative mutant of AMPK failed to induce mitochondria biogenesis
(O'Neill et al., 2011), whereas overexpression of a constitutively active AMPK in mice promotes
mitochondria biogenesis(Garcia-Roves et al., 2008).These studies establish AMPK as a
critical regulator of mitochondrial biogenesis. Several downstream molecules of AMPK are
involved in the regulation of mitochondrial biogenesis, with most of genes seem to be under
the control of the peroxisome proliferator-activated receptor-γ co-activator 1 (PGC1) family(Wu
et al., 1999). AMPK activates PGC1α via direct phosphorylation at Thr177 and Ser538 or
through several indirect mechanisms involving AMPK-dependent modulation of p38 MAPK,
HDAC5, or SIRT1(O'Neill et al., 2013). Activation of PGC1α interacts with PPARγ or estrogenrelated receptors (ERRs) to promote mitochondrial biogenesis genes(Eichner and Giguere,
2011). The effect of AMPK has great therapeutic implications in multiple pathological situations,
including muscular dystrophy and mitochondrial myopathy (Ljubicic and Jasmin, 2013; Peralta
et al., 2016).
1.3.4 AMPK Regulates Autophagy/Mitophagy
AMPK has been shown to regulate autophagy both in yeast(Wang et al., 2001) and in
mammalian cells(Meley et al., 2006) through two different steps. First, activation of AMPK
reduces mTOR activity through directly phosphorylating the mTOR upstream regulator TSC2
on Thr1227 and Ser1345 and the mTOR subunit RAPTOR on Ser722 and Ser792.
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Subsequently, the reduced mTOR activity lost their inhibition on ULK1 to activate
autophagy(Chan, 2009). Second, AMPK was shown to be essential for autophagy and cell
survival during starvation and metabolic stress through direct phosphorylating ULK1 on at
least four residues: Ser467, Ser555, Thr574, and Ser637(Egan et al., 2011).
Not only for general autophagy, activation of AMPK is also crucial for mitophagy. Inhibition
of AMPK-ULK1 axis promotes the accumulation of defective mitochondria in cells(Egan et al.,
2011). Activation of AMPK significantly reduce alcohol-induced liver injury and enhances
hepatocytes’ mitophagy level through enhancing UQCRC2 gene transcription(Lu et al., 2021).
Another pathway controlling mitophagy is the PINK1-Parkin-mediated elimination of
depolarized mitochondria, PINK1 is selectively stabilized on impaired mitochondria which in
turn recruits and phosphorylates the E3 ligase Parkin for mitochondria degradation by the
autophagy machinery(Eiyama and Okamoto, 2015). In cardiomyocytes, overexpression of
AMPKα2 rescues the impaired mitophagy after phenylephrine stimulation via directly
phosphorylation of PINK1 at Ser495. The phosphorylation of PINK1 recruits the E3 ligase
Parkin to remove depolarized mitochondria to prevent the progression of heart failure(Wang
et al., 2018).
1.3.5 AMPK and Redox Homeostasis
AMPK is not only functional as a redox sensor, but also plays an essential role in protecting
the oxidative stress. Activation of AMPK suppress oxidative stress through diminishing the
superoxide production or upregulating antioxidant gene expression. Activation of AMPK by
either salicylate or 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) prevents
palmitate induced endothelial dysfunction by suppressing mitochondrial ROS-associated
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endoplasmic reticulum stress (ER stress)(Li et al., 2015). The anti-diabetic drug miglitol can
prevent oxidative stress induced endothelial cell apoptosis and vascular relaxation via
enhancing AMPK activity(Aoki et al., 2012). In addition to mitochondria function, AMPK can
also regulate ROS production via suppressing nicotinamide adenine dinucleotide phosphate
oxidase (NOX). Deficiency of AMPKα2 in human umbilical vein endothelial cells (HUVECs)
increase NOX expression and the subsequent superoxide production, 26S proteasome activity,
kappa Bα degradation, and nuclear translocation of nuclear factor kappa B(Wang et al., 2010).
Treatment of MEFs with AMPK activator A-769662 blocks glucose starvation induced
mitochondrial

ROS

production

via

promoting

PGC-1α

dependent

antioxidant

response(Rabinovitch et al., 2017). Similar, metformin normalizes hyperglycemia-induced
mitochondrial ROS production by induction of manganese superoxide dismutase (MnSOD)
and

promotion

of

mitochondrial

biogenesis

through

activation

of AMPK-PGC1α

pathway(Kukidome et al., 2006). Both metformin and AICAR can suppress superoxide
production in HUVECs via increasing the expression of antioxidant gene UCP2(Xie et al.,
2008). All these data suggest activation of AMPK increases antioxidant potentials, which
provides potential value for treating oxidative stress-related disease in clinic.
1.3.6 AMPK in Cancers
AMPK acts as either a tumor suppressor or a tumor promoter, depending on the text.
Genetic loss of AMPK before tumors development exacerbating the disease(Vara-Ciruelos et
al., 2019), while inhibition of AMPK after the disease established attenuates it(Kishton et al.,
2016).
The idea that AMPK function as a tumor suppressor come from the findings that LKB1 is an
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essential upstream kinase required for AMPK activation(Hawley et al., 2003). LKB1 has been
identified a few years earlier to be a tumor suppressor(Collins et al., 2000). Following the
discovery of the link between AMPK and LKB1, the use of AMPK activator metformin to treat
type 2 diabetes was found to be associated with reduced risk of cancers(Noto et al., 2012).
Recent study showed that activation of AMPK by metformin induces phosphorylation and
degradation of PD-L1 in cancer cells, thereby promoting protective T-cell immunity(Cha et al.,
2018). However, these studies using metformin may have an AMPK-independent effects, and
not all confirm that AMPK is necessary by gene knockout. Thus, the genetic loss of AMPK is
needed to identify its role in cancer development in vivo. One of the first approach using AMPK
α1 global knockout mice suggests the expression of AMPKα1 prevent the development of B
cell lymphoma(Faubert et al., 2013). The following T cell specific AMPKα1 deletion mice
further demonstrates the anti-tumor effects of AMPK in lymphoma development(Vara-Ciruelos
et al., 2019).
In contrast to the tumor suppressor, AMPK can also promote tumor development in certain
contexts. Stimulation of AMPK by aerobic glycolysis in breast tumors promotes tumorassociated myeloid cell (MDSC) expansion, which contributes to cancer development(Li et al.,
2018). Activation of AMPK in mouse metastasis models drives pyruvate dehydrogenase
complex (PDHc) activation to promote cancer metastasis by adapting cancer cells to metabolic
and oxidative stresses (Cai et al., 2020). In a model of T cell acute lymphoblastic
leukemia/lymphoma, knocking out AMPK after tumor establishment results in a lower recovery
of T-ALL cells(Kishton et al., 2016). In lung epithelial cells, knocking out LKB1 enhanced KRas
mutated tumor growth, while by contrast, knockout of both AMPKα1 and α2 was found to
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reductions in the size and numbers of lung tumors. These data suggest that LKB1 is a tumor
suppressor in non-small-cell lung cancer, while presence of AMPK promote tumor growth
(Eichner et al., 2019).
1.3.7 AMPK, Cellular Senescence, and Aging
Cellular senescence is state of permanent cell-cycle arrest while continuing viability and
metabolic activity(Shakeri et al., 2018). Accumulation of senescent cells in tissues create a
proinflammatory environment which favors the onset and progression of age-related
diseases(Sharpless and Sherr, 2015). Cell senescence can be triggered by various
detrimental stimulus, including oxidative stress, shortened telomeres, DNA damage,
mitochondrial dysfunction, abnormal metabolism, and gene mutation(Matthews et al., 2006;
Regulski, 2017). There are two types of cell senescence. The first one is called replicative
senescence which characterized by irrevocable cell proliferation arrest, which is mediated by
telomere shortening(Kuilman et al., 2010). The second is stress-induced premature
senescence (SIPS), which is induced by distinct endogenous or exogenous(Kuilman et al.,
2010). Senescent cells have both beneficial and deleterious functions for the organism which
are treated as potential powerful targets for antiaging approaches(Soto-Gamez and Demaria,
2017).
Effective regulation of metabolic homeostasis is crucial to prevent cellular senescence. As
an important energy sensor, activation of AMPK has been shown to prevent aging or
senescence in many studies(Fang et al., 2018; Lee et al., 2015b; Salminen and Kaarniranta,
2012). Decreased AMPK has been observed in aging and age-related disease(Funakoshi et
al., 2011; Qiang et al., 2007), while overexpression of AMPK extends the lifespan in C.elegans
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or Drosophila(Apfeld et al., 2004; Funakoshi et al., 2011). Activation of AMPK by its
pharmacological activators, such as metformin, ACIAR, and berberine, have been
characterized to have therapeutic potential for age-related disease(Funakoshi et al., 2011;
Son et al., 2016). In humans, the application of metformin has been performed in clinical study
to evaluate its antiaging capacity, such as delaying the progression of age-related
diseases(Funakoshi et al., 2011; Konopka and Miller, 2019).
The singling targets of AMPK and their role in the regulation of aging process have been
extensive explored during the last ten years. AMPK has been shown to prevent senescence
and aging through activation of SIRT1, FOXO and PGC-1α(Salminen and Kaarniranta, 2012),
as well as the suppression of mTOR(Burkewitz et al., 2014). SIRT1 is a major regulator of
cellular energy metabolism which can enhance the cellular stress resistance and against the
aging process(Le Bourg, 2009). Activation of AMPK stimulates the functional activity of SIRT1
through increasing the intracellular concentration of NAD+, which activates several
downstream targets, e.g., PGC-1α, FoxP1 and FoxO3 and maintains mitochondrial
biogenesis(Nakahata et al., 2009). The mammalian FoxO family of Forkhead transcription
factors are involved in the regulation of several crucial cellular functions, which was observed
as a key player in longevity regulation(Lin et al., 1997). AMPK has been demonstrated to
directly phosphorylate FoxO3 protein at six threonine/serine residues, which promotes the
activation of FoxO3-mediated transcription and extends the lifespan in C. elegans. (Greer et
al., 2007). Activation of p53 pathway clearly prevents aging process and reduces age-related
damage via increasing expression of antioxidant genes(Matheu et al., 2007). AMPK controls
both the expression level and transactivation capacity of p53 via directly phosphorylation,
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which prevents IL-1-associated SASP production(Wiley et al., 2016).
Autophagy is a cellular mechanism that is required for cell survival when cells encounter
stress(Anding and Baehrecke, 2017). In general, autophagy appears to be constitutively active
while its activity decreases during aging process, which occurs in attenuated autolysosomes
and autophagic flux (Abdellatif et al., 2018). Growing evidence indicates that decreased
autophagy results in cellular senescence. Deficiency of the critical autophagy gene Atg7 in
VSMC causes accumulation of SQSTM1/p62 and promotes the development of stressinduced premature senescence, resulting in acceleration of ligation-induced neointima
formation and diet-induced atherogenesis(Grootaert et al., 2015). In contrast, activation of
autophagy by rapamycin was shown to inhibit replicative senescence via decreasing mTOR
signaling(Tan et al., 2016). AMPK is a major inducer of autophagy associated with the
reduction of energy metabolism(Egan et al., 2011). Activation of AMPK was shown to prevent
oxidative stress-induced cellular senescence via restoring autophagic flux and intracellular
NAD+ elevation(Han et al., 2016). In addition, activation of AMPK can also restrain the
production of pro-inflammatory SASP via suppression of the mTOR-NF-κB signaling loop(van
Vliet et al., 2021). All these data suggest the significant role of AMPK in maintaining cellular
housekeeping by autophagy and in that way can extend the organismal lifespan.
1.4 The Role of AMPK in T cells
1.4.1 AMPK in T cells
As we mentioned above, the catalytic α subunit of AMPK contains two isoforms (α1 and α2),
which are encoded by Prkaa1 and Prkaa2 genes, respectively. In T cells, AMPKα1 is the
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predominant isoform of the AMPKα subunit, whereas the expression of AMPKα2 is too low to
be detected in both resting and activated lymphocytes (MacIver et al., 2011; Tamas et al.,
2006). During T cell activation under TCR-CD3 stimulation, the activity of AMPK is increased
in a time-dependent manner, which indicates an essential role of AMPK in T cells (Zheng et
al., 2009). Indeed, activation of AMPK is required for T cells' long-term fitness and proliferation
via the regulation of ROS production (Lepez et al., 2020). However, genetic models using
AMPKα1 global knockout mice established that AMPKα1 is dispensable for T cell development
or the homeostasis of mature T cells(Mayer et al., 2008).
As with other cell types, metabolic stressors such as metformin, AMPK agonists, and
nutrient limitation can activate AMPK in T cells independent of immune stimulation(Pearce et
al., 2009; Rolf et al., 2013). Even though AMPK activity is controlled by LKB1 in T cells, LKB1
also exerts distinct effects on T cell biology through AMPK-independent pathways. The
deficiency of LKB1 disrupts T cell development and leads to enhanced CD4+ Th1 responses
not observed in AMPKα1-deficient CD4+ T cells(MacIver et al., 2011).
1.4.2 Regulation of T cell Metabolism by AMPK
Activated T cells need to produce sufficient ATP to meet their increased biosynthetic
demands of proliferation. AMPK is also required for T cells' metabolic adaptation and effector
responses as an essential metabolic regulator. Deficiency of AMPKα1 in T cells impaired
mitochondrial bioenergetics and ATP production in response to glucose limitation or
pathogenic challenges (Blagih et al., 2015). In response to the low glucose situation, AMPK
suppresses mTORC1-dependent IFNγ translation and induces cells to use glutamine to fuel
the TCA cycle and OXPHOS (Blagih et al., 2015). AMPKα1-deficient Teff cells show less

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

16

efficiency in inducing colitis in Rag2-/- mice and T cell-specific AMPKα1 knockout mice have
less ability to generate effective primary T cell responses to viral and bacterial infections
(Blagih et al., 2015).
1.4.3 Regulation of T Cell Fate by AMPK
Metabolic changes in cells have been broadly associated with inflammation and AMPK is
known as an essential regulator in anti-inflammatory immune responses(O'Neill and Hardie,
2013). Considerable evidence indicates that AMPK can influence T cell differentiation and fate.
AMPK has been linked to the proper generation of CD8+ memory T cell (Tmem). Impaired
TNFR/TLR signaling leads to defective CD8+ Tmem generation due to loss of AMPK activation
during Teff cell contraction (Pearce et al., 2009), and AMPKα1-deficient CD8+ OT-1 cells fail
to generate effective memory responses during bacterial infection(He et al., 2021). The impact
of AMPK on Tmem cell fate could be due to differential AMPK activity between Teff and Tmem
cells. Compared to Teff cells, Tmem cells have higher AMPK activity but lower mTORC1
activity, promoting long-term T cell survival (Pearce et al., 2009). In response to nutrient
limitations, deficiency of fructose-1,6-bisphosphate (FBP) promotes AMPK activation, which
further activates SENP1-Sirt3 signaling and enhances the survival and development of Tmem
cells(He et al., 2021). In this light, stimulating AMPK activity during initial T cell activation may
enhance Tmem cell differentiation. Indeed, administration of AMPK agonist metformin
promotes Tmem cell generation and consequently improves the efficacy of an experimental
anti-cancer vaccine(Pearce et al., 2009).
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1.4.4 AMPK in Regulatory T cells
Naturally occurring CD4+ regulatory T cells (Tregs) are a functionally distinct T cell
subpopulation engaged in maintaining of immunological self-tolerance and homeostasis
(Josefowicz et al., 2012; Sakaguchi, 2004). Tregs with specifically CD25 on the cell surface
and Foxp3 in their nucleus played an essential role in suppressing aberrant self-immune
against immune responses. Abnormal Treg cells can not only cause classical immunological
diseases but are also involved in the progress of tumors, obesity, atherosclerosis, tissue
regeneration, and degenerative disease(Sakaguchi et al., 2020). Thus, a further
understanding of the intracellular mechanism in controlling the adaptability and heterogeneity
of Tregs will provide state-of-art strategies for disease therapy.
The role of AMPK in regulatory T cells (Tregs) is still controversial. AMPK-dependent control
of fatty acid metabolism impacts the balance between T helper 17 (Th17) and Treg cells.
Compared to conventional T cells (Tconvs), Tregs have a higher activated AMPK (Michalek et
al., 2011). AMPK-dependent activation of fatty acid oxidation (FAO) and oxidative metabolic
supports the differentiation of Treg cells (Michalek et al., 2011). During autoimmune
development, the expression of AMPKα1 was decreased in Treg cells, and loss of AMPK
exacerbated the disease progression of autoimmune encephalomyelitis (Nath et al., 2009b).
Moreover, activation of AMPK by Pioglitazone promotes the induction of Foxp3 and generation
of Tregs, which stabilize atherosclerotic plaque(Tian et al., 2017).
However, genetic deletion of AMPK in Tregs does not lead to any obvious abnormalities in
mice before 1-year-old under normal conditions, which is different with its upstream LKB1 (He
et al., 2017). Deletion of LKB1, one of the well-known AMPK upstream, disrupted the metabolic
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and functional fitness of Treg cells and induced lethal autoimmunity(Yang et al., 2017).
Furthermore, LKB1 is also required to maintain Foxp3 expression by preventing CNS2
methylation(Wu et al., 2017). All these data suggest a distinct function of LKB1 and AMPK in
Treg cells. The precise role of AMPK in Treg cells is still far more known, which requires further
study.
1.4.5 AMPK and Anti-tumor Immunity
With the development of immune checkpoint inhibitors, cancer immunotherapy has
succeeded in clinical cancer treatment. T cells’ responses to tumor antigens significantly
contribute to cancer immunosurveillance and anti-tumor immunity. Recent work suggests that
metabolic constrains in the tumor microenvironment (TME) can negatively affect anti-tumor T
cell responses, in part by competition of nutrients between tumor infiltration lymphocytes (TIL)
and tumor cells(Chang et al., 2015). Glucose starvation promotes PD1 expression on
activated T cells, which reduces IFN-γ production and induces T cell exhaustion(Chang et al.,
2013). However, the production of lactic acid in the highly glycolytic TME upregulates PD1
expression in Treg cells which function as an active checkpoint for the function of Treg in
TME(Kumagai et al., 2022). Therefore, this high glucose consumption and lactate production
TME promotes tumor immune escape by depriving effector T cells and supporting regulatory
populations.
As an important metabolic regulator, the activity of AMPK shows both pro- and anti-tumor T
cell immunity. The immunomodulatory cytokines, IL-10, can suppress glycolytic metabolism in
immune cells, which triggers an AMPK-mediated metabolic checkpoint to suppress Teff cell
function(Krawczyk et al., 2010; Sag et al., 2008). However, other work indicates that metformin
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treatment enhances T cell-mediated tumor rejection with increased recruitment of functional
CD8+ tumor infiltrated T cells (TIL)(Eikawa et al., 2015). Meanwhile, metformin treatment
potentiates anti-PD1 immunotherapy efficacy through reversing TIL exhaustion(Scharping et
al., 2017). One disadvantage of these studies is that metformin may work through either
AMPK-independent pathway in T cells or effects on whole-body metabolism. Thus, the T cells
specific AMPK deficient mice is needed to further investigate the role of AMPK in anti-tumor T
cells immunity.
1.5 T cell Senescence and Atherosclerosis
Because of the highly increased life quality, the life expectancy of a human is significantly
increased. However, with increased life expectancy, advanced age is emerging as a risk factor
for chronic fatal diseases, such as cancer, autoimmunity, and cardiovascular disease (CVD)
(Niccoli and Partridge, 2012). Accumulation of senescent cells in diseased or impaired
cardiovascular systems plays an essential role in the pathogenesis of age-related CVD,
including atherosclerosis(Matthews et al., 2006).
1.5.1 Features of Cellular Senescence
Senescent cells show general characteristics with flattened and enlarged morphology,
upregulated senescence-associated beta-galactosidase (SA β-gal) activity, accumulation
of p16ink4a, p19Arf, and p21Cip1, and telomere attrition. Besides these, senescent cells also
display the senescence-associated secretory phenotype (SASP), secreting a variety of proinflammatory cytokines, growth factors, chemokines, and matrix metalloproteinases (MMPs)
(Song et al., 2020). These secreted SASPs enable the communication of senescent cells with
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their neighboring cells and promote the senescence of these neighboring cells, tissue
regeneration, and embryonic development (Munoz-Espin et al., 2013). Another essential
feature of senescent cells is that they are more resistant to pro-apoptotic stimulation, probably
due to pro-survival BH2 family proteins (Yosef et al., 2016).
1.5.2 Hallmarks of T cell Senescence
Proper and effective T cell responses are essential to the success of adaptive immunity
during the aging process. However, considerable evidence has suggested that T cells are one
of the major cell types which may undergo aging-related functional changes (Goronzy and
Weyand, 2019). T cell aging may be one of the primary manifestations of immunosenescence,
displaying the impaired ability to eliminate the harmful elements while increasing proinflammatory cytokine production that leads to autoimmune disease (Hakim et al., 2004).
Senescent T cells acquire general features of senescence, including short telomeres, DNA
damage, apoptosis resistance, and upregulated β-galactosidase activity. In addition,
decreased expression of the costimulatory molecules CD27 and CD28 and increased
terminal-differentiation markers have also been identified in senescent T cells(Akbar et al.,
2016). These increased senescent T cells secret abundant pro-inflammatory cytokines, such
as TNF and interferon-γ, reminiscent of a senescence-associated secretory phenotype
(SASP)(Callender et al., 2018).
Compared to CD4+ T cells, CD8+ T cells are more likely to acquire an immunosenescent
phenotype, perhaps due to the declined mitochondrial quality(Callender et al., 2020). Recent
studies showed that Treg cells are more likely to be senescence than effector T cells during
aging. Aged Tregs show less suppressive activity in restraining Teff proliferation and
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immunological aging while acquiring proinflammatory cytokines(Guo et al., 2020). Deficiency
of DDB1-and CUL4-associated factor (DCAF1) expression in Tregs promotes aberrant ROS
production via facilitating GSTP1 function, which leads to Treg senescence(Guo et al., 2020).
Overexpression of GSTP1 and ROS scavengers can recover these hallmarks of aged Treg
cells.
Age-associated mitochondrial dysfunction makes a great contribution to the acquisition of a
senescent phenotype in T lymphocytes. Even though T cells from older individuals contains
more mitochondrial proteins than those from young controls, they exhibit impaired oxidative
phosphorylation(Bektas et al., 2019). Genetic deletion of the mitochondrial transcription factor
A (TFAM) in T cells results in mitochondrial dysfunction and ultimately promotes ageassociated T cell dysfunction. Moreover, TFAM-deficient T cells display type 1 helper T (Th1)
proinflammatory phenotype, thus exacerbating inflammaging and promoting physical
disabilities and premature death(Desdin-Mico et al., 2020). Patients with AIDS accompany
with accelerated T cell senescence which contributes to the high mortality rate even when
active HIV infection is under control(Deeks and Phillips, 2009). Reduced mitochondrial fitness
in Tregs from HIV-infected people cause impaired Treg function, resulting failing to restore
CD4+ T cells pool during antiretroviral therapy(Younes et al., 2018). As an essential metabolic
modulator, activation of AMPK has also been shown to regulate glutamine-dependent
mitochondrial metabolism to maintain T cell bioenergetics and viability(Blagih et al., 2015).
However, whether activation of AMPK is essential to restrain T cell, especially Treg
senescence is still unknown.
With the development of individual aging, the immune system experiences profound
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changes that significantly impact health and survival (Grubeck-Loebenstein et al., 1998).
Immunological aging refers to immunosenescence (declined immunity) and inflammaging
(chronic nonspecific inflammation), which are considered major contributing factors to the
morbidity and mortality of elderly individuals (Fulop et al., 2017). The immunosenescence
causes declined immune response in later life, contributing to reduced efficacy of vaccination
and reactivation of latent viruses and tumors (Partridge et al., 2018). Despite the impaired
responsiveness of the immune system, a low-grade, chronic, and systemic pro-inflammatory
state is frequently observed in the elderly (so-called “inflammaging”)(Goronzy and Weyand,
2012). The inflammaging has been shown as an essential factor in the pathogenesis of many
age-related diseases, including cardiovascular disease and neurodegenerative syndromes
(Costantini et al., 2018; Liberale et al., 2020).
1.5.4 Immunosenescence in Atherosclerosis
Atherosclerosis is the leading cause of the cardiovascular disease (CVD), resulting in much
morbidity and mortality worldwide (Libby et al., 2019). With a high incidence of atherosclerosis
in elderly patients, the relationship between age-related immune changes and the
pathophysiology

process

of

atherosclerosis

has

attracted

significant

research

interest. Macrophages are the primary immune cells that play critical roles in atherosclerotic
plaque development, collagen content, and necrotic core formation (Stoneman et al., 2007).
During the development of atherosclerosis, the accumulation of senescent macrophages in
the sub-endothelial space was shown to de deleterious at all stages of atherosclerosis (Childs
et al., 2016). Accumulation of these senescent macrophages promoted the plaque instability
with decreased cap thickness, reduced collagen content, and increased the necrotic score by
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elevating SASP components, including MMP3 and MMP13. Interestingly, selective removal of
these senescent cells via genetic or pharmacological strategies can reverse atherosclerosis
in mice (Childs et al., 2016).
1.5.5 T cell Senescence and Atherosclerosis
Despite macrophages, accumulating evidence suggests that senescent T cells are also
implicated in the pathogenesis of atherosclerosis. Accelerated telomere shortening has been
shown to present in the peripheral blood mononuclear cells (PBMCs) and T cells of patients
with atherosclerosis (Samani et al., 2001). Infection with cytomegalovirus (CMV) has been
extensively investigated in the progression of immunosenescence (Pawelec, 2014). Patients
who have a higher frequency of senescent CD8+CD28null T cells after CMV infection have been
shown to have impaired vascular function and a high risk of atherosclerosis (Grahame-Clarke
et al., 2003; Zhu and Liu, 2020). A multiethnic study has found that increased senescent
memory CD4+ T cells are associated with subclinical atherosclerosis, such as coronary artery
calcification and carotid artery intimal media thickness (Olson et al., 2013). These findings are
consistent with another study that a higher frequency of CD8+CD28nullCD57+ T cells in HIVinfected patients was associated with an increased prevalence of carotid artery disease
(Kaplan et al., 2011). However, the direct role of senescent T cells in atherosclerosis
development is still not clear right now. In this regard, it has been hypothesized that senescent
T cells directly contribute to the pathophysiology of atherosclerosis by secreting IFN-γ to
induce macrophage activation or secreting perforin and granzymes to destroy endothelial and
vascular smooth muscle cells (Johnson, 2007; Leon and Zuckerman, 2005). Recent study
demonstrates that compare to conventional T cells (Tconv) cells Tregs are more likely to be
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senescence during aging, which shows less efficient in preventing Tconv aging(Guo et al.,
2020). However, whether and how senescent Tregs play their functions in the development of
atherosclerosis is unknown. Given the essential role of Tregs in preventing atherosclerosis,
studies focusing on the role of senescent Tregs in atherosclerosis may present a novel
therapeutic target for preventing atherosclerotic artery disease.
1.6 Gaps of Knowledge
Recent work established that AMPK is activated in T cells by immunological and
environmental stimuli, and activation of AMPK is required to maintains T cell metabolic
adaption and effector responses(Blagih et al., 2015). Despite both natural and inducible Treg
exhibit elevated levels of AMPK activity compared with Teff and naïve T cells, the role of AMPK
in Treg cells on the development of autoimmunity and cancer is still not clear.
Evidence suggest that Treg cells contribute to the anti-inflammatory response during
anthogenesis(Ait-Oufella et al., 2006; Gotsman et al., 2006). Recent studies indicated that
Treg cells would become plasticity during atherogenesis(Butcher et al., 2016). Recent data
suggests that senescent Tregs are dysfunctional and express high levels of inflammatory
cytokines. The contributions of Tregs senescence in atherosclerosis remained to be
determined. Finally, whether and how senescent Tregs become more plasticity remained to
be elucidated.
1.7 Research Objectives
Chapter 1: Activation of AMPKα1 is essential for regulatory T cell function and preventing
autoimmune liver disease
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The objective of project 1 was to investigate the role of AMPKα1 in regulatory T cells and
autoimmune disease. We plan to use AMPKα1 global knock out (Prkaa1-/-) mice, bone marrow
transplantation mice model, adoptive Treg transfer mice model, and Treg-specific AMPKα1
deletion (AMPKα1Treg-/-) mice to investigate the role of AMPK in Tregs and autoimmune liver
disease. We will also detect whether AMPK regulates Treg survival, differentiation,
proliferation, and function both in vitro and in vivo. Finally, we plan to determine whether and
how AMPK regulates the expression of Foxp3 in Treg cells.
Chapter 2: AMP-activated protein kinase alpha 1 promotes tumor development via FOXP3
elevation in tumor-infiltrating Treg cells.
The objective of project 2 was to determine the role of AMPKα1 in Treg cells and tumor
development. We plan to construct tumor models in Treg-specific AMPKα1 deletion () mice
and their littermate control mice to investigate the role of AMPK in Tregs and anti-tumor
immunity. We will also investigate whether expression of AMPK can maintain Foxp3
expression in tumor infiltrated Tregs. Finally, we will investigate the mechanism on how AMPK
regulates Foxp3 expression in Treg cells.
Chapter 3: Hypercholesterolemia-driven inhibition of AMP-activated protein kinase alpha 1
induces Treg senescence during atherosclerosis.
The goal of project 3 was to investigate the role of AMPKα1 in Treg senescence and the
development of atherosclerosis. Firstly, we will detect the expression of senescent Treg cells
in atherosclerosis developing mice. Secondly, we will adoptively transfer senescent Tregs and
non-senescent Tregs to investigate their role in the development of atherosclerosis. Thirdly,
we will detect whether AMPK regulates Treg senescence during atherogenesis both in vitro
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and in vivo. Next, we will construct the ApoE Treg-specific AMPKα1 deletion mice (ApoE-/AMPKα1Treg-/-) to test the role of AMPK in Tregs and atherosclerosis development. Finally, we
plan to adoptive transfer constitutive active AMPK (CA) AMPK-Tregs to western diet-fed ApoE/-

mice to test their protective role on atherosclerosis.
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2.1 Abstract
Regulatory T cells (Treg cells) are crucial for maintaining immune tolerance. Compromising the
regulatory function of Treg cells can lead to autoimmune liver disease. However, how Treg
function is regulated is still not fully clarified. Here we report that global knockout (KO) mice of
AMP-activated protein kinase alpha 1 (AMPKα1) spontaneously develop immune-mediated liver
injury, with massive lymphocyte infiltration in the liver, elevated serum alanine aminotransferase
level and higher production of autoantibody. Both transplantation of wild type bone marrow and
adoptive transfer of wild type Treg cells can rescue AMPKα1 KO mice from the liver injury. In
addition, Treg-specific AMPKα1 KO mice display histological features resembling autoimmune
liver disease, higher production of autoantibody and hyperactivation of CD4+ T cells. AMPKα1
deficiency significantly impairs Treg cell suppressive function while not affecting Treg cell
differentiation and proliferation. Furthermore, AMPK is activated upon T cell receptor (TCR)
stimulation, which triggers Foxp3 phosphorylation, suppressing Foxp3 ubiquitination and
proteasomal degradation. Importantly, the frequency of Treg cells and the phosphorylation levels
of AMPK at T172 from circulating blood is significantly lower in patients with autoimmune liver
diseases. Conclusion: Our data suggest that AMPK maintains the immune-suppressive function
of Treg cells and confers protection from autoimmune liver disease.
2.2 Introduction
Autoimmune liver disease is immune-mediated liver injury (hepatocellular or hepatobiliary) such
as autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and primary sclerosing
cholangitis (PSC)(Krawitt, 2006; Trivedi and Adams, 2013). Although the pathogenesis of
autoimmune liver disease is not fully understood, it is generally recognized that impairment of
immunoregulatory networks plays a crucial role(Lapierre and Lamarre, 2015; Liberal et al., 2015).
In a healthy population, circulating autoreactive T cells are suppressed by peripheral tolerance
mechanisms to limit autoimmune tissue damage, among which regulatory T cell (Treg cell)-
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exerted immune suppression plays a key role(Liberal et al., 2017; Sakaguchi et al., 2010).
Patients with autoimmune liver diseases display a reduced Treg cell frequency or function
compared to healthy subjects(Ferri et al., 2010; Grant et al., 2014; Longhi et al., 2004; Longhi et
al., 2009). In addition, adoptive transfer of ex vivo expanded Treg cells has been shown to restore
peripheral tolerance in an autoimmune hepatitis murine model(Lapierre et al., 2013). Therefore,
understanding the molecular mechanisms underlying Treg cell regulation is important for the
treatment of this disease.
AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine protein kinase
that functions as a key energy sensor and metabolic regulator to maintain cellular energy
balance(Hardie, 2007, 2011). Recent work has established that AMPK is activated in T cells by
both immunological and environmental stimuli, and plays an important role in T cell
metabolism(Ma et al., 2017). Global deletion of AMPKα1 increased T cell glycolysis and enhanced
production of interferon-γ (IFN-γ) and interleukin 17a (IL-17a)(MacIver et al., 2011). More recently,
AMPK was shown to be necessary for effector T cell response during viral and bacterial challenge
(Blagih et al., 2015) and to drive oxidative metabolism in leukemic T cells(Kishton et al., 2016).
AMPK has also been implicated in Treg cell regulation. Stimulation of AMPK in vivo with the AMPK
activator metformin has been shown to increase Treg cells(Michalek et al., 2011), attenuate
experimental autoimmune encephalomyelitis (EAE) and suppress systemic autoimmunity(Lee et
al., 2017; Sun et al., 2016). However, the mechanism behind AMPK’s effects on Treg cells and its
therapeutic potential in treating autoimmune liver disease is not yet known.
Forkhead Box P3 (Foxp3) is a lineage-specific transcription factor of Treg cells and is crucial
for developing mature Treg cells, and maintaining their immunosuppressive function (Rudensky,
2011). Foxp3 expression, stability, and activity are tightly modulated in cellular systems. This
regulation involves many epigenetic and post-translational modifications associated with the
immunosuppressive activity of Treg cells(Chen et al., 2013; Li et al., 2007; Liu et al., 2013; van
Loosdregt et al., 2013; van Loosdregt et al., 2010). Phosphorylation of Foxp3 is generally
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decreased in patients with rheumatoid arthritis and can affect Treg activity and cellular
functions(Nie et al., 2013). Foxp3 phosphorylation by proto-oncogene PIM2 and cyclin-dependent
kinase (CDK) cascade has been demonstrated to affect Foxp3 stability and immune
tolerance(Deng et al., 2015; Morawski et al., 2013). However, other kinase(s) responsible for
Foxp3 phosphorylation, especially those involved in autoimmune liver disease, remains undefined.
In this study, we found that globally knockout and Treg specific deletion of AMPKα1 impairs
Treg suppressive activity and leads to the development of autoimmune liver disease in mice.
Mechanistically, we found that AMPK activation triggers the phosphorylation of Foxp3 and
maintains Foxp3 protein stability. Clinically, patients with autoimmune liver diseases showed less
Treg frequency and AMPK phosphorylation. All these results demonstrated a critical role of AMPK
in Treg cells and that selective activation of AMPK in Treg might be a therapeutic target for the
treatment of autoimmune liver diseases.
2.3 Materials and Methods
2.3.1 Patients
Peripheral blood was collected from healthy control and primary biliary cholangitis (PBC)
patients. The diagnosis of PBC was based upon internationally accepted criteria. Briefly, 2 of the
following 3 criteria had to be met for a diagnosis of PBC: (1) serum AMA (titer>1:40) and/or ANA,
(2) a cholestatic pattern of liver biochemistry with at least 1 of serum bilirubin, alkaline
phosphatase, or gamma-glutamyl transpeptidase above the reference range, and (3) diagnostic
or compatible liver histology. PBC patients were classified into early stage PBC, moderate PBC,
and advanced-stage PBC according to the Rotterdam criteria(Kuiper et al., 2009). Clinical
characteristics of the patients were provided in Table 1.
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Table 1 Clinical characteristics of healthy control and PBC patients

Number
Sex(male/female)
Age
Early stage
Moderate stage
Advanced state
Treated with UDCA

Healthy control

PBC patients

12
5/7
47.0±13.0
N
N
N
N

21
4/17
56.1±10.4
1
8
12
17

2.3.2 Mice
Prkaa1−/− and Prkaa2−/− mice were generated as previously described(Jorgensen et al., 2004;
Viollet et al., 2003), and backcrossed into C57BL/6 background for at least ten generations.
Prkaa1flox/flox, Foxp3YFP-cre, Alb1cre, LysMcre, Rag1-/-, CD45.1+C57BL/6, C57BL/6 mice were
purchased from Jackson Laboratory (Bar Harbor, ME). Treg-specific AMPK α1 knock out (KO)
mice were obtained by crossing mice carrying a loxP-flanked Prkaa1 allele (Prkaa1fl/fl) with
Foxp3cre mice expressing yellow fluorescent protein-Cre (YFP-Cre) recombinase fusion protein
under the control of the Foxp3 promoter (referred to herein as Prkaa1fl/fl Foxp3cre). Myeloid-specific
AMPK α1 KO mice were generated by crossing Prkaa1fl/fl mice with LysMcre transgenic mice. All
mice were housed in specific pathogen-free conditions in the animal facilities at Georgia State
University. The animal protocol was reviewed and approved by Georgia State University Institute
Animal Care and Use Committee.
2.3.3 Bone Marrow Transplantation
Eight-week-old WT and Prkaa1−/− mice were subjected to 11-Gy lethal total-body irradiation
(two doses of 5.5 Gy within an interval of 4 h) to eliminate endogenous bone marrow stem cells
and bone marrow-derived cells, and immediately reconstitute with 5 × 106 donor bone marrow
cells isolated from the femurs and tibias of WT or Prkaa1−/− mice. The hematologic parameters
and liver tissue of recipient mice were analyzed 12 weeks after bone marrow transplantation.

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

32

2.3.4 Adoptive Treg Transfer
CD4+CD45RBhi naive T cells were induced to develop into Treg cells by exposure to antiCD3/CD28 antibodies in presence of TGFβ, IL-2, all-trans retinoic acid for 4 days. Induced Treg
cells (iTreg) were then adoptively transferred into Prkaa1-/- mice. Six weeks later, mice were
sacrificed and analyzed.
2.3.5 In Vitro Treg Cell Suppressive Assay
Sorted naive CD4+CD25-CD62LhiCD44loT cells (5 × 104 cells) were labeled with 5 μM CellTrace
Violet (Invitrogen, Carlsbad, CA) for 10 minutes at 37°C in PBS, wash twice in 0.1% BSA PBS,
and were then cocultured with sorted Tregs from Prkaa1+/+ Foxp3cre or Prkaa1fl/fl Foxp3cre mice in
the presence of T cell-depleted splenocytes (1 × 105 cells) and soluble anti-CD3 (2 μg/ml,
Invitrogen, Carlsbad, CA). Four days later, cells were harvested, and violet dilution was measured
by flow cytometric analysis.
2.3.6 In Vivo Treg Cell Suppressive Assay
Rag1–/– mice were i.v. injected with 4 × 105 Teff cells (CD4+CD45RBhi CD25-), either alone or
with 1 × 105 Treg cells from Prkaa1+/+ Foxp3cre (WT) or Prkaa1fl/fl Foxp3cre(KO) mice. Recipient
Rag1–/– mice were monitored weekly for 10 weeks. Cells from mesenteric lymph node were
subjected to cytometry analysis. Colon tissues were collected for H&E staining.
2.3.7 Serum Alanine Aminotransferase Level Measurement
Serum alanine aminotransferase levels were measured in Alanine Transaminase Colorimetric
Activity Assay Kit (Cayman, Ann Arbor, MI) according to manufacturer’s protocol. After ALT
Initiator was added to wells, absorbance at 340 nm was read immediately and every minute
following for a period of 5 minutes.
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2.3.8 Autoantibody Detection
For detection of ANA or dsDNA-specific antibodies, ELISA plates (Thermo Fisher Scientific,
Waltham, MA) were pre-coated with 5 μg/ml nuclear extract or double strand DNA from WT mouse
liver. The plates were incubated with 1:100 diluted serum samples, and the assay was developed
with HRP-labeled goat anti-mouse IgG (Thermo Fisher Scientific, Waltham, MA). Serum was
diluted to 1:10000. Total IgG levels were detected by incubating plates with biotinylated antimouse IgG (Thermo Fisher Scientific, Waltham, MA) followed by streptavidin-peroxidase
(eBioscience, San Diego, CA). Ig isotypes were detected by Isotyping multiplex assay (Millipore,
Billerica, MA).
2.3.9 Histopathology Staining
Mice were sacrificed, and their organs/ tissues were dehydrated, embedded in paraffin,
sectioned, and stained with H&E. Embedded samples were then sectioned and stained with
appropriate antibodies.
2.3.10 Flow Cytometry Analysis
The frequency and phenotypic properties of Treg cells or Teff were determined by flow
cytometry on a Becton Dickinson fluorescent activated cell sorter (FACScalibur, FACSCanto II or
LSRFortessa, Becton Dickinson, CA). FlowJo 2 or FACSDiva (Treestar Inc) software were used
for analysis. Each reaction was performed with 1 × 106 cells, and a minimum of 3 × 105 events
were recorded. Isotype controls were included for each sample tested. The antibodies used
include: fluorochrome-conjugated anti-mouse CD45 (Biolegend, San Diego, CA), CD4
(Biolegend), CD44 (Biolegend), CD62L (Biolegend), Foxp3 (eBiosceince, San Diego, CA), IL17
(Biolegend); anti-human CD25 (BD Bioscience), CD127 (eBiosceince), CD4 (Becton Dickinson,
CA), CD45 (BD).
Intracellular staining: the frequency of cells positive for Treg cells were determined by
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intracellular staining after cell fixation and permeabilization with Cytofix/Cytoperm (BD Bioscience)
and counterstaining with PE-conjugated anti-FOXP3, FITC-conjugated anti-CD4 antibodies. The
frequency of IL17 producing cells was detected after exposure to phorbol 12-myristate 13-acetate
(PMA) (10ng/ml)/Ionomycin (50ng/ml), incubation with Brefeldin A (10μg/ml, all from Sigma
Aldrich Company, St. Louis, MO) for 4 hours and counterstaining with fluorochrome-conjugated
anti- IL17 and CD4 monoclonal antibodies. To assess the phosphor-AMPK (T172) in Treg cells,
cells were initially stained with fluorochrome-conjugated anti-CD4, CD25 and CD127 monoclonal
antibodies, then treated with intracellular Cytofix/Cytoperm. After incubation at room temperature
for 30 minutes and centrifugation at 500g for 5 minutes, cells were stained with anti-p-AMPK (Cell
Signaling Technology, MA) at room temperature for 45 minutes, washed twice with Cytoperm
buffer, then stained with PE-conjugated anti-rabbit IgG and washed twice with Cytoperm buffer.
Flow cytometry was performed as above.
2.3.11 RNA Extraction and qRT-PCR
RNA was extracted by using RNeasy Mini Kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s instructions. cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-rad,
Hercules, CA). The expression of Foxp3 mRNAs was determined using quantitative realtime PCR
(qRT-PCR). Each cDNA sample was amplified using SYBR Green (Bio-rad, Hercules, CA) on Biorad CFX96 Touch Realtime PCR detection system. Primer sequences for Foxp3 were forward,
5’-CACAGCAACAGCACTGGAAC-3’; reverse, 5’-TTTTGGGCATTGCTTGAGGC-3’.
2.3.12 Western Blot Analysis
Antibodies against AMPKα, phospho-AMPKα (Thr172) were purchased from Cell Signaling
Technology (Danvers, MA). Anti-Foxp3 antibody was purchased from eBioscience (San Diego,
CA). Anti-phospho-serine/threonine antibody was from Abcam (Cambridge, UK) and anti-actin
was purchased from Santa Cruz Technology (Dallas, TX). Cells were lysed with NP-40 lysis buffer
(1% NP-40, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 50 mM NaF, 2 mM Na3VO4,
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and 10 μg/ml each of aprotinin and leupeptin) or were lysed with 1X SDS sample buffer (50 mM
Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, and 10% glycerol). Proteins were separated by SDSPAGE and transferred to nitrocellulose membranes (Millipore, Billerica, MA). Membranes were
visualized with an enhanced chemiluminescence detection system (Thermo Fisher Scientific,
Waltham, MA).
2.3.13 In Vitro Kinase Assay
In vitro kinase assay was performed as previously described(Shaw et al., 2004). Briefly, GSTFOXP3 recombinant protein (Abnova, Taiwan) was incubated in the absence or presence of
AMPKα1β1γ1 recombinant protein (a kind gift from Dr. Dietbert Neumann of Maastricht, the
University in Netherlands) in the kinase buffer (50 mM Tris, pH 7.5/10 mM MgCl2/1 mM DTT/200
µm AMP/200 µm ATP) at 37°C for 20 min. Reactions were stopped by addition of SDS sample
buffer, and samples were then subjected to SDS-PAGE and western blot analysis.
2.3.14 Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software,
CA). Results were analyzed with a student’s t-test (two groups) or ANOVA (more than two groups).
Data are present as mean values ± SD. A P value of <0.05 was statistically significant.
2.4 Results
2.4.1 AMPKα1 Deletion Leads to Liver Injury
AMPK is a conserved serine/threonine kinase consisting of α, β and γ subunits. The α subunit,
for which two isoforms exist (α1 and α2), is responsible for the catalytic activity of the
heterotrimeric complex. AMPK α1 is encoded by the Prkaa1 gene and AMPK α2 is encoded by
the Prkaa2 gene. We found that the liver of Prkaa1-/- mice exhibited white spots by gross
appearance (Figure 1A). Further histological analysis showed massive inflammatory cell
infiltration (Figure 1B). Moreover, total number of infiltrated leukocytes in the liver was
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dramatically increased in Prkaa1-/- mice (Figure 1C). However, all these abnormal liver
phenotypes were absent in Prkaa2-/- mice (Figure 2). We further analyzed serum level of alanine
aminotransferase (ALT) and found that it was higher in Prkaa1-/- mice than in WT mice (Figure
1D). In addition, serum level of total immunoglobulin G (IgG) was much higher in Prkaa1-/- mice
than in WT mice (Figure 1E). Further, Prkaa1-/- mice showed higher concentrations of serum
IgG2a, IgG2b and IgA (Figure 1F), as well as antinuclear antibodies (ANA) (Figure 1G).
Proportions of CD4+ T helper 17 (Th17) lymphocytes, which are key effector cells in autoimmune
diseases, were significantly increased in the liver of Prkaa1-/- mice (Figure 1H). Moreover, the
frequency of Treg cells in liver tissue was decreased in Prkaa1-/- mice than in WT mice (Figure
1I), however, the absolute number of Treg cells was slightly increased rather than decreased in
liver organ of Prkaa1-/- mice (Figure 1J), this is likely due to more infiltrated leukocyte in liver
organ of Prkaa1-/- mice. However, the frequency of Treg cells in peripheral blood was markedly
lower in Prkaa1-/- mice than in WT mice (Figure 1K). Collectively, these data suggest that AMPKα1
deletion in mice causes increased immune cell infiltration, resulting in immune-mediated liver
injury.
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Figure 1 AMPKα1 deletion leads to liver injury.
A Photograph of livers from 3-month-old WT and Prkaa1-/- mice. B H&E staining of liver. C Total number of
leukocytes isolated from whole livers (N = 5-7). D Serum level of alanine aminotransferase (N = 19–32). E
Quantified serum levels of total IgG in 8-month-old WT and Prkaa1-/- mice (N = 7–8). F Quantified serum
levels of Ig isotypes in 8-month-old WT and Prkaa1−/− mice (N = 3–4). G Quantified serum level of ANA
antibody in 8-month-old WT and Prkaa1-/- mice (N = 8–12). H IL17+/CD4+ cell population in livers (N = 4).
*p < 0.05; **p < 0.01 vs. WT. I Treg cell+/CD4+ cell population in livers (N = 4). J Absolute number of Treg
cells in livers. K The frequency of Treg cells in peripheral blood

Figure 2 AMPKα2 deletion does not lead to liver injury.
A,Photography of liver from 3 month-old WT and Prkaa2-/- mice. B, H&E staining of liver (scale bar=50μm).
C, Total number of leukocytes isolated from whole livers (N=5-7).
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2.4.2 Bone Marrow Transplantation and Adoptive Treg Transfer Rescue Prkaa1-/- Mice from
Liver Injury
We next investigated which cell type(s) contributes to the liver injury in Prkaa1-/- mice. We first
examined the liver-specific AMPK α1 knockout (KO) mice. As shown in Figure 3, liver-specific
AMPK α1 KO mice exhibited normal liver histology and no inflammatory cell infiltration, suggesting
that liver cells are not responsible for the injury. We then tested whether AMPK α1 deficiency in
hematopoietic cells may lead to the liver injury. To this end, we performed reciprocal bone marrow
transplantation between WT and Prkaa1-/- mice, in which bone marrow cells were transplanted
into irradiated mice. As shown in Figure 4A, liver inflammatory injury in Prkaa1-/- mice was
completely resolved after 12 weeks engraftment of WT bone marrow, whereas bone marrow from
Prkaa1-/- mice induced liver injury in WT mice. In addition, serum IgG levels in Prkaa1-/- mice
received WT bone marrow decreased to the same level as in WT mice, whereas serum IgG levels
in WT mice that received Prkaa1-/- bone marrow increased to the same level as in Prkaa1-/- mice
(Figure 4B). These data suggest that lack of AMPKα1 expression in bone marrow-derived cells
leads to liver inflammatory injury.

Figure 3 Liver-specific AMPKα1 deletion does not lead to liver injury.
H&E staining of liver from 3-month-old Prkaa1+/+ Albcre or Prkaa1fl/fl Albcre mice (N=8).
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Figure 4 Bone marrow transplantation and adoptive Treg cell transfer prevent liver injury in Prkaa1/- mice.
A H&E staining of liver sections obtained 12 weeks after irradiated mice were transplanted with bone
marrow from WT or Prkaa1-/- mice. B Quantified serum level of total IgG from transplanted mice (N = 5). C
H&E staining of livers from Prkaa1-/- mice adoptively transferred with PBS or WT Foxp3+ iTreg cells (scale
bar = 50 μm). D CD4+ cell population in the lymph nodes of Prkaa1-/- recipient mice. E Foxp3+/CD4+ cell
population in the lymph nodes of Prkaa1−/− recipient mice (N = 9). *P < 0.05

We then examined myeloid-specific AMPK α1 knockout (KO) mice. As shown in Figure 5,
deletion of AMPK α1 in myeloid cells does not result in liver injury, suggesting that other immune
cells may be involved. Since Tregs have been suggested to play an essential role in suppressing
liver inflammation in animal model studies(Bochtler et al., 2008; Kido et al., 2008; Lapierre et al.,
2013), we next tested whether the rescue effect of WT bone marrow on Prkaa1-/- mice is due to
the activity of Treg cells. To this end, induced Treg cells (iTreg) were adoptively transferred into
Prkaa1-/- mice. Six weeks later, Prkaa1-/- mice that received transfer of PBS as a control still
exhibited liver inflammatory injury, whereas Prkaa1-/- mice received transfer of WT iTreg cells
showed no more liver injury (Figure 4C). Compared to mice that received control, Prkaa1-/- mice
that received WT iTreg cells had similar levels of CD4+ T cells (Figure 4D), but higher levels of
Treg cells (Figure 4E). All these results suggest that deficiency of AMPK α1 in Tregs may
contribute to the liver injury in Prkaa1-/- mice.
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Figure 5 Myeloid-specific AMPKα1 deletion does not lead to liver injury.
H&E staining of liver from 3-month-old Prkaa1+/+ LysMcre or Prkaa1fl/fl LysMcre mice (N=5).

2.4.3 Treg-specific AMPK α1 Deletion Leads to Autoimmune Liver Disease
To understand more precisely the role of AMPKα1 in Treg cells, we crossed mice carrying a
loxP-flanked Prkaa1 allele (Prkaa1fl/fl) with Foxp3cre mice expressing yellow fluorescent proteinCre (YFP-Cre) recombinase fusion protein under the control of the Foxp3 promoter (referred to
herein as Prkaa1fl/fl Foxp3cre) (Figure 6A). The genotype was confirmed by PCR (Figure 6B).
Immunoblot analysis confirmed efficient and specific deletion of AMPKα1 in sorted YFP+ Treg
cells, but not YFP- conventional T cells from Prkaa1fl/fl Foxp3cre mice (Figure 6C). Interestingly,
we found that Prkaa1fl/fl Foxp3cre mice displayed histological features resembling human
autoimmune liver disease, including portal inflammation (presence of inflammatory infiltrates
surrounding hepatic portal tracts), interface hepatitis (portal infiltrates extending into the lobule),
and lobular inflammation (infiltrates within the liver parenchyma) (Figure 6D). In addition to those
histological manifestations, serum immunoglobulin G (IgG) level, serum antinuclear antibodies
(ANA) and anti-double stranded DNA (anti-dsDNA) levels were also significantly increased in
Prkaa1fl/fl Foxp3cre mice as compared to their wild type of littermate control (Figure 6E-6G).
Moreover, Prkaa1fl/fl Foxp3cre mice had a greater frequency of memory and effector CD4+ T cells
(CD44+ CD62L- CD4+), with a concomitantly lower frequency of naïve CD4+ cells (CD44- CD62L+
CD4+) (Figure 6H-6I), suggesting an activated phenotype in these mice. Consistent with these
findings, Prkaa1fl/fl Foxp3cre mice had a significant increase of CD4+ cells producing IL-17(Figure
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6J), whose elevation has been detected in both human and mouse autoimmune hepatitis(Yu et
al., 2010; Zhao et al., 2011). Collectively, all these data suggest that deficiency of AMPKα1 in Treg
cells leads to autoimmune liver disease.

Figure 6 Treg-specific AMPK α1 deletion leads to autoimmune liver diseases.
A, Breeding scheme for generation of Treg specific AMPKa1 KO mice. B. PCR identification of conditional
KO mice. C, Immunoblot identification of knockout efficiency in T regulatory cells (Treg) and conventional
T cells (Tconv). D, H&E staining of liver sections in one year-old Prkaa1+/+ Foxp3cre and Prkaa1fl/fl Foxp3cre
mice (N=8-9). E-G, Quantified serum levels of total IgG (E), ANA antibody (F), and anti-double strand DNA
antibody (G) in Prkaa1+/+ Foxp3cre and Prkaa1fl/fl Foxp3cre mice (N=13-20). H-I, FACS analysis of CD62L,
CD44 expression in conventional T cells from MLN in 8-week-old Prkaa1+/+ Foxp3cre and Prkaa1fl/fl Foxp3cre
mice. J, FACS analysis of IL17 production in CD4+ T cells from MLN of Prkaa1+/+ Foxp3cre and Prkaa1fl/fl
Foxp3cre mice (N=12). *, p<0.05.

2.4.4 AMPKα1 Deletion does not Affect Treg Cell Differentiation or Proliferation
Disruption of Treg homeostasis has previously been associated with autoimmune liver
disease(Diestelhorst et al., 2017; Ferri et al., 2010; Longhi et al., 2004), we thus next explored
whether AMPKα1 regulate Treg homeostasis. As shown in Figure 7A, Treg frequency in the
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thymus is comparable in Prkaa1-/- and WT mice, suggesting that AMPKα1 deletion does not affect
Treg differentiation. To further confirm this hypothesis, CD4+CD45RBhi naive T cells were induced
to develop into Treg cells by exposure to anti-CD3/CD28 antibodies in presence of TGFβ, IL-2,
all-trans retinoic acid for 2 or 4 days. As shown in Figure 7B, naive T cells from Prkaa1-/- mice
showed similar differentiation to those from WT mice. We further examined Treg cell proliferation
by using sorted Treg cells treated with anti-CD3/CD28 antibodies and IL-2. As shown in Figure
7C, Treg cells from Prkaa1-/- mice also showed a similar proliferation rate as Treg cells from WT
mice, suggesting that AMPKα1 does not regulate Treg cell proliferation.

Figure 7 AMPKα1 deletion does not affect Treg cell differentiation or proliferation.
A, Treg frequency in thymus from WT or Prkaa1-/- mice mice (N=6). B, FACS-sorted CD4+CD45RBhi naive
T cells were induced into Treg with anti-CD3/CD28 antibodies in presence of TGFβ, IL-2 and all-trans
retinoic acid for 2 or 4 days (N=4). C, Sorted YFP+ Treg cells were stimulated with anti-CD3/CD28
antibodies and IL-2 for 4 days. Cell Trace Violet dilution was examined by flow cytometry (N=4).

2.4.5 AMPKα1 Deletion Compromises Treg Suppressive Activity
Since Treg cells play a crucial role in maintaining immunological tolerance by actively
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suppressing self-reactive lymphocytes, we then examined whether AMPKα1 deficiency impairs
Treg suppressive function. To this end, an in vitro suppressive assay was first performed. As
shown in Figure 8A, Treg cells from AMPKα1-deficient mice did not inhibit the proliferation of Teff
cells as efficiently as their WT counterparts. We also tested the suppressive function of AMPKα1
deficient Tregs in vivo in a well-characterized Teff transfer-induced colitis model (CD4+CD45RBhi
cells injected into Rag1-/- mice, Figure 8B). As shown in Figure Figure 8C-8D, the transfer of Teff
cells alone elicited colitis in Rag1-/- recipient mice, as manifested by gradual weight loss,
splenomegaly and lymphadenopathy. However, co-transfer of WT Treg cells, but not AMPKα1deficient Treg cells, effectively suppressed weight loss and enlargement of the spleen and
mesenteric lymph nodes. Consistent with these findings, histological analysis of Rag1-/- mice that
received WT Tregs showed a lower degree of colon inflammation compared with mice that
received AMPKα1-deficient Treg cells (Figure 8E). These results suggest that AMPKα1 is
required for Treg suppressive activity.

Figure 8 AMPKα1 deletion compromises Treg suppressive activity.
A, Sorted naïve CD4+YFP-CD62L+CD44- T cells from Prkaa1+/+ Foxp3cre and Prkaa1fl/fl Foxp3cre mice were
labeled with violet, then co-cultured with CD4+ YFP+ T regulatory cells at 1:2 or 1: 1 ratio in the presence of
T cell-depleted splenocytes and anti-CD3. Violet dilution was assessed 4 days later by flow cytometry. Data
are representative of three independent experiments. B-E, CD4+CD45RBhi naïve T cells (Teff) were
transferred together with or without sorted Treg cells from Prkaa1+/+ Foxp3cre (WT) or Prkaa1fl/fl Foxp3cre
(KO) mice into Rag1-/- mice. C, Body weight of individual mouse was monitored every week for 10 weeks.
Data are compiled from three independent experiments. D, Representative images of spleen and MLNs
from Rag1-/- recipient mice. E, H&E staining of colon section and histology scores of sections from Rag1-/-
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recipient mice (N=6, *p<0.05).

2.4.6 Activation of AMPK Phosphorylates Foxp3 and Regulates its Stability
As Foxp3 is essential for the suppressive properties of Treg cell, we tested whether AMPKα1
regulates Foxp3. As shown in Figure 9A, Foxp3 protein levels were significantly decreased in
Treg cells isolated from Prkaa1fl/fl Foxp3cre mice as compared to WT mice. Conversely, the mRNA
levels of Foxp3 were not changed (Figure 9B), suggesting that AMPKα1 may regulate Foxp3 at
the post-transcriptional level.
It has been reported that TCR stimulation controls phosphorylation of Foxp3(Nie et al., 2013).
In

sorted YFP+ Treg cells, TCR

stimulation

(anti-CD3/anti-CD28)

increased AMPK

phosphorylation at threonine 172, which indicates AMPK activation, in a time-dependent manner
(Figure 9C). As AMPK is a serine/threonine kinase, we hypothesized that AMPK may be the direct
upstream kinase of Foxp3. To test this hypothesis, we performed an in vitro kinase assay. As
shown in Figure 9D, Foxp3 was phosphorylated by recombinant AMPK in a dose-dependent
manner. To further establish if AMPK phosphorylation alters Foxp3 levels in intact cells, 293A cells
were transfected to overexpress with a vector control or Foxp3 plasmid. Twenty-four hours after
transfection, the cells were stimulated with AMPK activator A769662 or the AMPK inhibitor
Compound C for 12 hours. As shown in Figure 9E, activation of AMPK by A769662 significantly
increased Foxp3 level. Conversely, inhibition of AMPK activity by Compound C significantly
decreased Foxp3 levels. Importantly, sorted Treg cells treated with A769662, or Compound C
showed similar results (Figure 9F). As Foxp3 expression is tightly regulated by polyubiquitinationmediated proteasomal degradation(Chen et al., 2013; van Loosdregt et al., 2013), we further
examined if AMPK regulates Foxp3 ubiquitination. As shown in Figure 9G, activation of AMPK
with A769662 significantly decreased Foxp3 ubiquitination, whereas selective AMPK inhibition
with Compound C had the opposite effect, abolishing the A769662-regudced Foxp3 ubiquitination.
Moreover, MG132, a potent 26S proteasome inhibitor, normalized AMPK-regulated Foxp3 levels
(Figure 9H). Taken together, these results imply that AMPK activation maintains Foxp3 stability
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in Treg cells.

Figure 9 Activation of AMPK phosphorylates Foxp3 and regulates its stability.
A, Immunoblot analysis of Foxp3 protein level in sorted Treg cells isolated from Prkaa1+/+ Foxp3cre or
Prkaa1fl/fl Foxp3cre mice (N=6, *p<0.05 versus control mice). B, Quantitative RT-PCR analysis of Foxp3
mRNA level in sorted Treg cells. C, Sorted Treg cells were stimulated with anti-CD3/CD28 antibodies for
indicated times. D, In vitro kinase assay to determine phosphorylation of Foxp3 by recombinant AMPK. E,
293A cell were transfected with vector control or Foxp3 overexpressing plasmid, and then stimulated with
AMPK activator A769662 or AMPK inhibitor compound C for 12 hours. F, Sorted Treg cells were stimulated
with A769662 or compound C for 12 hours. G, Ubiquitination of Foxp3 in 293A cells transfected with Foxp3
plasmid and stimulated with A769662 or compound C for 12 hours. H, 293A cell transfected with Foxp3
plasmid were stimulated with A769662 or compound C in the presence or absence of proteasome inhibitor
MG132. All immunoblot results are representative of at least three independent experiments. *p<0.05.

2.4.7 Reduced Treg cells and Decreased AMPK Phosphorylation in Treg Cells from Primary
Biliary Cholangitis (PBC) Patients
To test the relevance of our findings in human disease, we further obtained peripheral blood
from patients with primary biliary cholangitis (PBC) and healthy controls and assessed the
frequency of Treg cells and the level of phosphorylated AMPK in Treg cells. Fluorescent-activated
cell sorting (FACS) analysis indicated that the frequency of Treg cells from circulating blood is
significantly lower in PBC patients than in healthy controls (Figure 10A), moreover, the
phosphorylation levels of AMPK at T172 were decreased in PBC patients compared to controls

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

46

(Figure 10B-10C), This finding further implies a crucial role for AMPK activation in autoimmune
liver disease.

Figure 10 Reduced Treg cells and decreased AMPK phosphorylationin in Treg cells from primary
biliary cholangitis (PBC) patients.
A, FACS analysis of frequency of Treg cells (CD4+CD25+CD127low) in peripheral blood from healthy
control and PBC patients, N=16-21, *p<0.05 versus control group. B, Western blot for p-AMPK (T172) in
CD4+CD25+CD127low population of peripheral blood from healthy control and PBC patients. C, Western
was used to quantitatively evaluate the phosphorylation of AMPK at Thr-172 in CD4+CD25+CD127low
population of peripheral blood from healthy control and PBC patients, GAPDH as loading control. *p<0.05
versus control group.

2.5 Discussion
AMP-activated protein kinase (AMPK) is a crucial regulator in energy metabolism and stress
response pathways(Hardie, 2007, 2008; Hardie and Carling, 1997). Here we report that AMPKα1
plays a novel role in the control of Treg cell suppressive activity and prevention of autoimmune
liver disease.
During an immune response, changes in the proliferative and functional state of T cells are
accompanied by profound modifications in energy metabolism(Jones and Thompson, 2007). As
a central regulator of energy homeostasis, AMPK thus has long been implicated in regulating T
cell function(Ma et al., 2017). AMPKα1-deficient T cells displayed reduced metabolic plasticity in
response to glucose limitation in vitro and reduced metabolic activity and lower ATP levels during
pathogenic challenge in vivo(Blagih et al., 2015). However, T cells isolated from AMPKα1deficient mice display normal responses to mitogenic stimulation in vitro(MacIver et al., 2011),
whereas exacerbated T cell-mediated pathology was observed in an in vivo model of
autoimmunity with whole-body AMPKα1 deletion(Nath et al., 2009b). These results suggest that
AMPK might play an important role in regulatory immune cells. Indeed, it has been reported that
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in vivo administration of metformin, a pharmacological activator of AMPK, suppresses systemic
autoimmunity and attenuates the induction of experimental autoimmune encephalomyelitis (EAE)
in C57BL/6 mice(Lee et al., 2017; Nath et al., 2009a; Sun et al., 2016). In these studies, metformin
was found to either inhibit T cell-mediated immune responses and the production of Th1 or Th17
cytokines or suppress B cell differentiation into plasma cells and thus decrease serum levels of
anti-double stranded DNA antibodies. These studies suggest that AMPK may regulate Treg
function and indirectly, the development of autoimmunity. Consistent with this hypothesis, we
found that AMPKα1 deficiency impairs Treg suppressive function. Mice with Treg-specific deletion
of AMPKα1 spontaneously developed autoantibodies, hyperactivation of T cell responses, and
autoimmune liver disease. This is also consistent with a recent report that Berberine, a compound
which can activate AMPK, can attenuate Concanavalin A-induced autoimmune hepatitis in
mice(Wang et al., 2017).

More importantly, we found that in patients with primary biliary

cholangitis (PBC), one of the major types of autoimmune liver disease, the phosphorylation of
AMPK is dramatically decreased, and correspondingly, the frequency of Treg cells is significantly
decreased. This finding further suggest that AMPK activation is important for the maintenance of
Treg function and the prevention of autoimmune liver disease.
Moreover, we found that AMPKα1 phosphorylates Foxp3 and maintains Foxp3’s stability. As
the main transcriptional regulator of Treg cells, Foxp3 establishes Treg cell function and acts
largely as a repressor(Arvey et al., 2014). However, how Foxp3 in Treg cells is regulated remains
not entirely clear. Previously, intense investigation has been focused on transcriptional activation
at the Foxp3 locus. Recently, various studies have started to define important roles for posttranslational modification, especially phosphorylation, in Foxp3 regulation and Treg function(van
Loosdregt and Coffer, 2014). Indeed, TCR engagement triggers a signaling cascade with rapid
phosphorylation events and reprograms the proteomes and bioenergetic features for T cell
activation, proliferation, and differentiation(Tan et al., 2017). Here we showed that TCR stimulation
triggers the activation of serine/threonine kinase AMPK, which directly phosphorylates Foxp3 and
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decreases its ubiquitination and degradation. Therefore, our findings have revealed AMPK as a
novel kinase for phosphorylating and maintaining protein stability of Foxp3 under disease settings,
which may provide the molecular mechanism for pharmacological activation of AMPK in treating
autoimmune disorders.
In conclusion, we have identified AMPKα1 as a new regulator of Treg suppressive function and
autoimmune liver disease and our studies suggest the possibility of pharmacological activation of
AMPK in the treatment of this disorder.
2.6 Author Contributions
M.-H.Z. conceived the project, H.Z., Z.L., J.A., M.Z., Y.Q. designed the experiments, carried out
experiments and analyzed data, Z.L. and H.Z. wrote the manuscript.
2.7 Financial Support
This study was supported in part by the following grants: NHLBI (HL079584, HL080499,
HL089920, HL110488, HL128014, and HL132500), NCI (CA213022), NIA (AG047776), NSFC
(31870897), and NSFC (81900387). Dr. M.H. Zou is an eminent scholar of the Georgia Research
Alliance.
2.8 Competing Interests
The authors declare no competing interests.

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

49

3 AMP-Activated Protein Kinase Alpha1 Promotes Tumor Development via FOXP3
Elevation in Tumor-infiltrating Treg Cells.

An J, et al. iScience. 2021 Dec 4;25(1):103570.
Junqing An1, Ye Ding1, Changjiang Yu1, Jian Li1, Shaojin You1, Zhixue Liu1, Ping Song1*, Ming-Hui
Zou1,2*
1

Center for Molecular and Translational Medicine, Georgia State University, 157 Decatur Street
SE. Atlanta, GA 30303
2

Lead contact

*Corresponding author. Ping Song, Ph.D., 157 Decatur Street SE, Atlanta, GA 30303, Tel:1-404413-6636, E-mail: psong@gsu.edu. Ming-Hui Zou, M.D., Ph.D., 157 Decatur Street SE, Atlanta,
GA 30303, Tel:1-404-413-6637, E-mail: mzou@gsu.edu
3.1 Summary
Overwhelming evidence indicate that infiltration of tumors by Treg cells with elevated levels of
FOXP3 suppresses the host antitumor immune response. However, the molecular mechanisms
that maintain high expression of FOXP3 in tumor-infiltrating Treg cells remain elusive. Here, we
report that AMP-activated protein kinase alpha1 (AMPKα1) enables high FOXP3 expression in
tumor-infiltrating Treg cells. Mice with Treg-specific AMPKα1 deletion showed delayed tumor
progression and enhanced antitumor T cell immunity. Further experiments showed that AMPKα1
maintains the functional integrity of Treg cells and prevents interferon-γ production in tumorinfiltrating Treg cells. Mechanistically, AMPKα1 maintains the protein stability of FOXP3 in Treg
cells by downregulating the expression of E3 ligase CHIP (STUB1). Our results suggest that
AMPKα1 activation promotes tumor growth by maintaining FOXP3 stability in tumor-infiltrating
Treg cells and that selective inhibition of AMPK in Treg cells might be an effective anti-tumor
therapy.
Keywords: AMPK, antitumor immunity, Treg function, Foxp3
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3.2 Introduction
The recognition of tumor antigens by the host immune system promotes antitumor immune
responses (Carey et al., 1976). The promotion of tumor-specific T cell responses has been
recognized as a promising strategy for cancer therapy (Borst et al., 2018). However, the increased
expression of immunosuppressive molecules (PD1/PDL1) and enrichment of immunosuppressive
cells (myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T (Treg)
cells) in the tumor microenvironment (TME) limit antitumor immunity and promote tumor immune
escape (Han et al., 2020; Kumar et al., 2016; Petty and Yang, 2017; Tanaka and Sakaguchi, 2017).
Despite the great progress achieved with immune checkpoint blockers in cancer therapy, the
molecular mechanisms that determine the immunosuppressive character of the TME are still not
fully understood.
Treg cells are a heterogeneous population of lymphocytes that express the transcription factor
Foxp3 and play an essential role in immune balance and tissue homeostasis (Bonney et al., 2015;
Smigiel et al., 2014; Veiga-Parga et al., 2013). Stable expression of Foxp3 is required for the
development and function of Treg cells, whereas deficiency or mutation of Foxp3 impairs Treg
function and causes several autoimmunity disorders (Bacchetta et al., 2018; Bennett et al., 2001;
Fontenot et al., 2003). In cancers, enrichment of Treg cells in the TME promotes tumor
development, invasiveness, and metastasis (Hatziioannou et al., 2017), whereas depletion or
inhibition of Treg cells in the TME has shown as a promise strategy for cancer therapy
(Hatzioannou et al., 2020; Xiong et al., 2020). In contrast to Treg cells in peripheral blood and
other tissues, Treg cells that infiltrate the TME are predominantly Foxp3high effector Treg (eTreg)
cells, the accumulation of which is linked to poor prognosis of various cancers (Wing et al., 2019).
Multiple studies showed that destabilized FOXP3 in Treg cells promotes antitumor immunity and
suppresses tumor development (Cortez et al., 2020; Overacre-Delgoffe and Vignali, 2018; Yang
et al., 2020). Conversely, elevated Foxp3 expression in tumor-infiltrating Treg cells suppressed
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the proliferation of effector T cells and promoted gastric cancer progression (Yuan et al., 2010).
The molecular mechanism that maintains high Foxp3 expression in tumor-infiltrating Treg cells is
still unknown.
AMP-activated kinase (AMPK) is an essential energy sensor activated by the AMP/ATP ratio
(Herzig and Shaw, 2018). The activation of AMPK signaling has emerged as a controversial
regulator of tumor development (Hardie, 2015). One study showed that AMPK could suppress
lymphomagenesis by negatively regulating the Warburg effect (Faubert et al., 2013). Conversely,
other studies showed that deletion of AMPK was detrimental to the growth of KrasG12Dp53f/f tumors
(Eichner et al., 2019), and inhibition of AMPK activity by Compound C blocked cell cycle
progression and prevented B16F1 melanoma growth (Lee et al., 2019). In addition to its effects
on cancer cells, AMPK was shown to increase the antitumor activity of tumor-infiltrating CD8+ T
cells by suppressing the transcription of Pdcd1 (Zhang et al., 2020). The relationship between
AMPK and Foxp3 and the role of AMPK in tumor-infiltrating Treg cells remain poorly understood.
We used in vitro and in vivo experiments to analyze the role of AMPKα1 in the tumor-promoting
effects of Treg cells. Mice with Treg-specific AMPKα1 deficiency showed increased antitumor
immunity and delayed tumor progression. Conditional deletion of AMPKα1 impaired the
immunosuppressive capacity of Treg cells. Furthermore, AMPKα1 deficiency increased the
expression of E3 ligase CHIP and promoted the ubiquitination and proteasomal degradation of
FOXP3 in Treg cells. Although further studies are necessary, our results indicate that AMPK
suppression in Treg cells might be an effective strategy for cancer immunotherapy.
3.3 Results
3.3.1 AMPKα1 is Upregulated in Tumor-Infiltrating Treg Cells but is Dispensable for T cell
Development.
AMPK is a heterotrimeric complex kinase consisting of α, β, and γ subunits, the former of which
is responsible for the catalytic activity of the enzyme (Steinberg and Carling, 2019). The two
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isoforms of AMPKα, AMPKα1, and AMPKα2, are encoded by the Prkaa1 and Prkaa2 genes,
respectively (Steinberg and Carling, 2019). AMPKα1 is the predominant isoform in T cells, which
also express AMPKα2 but at lower levels (Mayer et al., 2008; Tamas et al., 2006). To explore the
regulation and function of AMPK signaling in tumor-infiltrating Treg cells, we monitored AMPKα1
expression in Treg cells from tumors and spleens of mice bearing B16F10 melanoma tumors.
Flow cytometry revealed that the frequency of Treg cells was higher in the TME than in the spleen
(Figure 11A) and that the AMPKα1 expression level was higher in Treg cells from tumors than in
Treg cells from the spleen (Figure 11B).

Figure 11 AMPKα1 is upregulated in tumor-infiltrating Tregs.
(A) Representative flow cytometry images and quantification of CD4+Foxp3+ frequency in mouse spleens
and tumors on day 10 after B16F10 melanoma implantation (n = 4 in each group; data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (B) Representative flow cytometry
images and quantification of AMPKα1 mean fluorescence intensity (MFI) in Treg cells from mouse spleens
and tumors (n = 4 in each group; data are presented as individual values and mean ± SD and analyzed by
Student’s t test).

To further examine the role of AMPKα1 in Treg cells, we generated Treg-specific AMPKα1deficiency mice (Prkaa1fl/flFoxp3Cre/YFP, hereafter referred to as AMPKα1Treg-/-) by crossing mice
bearing

loxp-flanked Prkaa1 alleles

with

Foxp3-Cre/YFP mice

(littermate

controls

Prkaa1+/+Foxp3Cre/YFP referred to as AMPKα1Treg+/+). We then confirmed that the AMPKα1 protein
level was deleted in Foxp3-YFP+ Treg cells but not in CD4+Foxp3-YFP- Tconv cells (T
conventional cells) from the AMPKα1Treg-/- mice (Figure 12A). Flow cytometry analysis showed
no difference in the frequencies of Treg cells and other T cell phenotypes in the thymus between
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the AMPKα1Treg-/- mice and the AMPKα1Treg+/+ mice (Figure 12B-12D), implying that AMPKα1
plays a dispensable role in the development of Treg cells.

Figure 12 AMPKα1 deficiency has a mild effect on the development of different T cell phenotypes.
(A) Immunoblot identification of knockout efficiency in conventional T cells (Tconv) and T regulatory cells
(Treg). (B) Representative FACS plot and frequency of CD4 +Foxp3-YFP+ Treg cells in thymus of
AMPKα1Treg+/+ and AMPKα1Treg-/- mice. (n = 5 in each group; data are presented as individual values and
mean ± SD and analyzed by Student’s t test).(C) Representative FACS plot of different T cell phenotypes
in thymus of AMPKα1Treg+/+ and AMPKα1Treg-/- mice. (D) Frequency of different T cell phenotypes in thymus
(n = 5 in each group; data are presented as individual values and mean ± SD and analyzed by Student’s t
test).

3.3.2 AMPK Deletion in Treg Cells Suppresses Tumor Progression.
We challenged AMPKα1Treg-/- mice and AMPKα1Treg+/+ mice with B16F10 melanoma cells to
explore how AMPKα1 expression in Treg cells affects tumor development. Compared with the
AMPKα1Treg+/+ mice, the AMPKα1Treg-/- mice showed decreased tumor size (Figure 13A).
Furthermore, the growth of the melanoma cells was largely attenuated in the AMPKα1Treg-/- mice
relative to that in the AMPKα1Treg+/+ mice (Figure 13B). Moreover, AMPKα1Treg-/- mice had lower
tumor weight (Figure 13C), less tumor blood vessel formation (Figure 13D), and lower
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frequencies of Ki-67+ proliferating cells in their tumors (Figure 13E). Similarly, AMPKα1Treg-/- mice
showed decreased tumor sizes and delayed tumor progression when compared with
AMPKα1Treg+/+ mice after implantation with Lewis lung carcinoma cells (LLCs; Figure 14A-14C).
These findings indicate that deficiency of AMPKα1 in Treg cells impairs tumor progression in mice.

Figure 13 Deficiency of AMPKα1 in Treg prevent tumor development.
(A) Representative images of tumors from AMPKα1Treg+/+ and AMPKα1Treg-/- mice on day 13 after
implantation with B16F10 cells. (B) Tumor volume in AMPKα1Treg+/+ and AMPKα1Treg-/- mice after
implantation with B16F10 cells (n = 13 in AMPKα1Treg+/+ group and n = 15 in AMPKα1Treg-/- group; data are
presented as mean ± SEM and analyzed by two-way ANOVA). (C) Tumor weight in AMPKα1Treg+/+ and
AMPKα1Treg-/- mice on day-13 after implantation with B16F10 cells (n=13 in AMPKα1Treg+/+ group and n = 15
in AMPKα1Treg-/- group; data are presented as individual values and mean ± SD and analyzed by Student’s
t test). (D) Representative images of immunofluorescence and quantification of CD31 intensity in tumors
from AMPKα1Treg+/+ and AMPKα1Treg-/- mice on day 10 after implantation with B16F10 cells (n = 6 in each
group; data are presented as individual values and mean ± SD and analyzed by Student’s t test). Three or
more fields per tumor were quantified. Scale bar: 100 μm.(E) Representative images of
immunofluorescence and percentage of Ki67+ cells in tumors from AMPKα1Treg+/+ and AMPKα1Treg-/- mice
on day 10 after implantation with B16F10 cells (n = 5 in AMPKα1Treg+/+ group and n = 6 in AMPKα1Treg-/group; data are presented as individual values and mean ± SD and analyzed by Student’s t test). Three or
more fields per tumor were quantified. Scale bar: 50 μm.
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Figure 14 Mice with Treg-specific AMPKα1 deletion showed delayed tumor progression.
(A) Representative images of tumors from AMPKα1Treg+/+ and AMPKα1Treg-/- mice on day 13 after LLC tumor
inoculation. (B) Tumor volumes of AMPKα1Treg+/+ and AMPKα1Treg-/- mice after LLC inoculation (n = 7 in each
group; data are presented as mean ± SEM and analyzed by two-way ANOVA). (C) Tumor weights from
AMPKα1Treg+/+ and AMPKα1Treg-/- mice on day 13 after LLC tumor inoculation (n = 7 in each group; data are
presented as individual values and mean ± SD and analyzed by Student’s t test).

3.3.3 AMPKα1 Deficiency in Treg Cells Promotes Antitumor T Cell Responses.
Histological analysis revealed that tumor tissues from AMPKα1Treg-/- mice had more
inflammatory cells infiltration than those from AMPKα1Treg+/+ mice (Figure 15A). Further analysis
showed the tumors from the AMPKα1Treg-/- mice had more CD3+, CD4+ and CD8+ T cell infiltration
than the tumors from the AMPKα1Treg+/+ mice (Figure 15B and 15C); however, the frequency of
tumor-infiltrating B cells was comparable between the two mouse strains (Figure 15D). These
data indicate an enhanced antitumor immunity in the AMPKα1Treg-/- mice.
Next, we performed flow cytometry analysis of the tumors to further explore the antitumor
effects of AMPKα1 deletion in Treg cells (Figure 16A). Compared with the tumors from the
AMPKα1Treg+/+ mice, the tumors from the AMPKα1Treg-/- mice had increased numbers of CD45+
leukocytes, CD3+ T cells, CD4+ T cells, and CD8+ T cells (Figure 16B). Meanwhile, the
proportions of CD45+ cells in tumors and the frequency of CD3+ and CD8+ T cells in CD45+ cells
significantly increased in tumor tissues from AMPKα1Treg-/- mice (Figure 16C). The expression of
IFN-γ, an important cytotoxic cytokine, by tumor-infiltrating CD8+ T cells was also higher in
AMPKα1Treg-/- mice than that in AMPKα1Treg+/+ mice (Figure 16D and 16E). However, the
frequency and numbers of tumor-infiltrating CD45+IFNγ+ and CD4+IFNγ+ T cells were comparable
between AMPKα1Treg+/+ mice and AMPKα1Treg-/- mice (Figure 16F and 16G). These findings

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

56

suggest that the absence of AMPKα1 in Treg cells promotes CD8+ T cells mediated antitumor
immunity.

Figure 15 Deficiency of AMPKα1 in Treg cells had mild effects on B cell infiltration in tumors.
(A) Representative H&E images of day-10 B16F10 induced tumors from AMPKα1Treg+/+ and AMPKα1Treg-/mice (Black arrows indicate inflammatory cell infiltrations). Scar bar, 20X, 100μm, 40X, 50μm. (B)
Representative immunofluorescence staining images of CD3e, CD4, and CD8a in tumor sections from
AMPKα1Treg+/+ and AMPKα1Treg-/- mice. Scale bar: 50 μm.(C) Cell numbers of CD3+, CD4+, and CD8+ T cells
per 40 field in tumor sections from AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 5 in each group; data are
presented as individual values and mean ± SD and analyzed by Student’s t test). Five or more fields per
tumor were quantified. (D) Representative B220 immunofluorescent image and number of B220+ B cells in
tumor sections per 40 field from day-10 B16F10 tumors of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 5 in
each group; data are presented as individual values and mean ± SD and analyzed by Student’s t test). Scar
bar, 50 μm.
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Figure 16 Treg-specific AMPKα1 deficient mice show increased antitumor immunity.
(A) Gating strategy of CD45+ lymphocytes, CD3+, CD4+, and CD8+ T cells in tumor tissues.(B) Cell numbers
of CD45+ (n = 6), CD3+ (n = 6), CD4+ (n = 6), and CD8+ (n = 5) T cells per 1  106 tumor cells from day-13
tumor tissues of AMPKα1Treg+/+ and AMPKα1Treg-/- mice measured by flow cytometry (data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (C) Proportions of CD45+ (n = 6), CD3+
(n = 6), CD4+ (n = 6), and CD8+ (n = 5) T cells in day-13 tumor tissues of AMPKα1Treg+/+ and AMPKα1Treg-/mice analyzed by flow cytometry (data are presented as individual values and mean ± SD and analyzed by
Student’s t test). (D) Representative FACS images of IFN-γ–producing CD8+ cells from day-13 tumor
tissues of AMPKα1Treg+/+ and AMPKα1Treg-/- mice. (E) Frequency and numbers of IFN-γ–producing CD8+
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cells per 1106 tumor cells from tumor tissues of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 6 in each group;
data are presented as individual values and mean ± SD and analyzed by Student’s t test). (F) Frequency
and numbers of IFN- γ –producing CD45+ cells per 1  106 tumor cells from tumor tissues of AMPKα1Treg+/+
and AMPKα1Treg-/- mice (n = 6 in each group; data are presented as individual values and mean ± SD and
analyzed by Student’s t test). (G) Frequency and numbers of IFN- γ –producing CD4+ cells per 1  106
tumor cells from tumor tissues of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 6 in each group; data are
presented as individual values and mean ± SD and analyzed by Student’s t test).

3.3.4 AMPKα1-Deficient Treg Cells Present a ‘Fragile’ Phenotype in TME.
Our observations of increased antitumor immunity in AMPKα1Treg-/- mice led us to assess
possible changes in the Treg populations. Intra-tumoral Treg cells can present a ‘fragile’
phenotype, marked by aberrant IFN-γ expression but loss of Treg signature genes, was shown to
promote more efficient antitumor immunity (Lim et al., 2021; Overacre-Delgoffe et al., 2017). Next,
we tested whether AMPK could influence the formation of ‘fragile’ Treg cells in TME. Several cell
surface markers are related to the immunosuppressive function of Treg cells and have been
exploited as cancer therapeutic targets (Ohue and Nishikawa, 2019). Analysis these cell surface
markers revealed decreases in CD25, CTLA-4, and PD1 expression in AMPKα1-deficient Treg
cells in TME compared with that in wild-type (WT) Treg cells (Figure 17A-17C). In addition, both
the frequency and mean fluorescence intensities (MFIs) of IL-10, an inhibitory cytokine expressed
by Treg cells, were decreased in tumor infiltrating CD4+Foxp3-YFP+ Treg cells after AMPKα1
deletion (Figure 17D-17E). These data indicate that the functional integrity of Treg cells was
compromised after AMPKα1 deficiency in TME. Analysis the expression of IFN-γ in tumor
infiltrating Treg cells, we found an increased frequency of IFN-γ+ Treg cells in tumors from
AMPKα1Treg-/- mice compared with controls (Figure 17F). Meanwhile, the expression of IFN-γ in
tumor-Treg cells also showed increased in AMPKα1Treg-/- mice (Figure 17G). Overall, these data
point towards an essential role of AMPKα1 in maintaining the function profile of Treg cells in TME
and preventing the induction of fragile Treg cells.
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Figure 17 AMPKα1-deficient Treg cells present a ‘fragile’ phenotype in TME.
(A) Gating strategy of CD4+YFP+ Treg cells from tumor tissues. (B) Representative FACS images of ICOS,
CD25, CTLA-4, GITR, PD1 and Nrp1 expression on CD4+Foxp3-YFP+ Treg cells from day 13 tumor tissues
of AMPKα1Treg+/+ and AMPKα1Treg-/- mice. (C) Relative MFI of cell surface ICOS (n = 5), CD25 (n = 6), CTLA4 (n = 6), GITR (n = 6), PD1(n = 6) and Nrp1 (n = 5) on CD4 +Foxp3-YFP+ Treg cells from day 13 tumor
tissues of AMPKα1Treg+/+and AMPKα1Treg-/-mice. (Data are presented as individual values and mean ± SD
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and analyzed by Student’s t test). (D) Representative FACS images and frequency of YFP +IL-10+ Treg cells
in CD4+Foxp3-YFP+ Treg cells from day 13 tumor tissues of AMPKα1Treg+/+and AMPKα1Treg-/-mice. (n = 6 in
each group, data are presented as individual values and mean ± SD and analyzed by Student’s t test). (E)
Relative MFI of IL-10 in CD4+Foxp3-YFP+ Treg cells from day 13 tumor tissues of AMPKα1Treg+/+and
AMPKα1Treg-/-mice. (n = 6 in each group, data are presented as individual values and mean ± SD). (F)
Representative FACS images and frequency of YFP+IFN-γ+ Treg cells in CD4+Foxp3-YFP+ Treg cells from
day 13 tumor tissues of AMPKα1Treg+/+and AMPKα1Treg-/-mice. (n = 6 in each group, data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (G) Relative MFI of IFN-γ in CD4+Foxp3YFP+ Treg cells from day 13 tumor tissues of AMPKα1Treg+/+and AMPKα1Treg-/-mice. (n = 6 in each group,
data are presented as individual values and mean ± SD and analyzed by Student’s t test).

3.3.5 AMPKα1 Maintains FOXP3 Expression in Treg Cells.
As a key transcriptional factor, Foxp3 controls the development and functional integrity of Treg
cells(Fontenot et al., 2003). Unstable FOXP3 expression promotes IFN-γ transcription in Treg
cells (Yang et al., 2020). Immunofluorescence staining of FOXP3 showed similar numbers of
Foxp3+ cells in tumor sections from AMPKα1Treg+/+ and AMPKα1Treg-/- mice (Figure 18A).
Nonetheless, the FOXP3 fluorescence intensity in Foxp3+ cells from the tumors of AMPKα1Treg-/mice was lower than that from the tumors of AMPKα1Treg+/+ mice (Figure 18A and 18B), indicating
that AMPKα1 deficiency decreases FOXP3 protein level in in Treg cells during tumor development.
To establish the role AMPK in Foxp3 regulation in Treg cells, we analyze the expression of
yellow fluorescent protein (YFP), a reporter of transcriptional induction of Foxp3. We found that
deficiency of AMPKα1 has a mild effect on the frequency of CD4+YFP+ cells and the MFIs of YFP,
but significantly decreased FOXP3 expression in tumor infiltrated CD4+YFP+ Treg cells (Figure
18C and 18D). These data suggest that deletion of AMPKα1 does not affect the induction of the
Foxp3 gene, but it compromises the expression of the FOXP3 protein after tumor implantation.
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Figure 18 AMPKα1 deficiency impairs FOXP3 expression in tumor-infiltrated Treg cells.
(A) Representative immunofluorescence images of FOXP3 and quantification of Foxp3 + cell numbers on
tumor sections from AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 5 in each group; data are presented as
individual values and mean ± SD and analyzed by Student’s t test). Five or more fields per tumor were
quantified. Scale bar: 50 μm. (B) Quantification of FOXP3 fluorescence intensity in Foxp3+ cells. (n = 5 in
each group; data are presented as individual values and mean ± SD and analyzed by Student’s t test). Five
or more field per tumor were quantified. (C) Representative FACS images and percentage of CD4+YFP+
Treg cells in day-13 tumor tissues of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 7 in each group; data are
presented as individual values and mean ± SD and analyzed by Student’s t test). (D) Relative MFI of YFP
and FOXP3 in tumor infiltrated CD4+YFP+ Treg cells of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 7 in each
group; data are presented as individual values and mean ± SD and analyzed by Student’s t test).

To test whether this effect also happened in steady state, we used both GFP antibody (YFP
signal can be detected by GFP antibody) and Foxp3 antibody to analyze the CD4+YFP+ and
CD4+Foxp3+ Treg frequency respectively in the spleen of AMPKα1Treg+/+ and AMPKα1Treg-/- mice
without tumor implantation. Both the frequency of CD4+YFP+ Treg cells and expression of YFP
were comparable between both strains, while the frequency of CD4+Foxp3+ Treg cells and
expression of Foxp3 were significant decreased in AMPKα1Treg-/- mice (Figure 19A-19D).
Therefore, both in TME and stable state, AMPKα1 is required for Foxp3 protein level but not affect
the survival/proportion of Treg cells.
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Figure 19 AMPKα1 is required Foxp3 protein expression in basal condition.
(A) Representative FACS images and frequency of CD4 +YFP+ Treg cells in the spleens of AMPKα1Treg+/+
and AMPKα1Treg-/- mice under steady state (n=8 in each group; data are presented as individual values and
mean ± SD and analyzed by Student’s t test). (B) Relative MFI of YFP in CD4+YFP+ Treg cells from
AMPKα1Treg+/+ and AMPKα1Treg-/- mice under steady state (n =8 in each group; data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (C) Representative FACS images and
frequency of CD4+Foxp3+ Treg cells in the spleens of AMPKα1Treg+/+ and AMPKα1Treg-/- mice under steady
state (n = 8 in each group; data are presented as individual values and mean ± SD and analyzed by
Student’s t test). (D) Relative MFI of FOXP3 in Treg cells from AMPKα1Treg+/+ and AMPKα1Treg-/- mice under
steady state (n = 8 in each group; data are presented as individual values and mean ± SD and analyzed
by Student’s t test).

3.3.6 Deficiency of AMPKα1 Impairs FOXP3 Protein Stability.
T cell receptor (TCR) signaling is required for Foxp3 expression, either through induction of
Foxp3 transcription or through post-translational modification (Ono, 2020). Activation of TCR
signaling by CD3/CD28 Dynabeads promoted AMPKα1 expression in AMPKα1-sufficient (WT)
Treg cells but not in AMPKα1-deficient (KO) Treg cells (Figure 20A and 20B). Although FOXP3
expression was also increased in both types of Treg cells after CD3/CD28 treatment, the folds of
increase in the AMPKα1-deficient (KO) Treg cells were smaller than that those of the AMPKα1sufficient (WT) Treg cells (Figure 20C and 20D). These data suggest that AMPKα1 is partially
required for TCR-induced FOXP3 upregulation.
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To further investigate the intracellular mechanism by how AMPKα1 regulates Foxp3 expression
in Treg cells, we isolated Treg cells from AMPKα1Treg+/+ and AMPKα1Treg-/- mice and compared the
protein and mRNA levels of Foxp3. We found that the FOXP3 protein level was much lower in the
AMPKα1-/- Treg cells than those in the AMPKα1+/+ Treg cells (Figure 20E), whereas the Foxp3
mRNA level was similar (Figure 20F).
Next, we asked whether AMPK regulates FOXP3 protein stability. We transfected human
embryonic kidney (HEK) 293 cells with Flag-Foxp3 plasmid together with AMPKα1 plasmid or
AMPKα1 siRNA (Figure 20G and 20H). We found that AMPKα1 overexpression prevented
cycloheximide (CHX)-induced reduction of FOXP3 levels (Figure 20G), whereas AMPKα1
silencing decreased the protein stability of FOXP3 (Figure 20H). These data suggest that
AMPKα1 stabilizes the FOXP3 protein through post-translational modification.
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Figure 20 AMPKα1 maintains the protein stability of FOXP3.
(A) Isolated primary Treg cells (CD4+YFP+) from AMPKα1Treg+/+ (WT) and AMPKα1Treg-/- (KO)mice were
treated with Dynabeads CD3/CD28 beads at 1:1 ratio for 24 h. The expression of AMPKα1 and FOXP3
were detected by western blot. (B) Quantification of relative AMPKα1 expression in Treg cells from
AMPKα1Treg+/+ (WT) and AMPKα1Treg-/- (KO) mice stimulated with or without Dynabeads CD3/CD28 (n = 3
in each group; data are presented as individual values and mean ± SD and analyzed by Student’s t test).
(C) Quantification of relative FOXP3 expression in Treg cells from AMPKα1Treg+/+ (WT) and AMPKα1Treg-/(KO) mice stimulated with or without Dynabeads CD3/CD28 (n = 3 in each group; data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (D) Quantification of the increased
FOXP3 level (ΔFoxp3) after CD3/CD28 treatment between Treg cells from AMPKα1Treg+/+ (WT) and
AMPKα1Treg-/- (KO)mice (n = 3 in each group; data are presented as individual values and mean ± SD and
analyzed by Student’s t test). (E) Representative western blot and quantification of FOXP3 protein levels in
AMPKα1+/+ and AMPKα1-/- Tregs (n = 5 in each group; data are presented as individual values and mean
± SD and analyzed by Student’s t test). (F) Quantification of relative Foxp3 mRNA levels in in AMPKα1+/+
and AMPKα1-/- Tregs (n = 6 in each group; data are presented as individual values and mean ± SD and
analyzed by Student’s t test). (G) Western blot and quantitative analysis of relative FOXP3 protein levels in
HEK293T cells treated with cycloheximide (CHX) in combination with control vector or AMPKα1 plasmid (n
= 3 in each group/time point; data are presented as mean ± SEM and analyzed by two-way ANOVA). (H)
Western blot and quantitative analysis of relative FOXP3 protein levels in HEK293T cells treated with CHX
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in combination with siControl or siAMPKα1 (n = 3 in each group/time point; data are presented as mean ±
SEM and analyzed by two-way ANOVA).

3.3.7 Deficiency of AMPKα1 Promotes FOXP3 Degradation through E3 Ligase CHIP.
The stability of FOXP3 is tightly regulated by proteasomal degradation (Barbi et al., 2015). We
therefore asked whether the reduced protein level of FOXP3 in AMPKα1-deficient Treg cells could
be recovered by blocking proteasomal degradation. As shown in Figure 21A, treatment with the
proteasome inhibitor MG132 normalized Foxp3 levels in Treg cells from AMPKα1Treg-/- and
AMPKα1Treg+/+ mice. Since post-translational ubiquitination of FOXP3 affects FOXP3 stability and
Treg function (Barbi et al., 2015), we determined whether AMPKα1 regulates FOXP3
ubiquitination. To this end, flag-Foxp3 plasmid were transfected into HEK 293T cells after being
transfected with either control siRNA or AMPKα1 siRNA. We then treated the cells with MG132
and performed flag-Foxp3 pull-down and immunoblot to assess ubiquitin species. We found that
ubiquitination of FOXP3 was increased when AMPKα1 was knocked down (Figure 21B). These
results imply that deficiency of AMPKα1 promotes Foxp3 degradation through polyubiquitinationmediated proteasomal degradation, which results in a decrease of Foxp3 levels in Treg cells.

Figure 21 Deficiency of AMPKα1 promotes FOXP3 ubiquitination and proteasome degradation.
(A) Western blot and quantitative analysis of FOXP3 in AMPKα1-suficient (AMPKα1+/+) and AMPKα1deficienct (AMPKα1-/-) Treg cells (CD4+YFP+) in the presence or absence of proteasome inhibitor MG132
(n = 3 in each group; data are presented as individual values and mean ± SD and analyzed by Student’s t
test). (B) Effect of AMPKα1 knockdown on FOXP3 ubiquitination. Flag-Foxp3 together with siControl or
siAMPKα1 were transfected into HEK293T cells. The cells were then treated with 5 μM MG132 for 4 h
before harvest and lysis. Ubiquitination of FOXP3 proteins was detected by western blot.
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Finally, we investigated how AMPK regulates FOXP3 ubiquitination and degradation. The
polyubiquitination and degradation of FOXP3 are controlled by E3 ligase CHIP (STUB1) and
deubiquitinase USP7 (Chen et al., 2013; van Loosdregt et al., 2013). We found that the expression
of deubiquitinase USP7 was comparable between WT and AMPKα1-deficient Treg cells (Figure
22A); however, both the protein and mRNA level of CHIP were higher in AMPKα1-deficient Treg
cells than those in WT Treg cells (Figure 22B and 22C). We observed a similar effect in tumor
infiltrating Treg cells, which showed increased CHIP expression after AMPKα1 deletion (Figure
22D and 22E). Furthermore, CHIP knockdown by shCHIP lentivirus partially recovered the
reduced Foxp3 expression in AMPKα1-deficient Treg cells (Figure 22F and 22G). These results
indicated that CHIP is only partially responsible for the modulation of Foxp3 protein stability by
AMPKα1.

Figure 22 Deficiency of AMPKα1 promotes FOXP3 degradation through E3 ligase CHIP.
(A) Western blot analysis of AMPKα1, USP7, CHIP, and FOXP3 protein levels in sorted AMPKα1-suficient
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(AMPKα1+/+) and AMPKα1-deficienct (AMPKα1-/-) Treg cells (CD4+YFP+). (B) Quantification of relative
CHIP expression in sorted AMPKα1-suficient (AMPKα1+/+) and AMPKα1-deficienct (AMPKα1-/-) Treg cells
(CD4+YFP+) (n = 3 in each group; data are presented as individual values and mean ± SD and analyzed by
Student’s t test). (C) Quantification of relative CHIP mRNA levels in sorted AMPKα1-suficient (AMPKα1+/+)
and AMPKα1-deficienct (AMPKα1-/-) Treg cells (CD4+YFP+) (n = 6 in each group; data are presented as
individual values and mean ± SD and analyzed by Student’s t test). (D) Representative
immunofluorescence images of FOXP3 (Green) and CHIP (Red) from day-10 tumors of AMPKα1Treg+/+
and AMPKα1Treg-/- mice. Scar bar, 50 μm. (E) Quantification of relative CHIP mean fluorescence intensity
in Foxp3+ cells from day-10 tumors of AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n = 5 in each group;
data are presented as individual values and mean ± SD and analyzed by Student’s t test). Five or more
fields per tumor were quantified. (F) Western blot analysis of FOXP3 protein levels in AMPKα1-suficient
(AMPKα1+/+) and AMPKα1-deficienct (AMPKα1-/-) Treg cells (CD4+YFP+) in the presence of shControl
lentivirus or shCHIP lentivirus. (G) Quantification of relative FOXP3 expression in AMPKα1-suficient
(AMPKα1+/+) and AMPKα1-deficienct (AMPKα1-/-) Treg cells (CD4+YFP+) in the presence of shControl or
shCHIP lentivirus (n = 4 in each group; data are presented as individual values and mean ± SD and
analyzed by Student’s t test).

3.4 Discussion
Accumulating evidence suggest that cell-intrinsic molecules that potentiate Foxp3 expression
in tumor-infiltrating Treg cells can provide new targets for cancer therapy (Cortez et al., 2020;
Hatzioannou et al., 2020; Xiong et al., 2020). In this study, we found that AMPKα1 is highly
expressed in tumor-infiltrating Treg cells and is indispensable in these cells for FOXP3 expression
and functional integrity of Treg cells in TME. Tumor-exposed Treg-specific AMPKα1 deficiency
mice exhibited increased numbers of tumor-infiltrating T cells and more efficient antitumor
immunity. AMPKα1 maintained the protein stability of FOXP3 while not affecting the transcription
of Foxp3 in Treg cells. Furthermore, increased E3 ligase CHIP (STUB1) expression in AMPKα1deficient Treg cells promote the ubiquitination and proteasomal degradation of FOXP3,
decreasing FOXP3 levels in Treg cells.
AMPK signaling activates both antitumor and protumor immune responses in the TME.
Activation of AMPK by its agonist, metformin, promotes the phosphorylation and degradation of
PD-L1, which promotes antitumor immunity (Cha et al., 2018). Conversely, inhibition of AMPK
activity in tumor-bearing mice, as well as conditional deletion of AMPKα1 in myeloid cells,
improves protective T cell immunity by suppressing the immunoregulatory function of myeloidderived suppressor cells (Trillo-Tinoco et al., 2019). In addition, AMPK inhibition reduces
immunosuppressive phenotypes in tumor-associated macrophages and unleashes an antitumor
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effector T cell response (Wang et al., 2019; Xu et al., 2018). Thus, the modulation of AMPK has
combined effects in different cell populations within the TME. The nutrient sparse, hypoxic, and
acidic environment of tumor tissues negatively affects T effector cell function while supporting
Treg cell function (Watson et al., 2021; Zappasodi et al., 2021). AMPK is upregulated and
activated in the hypoxic and nutrient-limited TME (Gutierrez-Salmeron et al., 2020; Hao et al.,
2015); however, the regulation and role of AMPK in tumor-infiltrating Treg cells are largely
unknown. Our results show that AMPK upregulation in tumor-infiltrating Treg cells prevents
antitumor T cell response and thus promotes tumor progression, suggesting that specific inhibition
of AMPK signaling in Treg cells might have therapeutic value for cancer treatment.
Our results support AMPKα1 is required for FOXP3 protein stability and functional integrity of
Treg cells in TME. Consistently with our observations, Michalek et al. reported showed that pAMPK expression was higher in Treg cells than in conventional T cells, and that AMPK activation
promoted the generation of Treg cells in vivo by regulating fatty acid oxidation (FAO) (Michalek et
al., 2011). Consistent with these findings, pioglitazone and metformin were shown to enhance
Treg cell expansion and inhibit the progression of plaque instability and autoimmune
encephalomyelitis through activation of AMPK signaling (Sun et al., 2016; Tian et al., 2017). By
contrast, other studies showed that absence of AMPKα1 and AMPKα2 had only a mild impact on
immune homeostasis and the survival of Treg cells (Timilshina et al., 2019; Yang et al., 2017).
The discrepancy between our results and the previous results might be due to different animal
models, as the previous studies were mainly focused on the autoimmune disease caused by
LKB1 and used very young mice in steady state. In addition, recent studies showed that SREBPs
or CoREST (REST corepressor 1) deletion in Treg cells could promote antitumor effects while
having limited impacts on immune homeostasis in steady state (Lim et al., 2021; Xiong et al.,
2020), which matches the heterogeneous results regarding AMPK deletion. The role of AMPK in
Treg cells warrants further investigation.
Stabilization of Foxp3 maintains Treg lineage plasticity and hampers the antitumor immune
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response (Martin et al., 2010). Uncovering the fundamental regulators that control Foxp3
expression is therefore essential for understanding and exploiting efficient Treg therapies for
cancer treatment (Cortez et al., 2020). Loss of Foxp3 expression transforms Treg cells into socalled ex-Treg cells, which have no immunosuppressive ability but acquire effector Th cell-like
phenotypes (Hori, 2014). This has potential clinical relevance, because the accumulation of exTreg cells in the TME potentiates immunotherapy (Hatzioannou et al., 2020; Li et al., 2020a). The
decreased FOXP3 protein stability and normal Foxp3 gene induction observed in AMPKα1deficient Treg cells in our study is not fully in accordance with the phenotype of ex-Treg cells;
however, impaired FOXP3 protein stability without impairment of Foxp3 gene expression was also
shown to impair Treg lineage stability and promote ex-Treg transformation in one recent study
(Liu et al., 2019). It would therefore be interesting to investigate the effect of AMPKα1 deficiency
on ex-Treg transformation by crossing Prkaa1fl/fl mice with Treg lineage-tracking Foxp3IRES-YFP-CreRosa26-loxp-td-RFP-loxp

mice (Gaddis et al., 2018). Fragility of Treg cells in TME was shown to promote

antitumor immunity which potentiates the therapeutic effects of immune checkpoint therapy
(Hatzioannou et al., 2020; Lim et al., 2021). However, the intracellular mechanism on how
intratumoral Treg cells to prevent fragile IFN-γ-expressing Treg cells in TME remains largely
unknown. Our findings demonstrate an essential role of AMPK in the prevention of induction of
fragile Treg cells during tumor development.
FOXP3 ubiquitination and Treg function are tightly regulated by the E3 ubiquitin ligase CHIP
(STUB1) (Chen et al., 2013). We found that AMPKα1 deficiency upregulated CHIP expression in
Treg cells in vivo and in vitro; however, the increased CHIP expression in tumors of AMPKα1Treg/-

mice was not confined to Foxp3+ Treg cells but also appeared in non-Treg cells. A previous study

showed that CHIP transcription and expression were tightly correlated with inflammatory
cytokines (Chen et al., 2013). Therefore, we hypothesize that the increased CHIP expression in
non-Treg cells in our experiments was due to the strong inflammatory conditions in the tumors of
the AMPKα1Treg-/- mice. In addition to inflammatory cytokines, CHIP transcription is linked to
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different stresses such as heat shock and oxidative damage (Chen et al., 2013; Paul and Ghosh,
2014; Stankowski et al., 2011). Because of the crucial role of AMPK in oxidative stress regulation,
the upregulation of CHIP in AMPKα1-deficient Treg cells might be due to increased oxidative
stress (Ren et al., 2020). Some post-translational modifications were also reported to regulate the
expression or activity of CHIP (Paul and Ghosh, 2014; Zemanovic et al., 2018). Furthermore, one
previous study showed a direct association between CHIP and AMPK levels in cardiomyocytes
(Schisler et al., 2013), suggesting that another possible mechanism of CHIP regulation is direct
phosphorylation of CHIP by AMPK. Although the E3 ligase function of CHIP is well known, the
mechanism by which CHIP itself is regulated is much less clear. Further experiments are needed
to determine how AMPK regulates CHIP in Treg cells.
In conclusion, AMPKα1 is a critical mediator controlling FOXP3 stability and the functional
integrity of Treg cells in TME. Further studies are warranted to investigate whether therapeutic
inhibition of AMPK activity in Treg cells bolsters antitumor immunity.
3.5 Limitation of Study
In this study, we showed that AMPKα1 promotes tumor development through elevation the
protein stability of Foxp3 in Treg cells. Mechanismly, AMPKα1 downregulates CHIP, a well-known
E3 ligase of Foxp3, which prevents Foxp3 ubiquitination and degradation. However, this specific
mechanism on how AMPK regulates CHIP expression in Treg cells still lack exploitation. It is
meaningful to further investigate how AMPK regulates CHIP expression in Treg cells. In addition,
the exploitation of AMPK role in Treg cells in clinical value need to be further studied
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3.9 Star Methods
3.9.1 Resource Availability
Lead contact
Requests for further information and reagents may be directed to the lead contact, Ming-Hui
Zou (mzou@gsu.edu).
Materials availability
Unique reagents generated in this study are available from the lead contact with a completed
Material Transfer Agreement. All antibodies, reagents, and resources are list on table 2.
Table 2 Key resource table

REAGENT or RESOURCE
Antibodies
Flow cytometry: PE anti-mouse CD45
antibody (30-F11)
Flow cytometry: Pacific blue anti-mouse
CD45 antibody (30-F11)
Flow cytometry: Alexa Fluor 700 antimouse CD45 antibody (30-F11)
Flow cytometry: Brilliant Violet 605TM antimouse CD3e antibody (17A2 ).

SOURCE

IDENTIFIER

BioLegend

103106

BioLegend

103126

BioLegend

103128

BioLegend

100237

Flow cytometry: Pacific blue anti-mouse BioLegend
CD4 antibody (RM4-5)

100531
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Flow cytometry: PE/Cyanine 7 anti-mouse
CD4 antibody (GK1.5)
Flow cytometry: Alexa Fluor 488 antimouse CD8a (53-6.7)
Flow cytometry: Alexa Fluor 488 antimouse/rat/human Foxp3 antibody (150D)
Flow cytometry: PE anti-mouse Foxp3
antibody (MF-14)
Flow cytometry: Alexa Fluor 488 antimouse Foxp3 antibody (MF-14)
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Data and code availability
All data produced in this study are available from the lead contact upon request.
This paper has no original code.
Any additional information required to reanalyze the data showed in this paper is available from
the lead Contact upon request.
3.9.2 Experimental Model and Subject Details
Cell lines
HEK 293T cells, B16-F10-luc2 cells, and LLC cells were cultured in Dulbecco's Modification of
Eagle's Medium (CORNING) containing 4.5 g/L glucose, L-glutamine, and sodium pyruvate,
supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin in a 37℃ incubator
with humidity and 5% CO2. Moreover, primary mouse cells were isolated from 6–8 mice/group on
the same day.
Mouse strains
Prkaa1fl/fl, Foxp3Cre/YFP, and C57BL/6 mice were purchased from Jackson Laboratory (Bar
Harbor, ME). All genetic models had the C57BL/6 background. Prkaa1fl/flFoxp3Cre/YFP mice
were used at 10-16 weeks of age unless otherwise noted. Age-matched and sex-matched
Foxp3Cre/YFP mice were used as controls.
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All mice were housed in specific pathogen-free conditions in the animal facilities at Georgia
State University. The animal protocol was reviewed and approved by the Georgia State University
Institutional Animal Care and Use Committee.
Tumor models
B16-F10 murine melanoma cells and LLC cells were purchased from the ATCC. First, we
confirmed that the cell lines were negative for Mycoplasma spp. We subcutaneously implanted
5x105 B16-F10 melanoma cells or 5x105 LLC cells on the backs of 10–12-week-old male
AMPKα1Treg+/+ and AMPKα1Treg-/- mice. The mice were monitored every day, and tumor growth
and tumor size were determined based on tumor volume (0.5 x width2 x length). Tumors were
collected 10-13 days after inoculation unless otherwise noted.
3.9.3 Method Details
Cell isolation from tumors and lymphoid organs
Tumor-infiltrating lymphocytes were isolated by incubating tumor tissues in collagenase D (1
mg/ml, Roche) and DNase I (0.25 mg/ml, Sigma) for one hour. Single-cell suspensions from
tumors were generated by passing the digested tumor tissues through a 40-μm cell strainer.
Single-cell suspensions from spleen and lymph nodes were obtained directly by passing the
tissues through a 40-μm cell strainer.
Flow cytometry
Each reaction was performed with more than 1 × 106 cells, and a minimum of 1 × 105 events
were recorded. Fluorescence-positive cells were analyzed with a FACScalibur or LSRFortessa
device (Becton Dickinson, CA). Cells were processed for viability staining using eBioscience
LIVE/DEAD fixable Dye eFluor 660 or eFluor 780 (Thermofisher). For analysis of cell surface
markers, cells were stained in stain buffer (BD bioscience) with the appropriate antibodies.
Information on antibodies, clones, and fluorophores is provided in the Key resources table. A
Foxp3/transcription factor staining buffer set from eBioscience was used for intracellular staining.

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

76

For staining intracellular cytokines, cells were stimulated for 6-18 h with a cell stimulation cocktail
(Thermofisher) conjunction with protein transport inhibitor cocktail (Thermofisher) before being
stained. After stimulation, the cells were stained with appropriate antibodies following the
manufacturer's instructions. For YFP staining, Alexa Fluor 488 anti-GFP or PE anti-GFP antibody
from BioLegend was used.
Histopathology and immunofluorescent staining
Organs were fixed with 10% (v/v) neutral buffered formalin, embedded in paraffin, sectioned,
and stained with hematoxylin and eosin. For immunofluorescent staining, 4-μm sectioned paraffin
slides were subjected to xylene and alcohol for dehydration. Then, the slides were subjected to
antigen retrieval, permeabilized with 0.2% Triton X-100, and blocked with protein block goat
serum (BioGenex, Fremont, CA). Then, the slides were incubated with CD31, anti Ki67, Foxp3,
CD3e, B220, CD4, CD8, or CHIP antibodies at 4℃ overnight. Alexa Fluor 555 and Alexa Fluor
488 goat anti-rabbit, anti-rat, or anti-mouse were used as secondary antibodies, incubated at
room temperature for one h. Cell nuclei were stained with DAPI and mounted with
VectaMountTMAQ (#5501, Vector Laboratories) for fluorescence microscopy. Quantification was
performed using Image J software.
Cell purification and culture
Lymphocytes were isolated from spleens, and CD4+CD25+ Treg cells were isolated using a
Dynabeads CD4+CD25+ Isolation Kit (ThermoFisher). CD4+ T cells were isolated using a
Dynabeads CD4+ T cell Isolation Kit (ThermoFisher). Then, CD4+YFP+ Treg cells were purified
by YFP (GFP staining) using FACSAria II (BD Bioscience). The purified cells were cultured in
RPMI 1640 supplemented with 10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and β
mercaptoethanol.
RNA extraction and qRT-PCR
According to the manufacturer's instructions, RNA was extracted using the RNeasy Mini Kit
(QIAGEN, Hilden, Germany). cDNA was synthesized using the iScript cDNA Synthesis Kit. The
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expression of Foxp3 and CHIP mRNAs was determined by quantitative real-time PCR (qRTPCR). Each cDNA sample was amplified using SYBR Green (Bio-rad, Hercules, CA) on a Biorad CFX96 Touch Real-time PCR detection system.
Western blot analysis
Cells were lysed with NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5
mM EDTA, 50 mM NaF, 2 mM Na3VO4, and 10 μg/ml each of aprotinin and leupeptin) or with 1×
SDS sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, and 10% glycerol). Proteins
were separated by SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica,
MA). Membranes were visualized with an enhanced chemiluminescence detection system
(Thermo Fisher Scientific, Waltham, MA). When necessary, the membranes were stripped by
incubation in stripping buffer (Thermo Fisher Scientific, Waltham, MA) for 15 - 30 min with
constant agitation, washed, and then re-probed with various other antibodies.
Immunoprecipitation
For immunoprecipitation, HEK293T cells were transfected with lipo2000 or RNA iMAX. Fortyeight hours after transfection, the cells were treated with MG132 for six h and then lysed in lysis
buffer (50 mM Tris-HCL pH 7.5, 0.5% Nonidet p40 (US Biological), 1 mM EDTA and 40 mM NaCl
with 1% protease inhibitor cocktail (ThermoFisher)). Anti-FLAG M2 affinity gel was used for
immunoprecipitation. The precipitated samples were then boiled and analyzed by western blot.
Lentiviral shRNA transduction
CHIP (Stub1) shRNA(m) lentiviral particles were obtained from Santa Cruz. Purified CD4+YFP+
Treg cells were activated with Dynabeads CD3/CD28 plus IL-2 (200 U/ml) for 48 h and then
transduced with lentivirus in the presence of 10 μg/ml polybrene by centrifugation at 900 g for 3
h. The transduced cells were then cultured in RPMI 1640 medium for 48 h and subsequently lysed
for western blot analysis.
Quantification and Statistical Analysis
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All statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software,
CA). Student’s t test was used for analysis comparing two samples. One-way ANOVA tested
differences among multiple samples. Two-way ANOVA was applied to study the effect of two
parameters (i.e., time and treatment) and their interaction. P < 0.05 was considered statistically
significant.

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

79

4 Hypercholesterolemia-Driven Inhibition of AMP-Activated Protein Kinase α1 Induces
Treg Senescence during Atherogenesis
Junqing An1, Ming-Hui Zou1*
1

Center for Molecular and Translational Medicine, Georgia State University, 157 Decatur Street
SE. Atlanta, GA 30303
*Corresponding author. Ming-Hui Zou, M.D., Ph.D., 157 Decatur Street SE, Atlanta, GA 30303,
Tel:1-404-413-6637, E-mail: mzou@gsu.edu

4.1 Abstract
Background: Aging is the most important and irreversible risk factor in cardiovascular diseases
(CVD). Regulatory T cells (Tregs) senescence, which display plasticity-like phenotype, plays an
important role in CVD. Elevated evidences suggest that atherosclerotic environments drives Treg
plasticity and Tregs dysfunction. How Tregs becomes senescence and whether or not
atherosclerotic environments promote Tregs senescence and plasticity remain unknown.
Methods: In a western diet-induced atherosclerosis mice model, the accumulation of senescent
Tregs in the spleen, para-aorta lymph nodes and aorta tissues was monitored. The role of
senescent Tregs in atherogenesis was determined by adoptive Treg transfer. The involvement of
AMPK in Treg senescence was further evaluated in AMPKα1 global knockout (Prkaa1-/-) mice
and Treg-specific AMPKα1 deletion mice (AMPKα1Treg-/-). The role of AMPK in Tregs and
atherogenesis was analyzed by constructing Apoe (apolipoprotein E) knockout with specific
deletion of AMPKα1 in Tregs and adoptive transfer CA AMPK (constitutive active AMPK) Tregs
into western diet-induced atherosclerotic mice.
Results: We observed significantly increased senescent Tregs in spleen, para-aorta lymph node,
and aorta tissues of western fed ApoE-/- mice. Compared to thoracic and abdominal aorta, Tregs
in aorta arches showed higher levels of senescent related markers. Adoptive transfer of non-
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senescent Tregs but not senescent Tregs significantly ablated the development of atherosclerosis.
Compared to non-senescent Tregs, senescent Tregs are more likely to be plasticity and
dysfunctional. Mechanically, we revealed that AMPKα1 was downregulated in Tregs from both
aged and western diet-fed ApoE-/- mice and AMPK reduction promoted Treg senescence via
upregulation of reactive oxygen species (ROS). Furthermore, a deficiency of AMPKα1 in Tregs
promoted arterial inflammation and atherosclerosis in ApoE-/- mice. Finally, adoptive transfer of
CA AMPK-Tregs significantly retarded atherosclerosis progression and reduced plaque
vulnerability.
Conclusions: we conclude that AMPKα1 reduction in Tregs promotes Treg senescence, resulting
in accumulation of dysfunctional plasticity Tregs that accentuated arterial inflammation and
atherogenesis. Adoptive transfer of CA AMPK-Tregs could be a novel therapeutic method to treat
atherosclerotic diseases and vulnerable plaques.
4.2 Introduction
Atherosclerosis is a chronic inflammatory disease and one of the major causes of vascular
death worldwide (Herrington et al., 2016; Wolf and Ley, 2019). Accumulation of modified
lipoproteins caused by hyperlipidemia induces abnormal vascular immune responses and drives
atherosclerosis (Rao et al., 2015b; Yin et al., 2015). Familial hypercholesterolemia (FH), with 1 in
500 prevalence worldwide, is the epitomized disease that causes cholesterol deposition in arteries
and premature atherosclerosis(Hopkins et al., 2011; Nordestgaard et al., 2013). Given the
extensive immune-inflammatory activation, immunomodulation has emerged as a potential
therapy method for atherosclerosis(Back et al., 2019). As an important immune regulator,
regulatory T cells (Tregs) are shown to maintain the immune homeostasis to prevent tissue
damage(Munoz-Rojas and Mathis, 2021). Presentation of Tregs within atherosclerotic plaques
play protective roles on atherosclerosis via regulating immune cells activation and
inflammation(Ait-Oufella et al., 2006). However, hyperlipidemia-induced Treg plasticity leads to

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

81

their impaired immunosuppressive function. The reshape of physiological Tregs into pathological
Tregs dampens its protective effect on atherosclerosis progression and plaque stability(Butcher
et al., 2016; Gaddis et al., 2018; Shao et al., 2021). However, it is still unclear how the
hyperlipidemia environment dampens Treg function and increases Treg plasticity.
Recent studies showed cellular senescence is associated with atherosclerosis and is
recognized as a risk factor for atherosclerosis formation and progression (Wang and Bennett,
2012; Wu et al., 2020). Accumulation of senescent immune cells such as macrophages and T
cells in atherosclerotic lesions was detrimental throughout the disease pathogenesis. Selective
removal of these senescent cells is emerging as a promising therapeutic strategy to prevent
atherosclerosis progression(Childs et al., 2016; Childs et al., 2018; Song et al., 2020). A recent
study showed Tregs senesce more severely than Tconv cells with age, with preferential
upregulation

of

senescence-related

markers.

Senescent

Tregs

displayed

less

immunosuppressive activity while higher expression of inflammatory cytokines, which is similar to
the plasticity of Tregs(Guo et al., 2020). However, it is unknown whether and how senescent Tregs
play their roles in atherogenesis.
Here, we reported that Tregs senescence is a primary reason causing Treg plasticity in
atherosclerosis. In addition, we found that age-related decline of AMPK caused Tregs senescence
resulting in an uncontrolled aortic inflammation with enhanced atherosclerosis in mice in vivo.
4.3 Methods
4.3.1 Animals
Prkaa1flox/flox, Foxp3YFP-Cre, ApoE-/-, and C57BL/6 mice were purchased from Jackson Laboratory
(Bar Harbor, ME). Prkaa1-/- and Treg-specific AMPKα1 knock out mice (Prkaa1fl/flFoxp3YFP/Cre)
were generated as previous described(Jorgensen et al., 2004; Zhu et al., 2021). Treg-specific
AMPKα1 knock out mice in ApoE-/- background (ApoE-/- Prkaa1fl/flFoxp3YFP/Cre) were obtained by
crossing ApoE-/- mice with Prkaa1fl/flFoxp3YFP/Cre mice. Mice were used for experiments at 8-10
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weeks of age. Mice of both sexes were used, and all mice were randomly selected for different
treatment groups. For atherosclerosis studies, ApoE-/- mice were fed a Western diet (42% from
fat, 0.2% from cholesterol) (Research Diets, D12079B). All mice were housed in specific
pathogen-free conditions in the animal facilities at Georgia State University. The animal protocol
was reviewed and approved by Georgia State University Institute Animal Care and Use
Committee.
4.3.2 Preparation of Cell Suspensions from Aorta and Lymphoid Organs
Single cell suspensions from aorta tissues were prepared by digesting cleaned aorta with 2 mg/ml
collagenase I, 1 mg/ml collagenase XI, 120 U/ml hyaluronidase, and 150 μg/ml DNase I in HBSS
for 1 hour at 37℃ before passing the suspensions through a 40-μm cell strainer. Single cells from
lymphoid organs such as spleen, peri-aortic lymph nodes, and peripheral lymph nodes were
obtained directly by passing the tissues through a 40-μm cell strainer.
4.3.3 Flow Cytometry
Single cell suspensions were incubated with TruStain FcXTM PLUS (anti-mouse CD16/CD32)
antibodies for 15 minutes at room temperature before incubating with appropriate antibodies for
30 minutes for cell surface markers. Cells were processed for viability staining using eBioscience
LIVE/DEAD fixable Dye eFluor 660 or eFluor 780 (Thermofisher). Intracellular staining was
performed by using eBioscienceTM Foxp3 transcription factor staining buffer set (00-5523-00)
according to the manufacturer’s instructions. For intracellular cytokine staining, the cell
suspensions were stimulated with eBioscienceTM cell stimulation cocktail (00-4970-03) and
eBioscienceTM protein transport inhibitor cocktail (00-4980-93) for 18 hours before staining with
appropriate antibodies following intracellular staining procedure. For YFP staining, Alexa Fluor
488 anti-GFP or PE anti-GFP antibody from BioLegend was used. All the flow cytometry
antibodies were listed in table 3. The staining cells were analyzed on the LSR-Fortessa machine
(BD Bioscience).
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Table 3 Primary antibody information
REAGENT or RESOURCE
Antibodies
Flow cytometry: PE anti-mouse CD45
antibody (30-F11)
Flow cytometry: Pacific blue anti-mouse
CD45 antibody (30-F11)
Flow cytometry: Brilliant Violet 605TM antimouse CD3e antibody (17A2).
Flow cytometry: Alexa Fluor 700 anti-mouse
CD4 antibody (Gk1.5)
Flow cytometry: Pacific blue anti-mouse
CD4 antibody (RM4-5)
Flow cytometry: PE/Cyanine 7 anti-mouse
CD8 antibody (53-6.7)
Flow cytometry: Alexa Fluor 488 anti-mouse
CD8a (53-6.7)
Flow cytometry: Alexa Fluor 488 antimouse/rat/human Foxp3 antibody (150D)
Flow cytometry: PE anti-mouse Foxp3
antibody (MF-14)
Flow cytometry: Pacific blue anti-mouse
Foxp3 antibody (MF-14)
Flow cytometry: Alexa Fluor 488 anti-GFP
(FM264G)
Flow cytometry: PE anti-GFP(FM264G)
Flow cytometry: PE Rat anti-mouse
CD25(3C7)
Flow
cytometry:
APC
anti-mouse
CD25(PC61)
Flow cytometry: PE CD278(iCOS) (15F9)
Flow cytometry: PE anti-mouse IFNγ(XMG1.2)
Flow cytometry: PE-Cy7 anti-mouse CD357
(GITR) (YGITR 765)
Flow cytometry: PE anti-mouse CD152
(CTLA-4) (UC10-4B9)
Flow cytometry: PE anti-mouse CD279
(PD1) (RMP1-30)
Flow cytometry: PE anti-mouse IL10 (JES516E3)
Flow cytometry: PE anti-mouse CD304
(Nrp1) (3E12)
Flow cytometry: PE anti-mouse CD223
(LAG-3) (C9B7W)

SOURCE

IDENTIFIER

BioLegend

103106

BioLegend

103126

BioLegend

100237

BioLegend

100430

BioLegend

100531

BioLegend

100722

BioLegend

100723

BioLegend

320012

BioLegend

126404

BioLegend

126410

BioLegend

338008

BioLegend
BioLegend

338004
101904

BD Pharmingen

557192

BioLegend
BioLegned

107705
505808

BioLegend

120222

BioLegend

106305

BioLegend

109103

BioLegend

505008

BioLegend

145204

BioLegend

125208

4.3.4 SA-β-gal Activity Assay in T cells
The SA-β-gal activity in T cells was detected by staining with the fluorescent β-galactosidase
substrate C12FDG following previous protocol(Zhang et al., 2021). Briefly, fresh isolated
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lymphocytes, CD4+ T cells, or CD4+YFP+ Tregs were pretreated with 100 nM bafilomycin A1
(Millipore Sigma SML1661) before adding 33 μM C12FDG (ab273642) for another 2 hours in 37 ℃
incubator. The cell suspensions were then washed with cold 1x PBS for 3 times and stained with
appropriate antibodies following flow cytometry procedure.
4.3.5 Adoptive Treg Transfer Experiments
Splenic senescent Tregs (C12FDGhigh-Treg) and non-senescent Tregs (C12FDGlow-Treg) were
sterilely sorted from 8-week-old ApoE-/- mice fed with 20 weeks western diet. GFP-Tregs and
GFP-CA AMPK-Tregs were obtained by transfecting pLenti-XI-Neo-eGFP-Constitutively Active
AMPK, and pLenti-XI-Neo-eGFP lentivirus to fresh isolated Tregs. Then the cells were
subsequently labeled with CSFE (ThermoFisher C34554) for 10 minutes at 37 ℃ and washed
with 1x PBS for 3 times. The labeled cells (2x105 Tregs/mice) were then injected into 8-week-old
ApoE-/- mice fed with 4 weeks western diet. After another 4 weeks western diet, the aorta, spleens,
serum and hearts were collected for flow cytometry, lipid assay, and lesion size detection.
4.3.6 ROS Detection in T Cells
CM-H2DCFDA was used to detect the ROS expression in T cells following previous
described(Jackson et al., 2004).fresh isolated lymphocytes and T cells were washed with 1x PBS
and seeded in prewarmed medium. 2 μM CM-H2DCFDA (ThermoFisher C6827) was added into
the medium and cells were cultured for 20 minutes. After that, cells were washed with 1x PBS for
3 times and staining with appropriate antibodies for flow cytometry. For ROS scavengers, cells
were treated with 10 mM GSH (VWR, IC10181405) and 10 μM Mito TEMPO (Millipore Sigma
SML0737) for 24 hours.
4.3.7 Cell Isolation
CD4+ T cells were isolated from the spleen of mice by DynabeadsTM UntouchedTM Mouse CD4
Cells Kit (ThermoFisher 11415D). For Treg isolation from Prkaa1+/+Foxp3YFP/Cre and
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Prkaa1fl/flFoxp3YFP/Cre mice, splenocytes were stained with CD3, CD4, and GFP (for YFP
staining) antibodies, and then CD3+CD4+GFP+ cells were sorted by Fortesea in the core facility
of Georgia State University. For senescent and non-senescent Treg cell isolation, splenocytes
were first isolated from the 20 weeks western diet fed ApoE-/- mice, and then staining with CD3,
CD4, CD25 antibodies, and C12FDG fluorescence. Senescent and non-senescent Treg cells
were sorted by CD3+CD4+CD25+C12FDGhigh and CD3+CD4+CD25+C12FDGlow separately.
4.3.8 Quantification of Atherosclerotic Lesions
The aorta roots were embedded in OCT and then serially sectioned at 8-μm thickness. For oil red
staining, six to eight serial cryosections were collected from each mouse and stained with Oil Red
O for 1 hour in 37℃, and then counterstained with hematoxylin to visualize nuclei. The plaque
images were captured using the Olympus microscope, and quantification was performed with
Image J software (National Institute of Health). To assay the lesion are in while aorta, the intimal
surface was exposed by a longitudinal cut from the ascending arch to the left subclavian artery.
The aorta was stained with 0.5% Sudan IV in 35% ethanol and 50% acetone for 10 min, and then
rinsed with phosphate-buffered saline.
4.3.9 Immunofluorescence Staining
For immunofluorescence staining, sliced aorta root tissues were rinsed with ddH2O and then fixed
in ice-cold acetone for 10 minutes. After that, the slides were washed with PBS and blocked with
protein block (BioGenex, HK112-9K) for 30 minutes. Then the slides were incubated with primary
antibody (anti-CD68, Bio-rad, 1:200) at 4℃ overnight. Alexa Fluor 555 goat anti-rat was used as
secondary antibodies, incubated at room temperature for one h. Cell nuclei were stained with
DAPI and mounted with VectaMountTMAQ (#5501, Vector Laboratories) for fluorescence
microscopy. Quantification was performed using Image J software.
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4.3.10 RNA Extraction and qRT-PCR
According to the manufacturer's instructions, RNA was extracted using the RNeasy Mini Kit
(QIAGEN, Hilden, Germany). cDNA was synthesized using the iScript cDNA Synthesis Kit. The
expression of p16lnk4a, p19Arf, p21Cip1, Prkaa1, IFNγ, IL6, IL1β，IL17, and TNFα mRNAs was
determined by quantitative real-time PCR (qRT-PCR). The primers of these genes were listed in
table 4. Each cDNA sample was amplified using SYBR Green (Bio-rad, Hercules, CA) on a Biorad CFX96 Touch Real-time PCR detection system.
Table 4 Primer’s information
Oligo name
mAMPKα1 R
mAMPKα1 F
mIL17R
mIL17F
mIL1b R
mIL1b F
m-Tnf-F
m-Tnf-R
m-Il6-F
m-Il6-R
m-Ifng-F
m-Ifng-R
mGAPDH_F
mGAPDH_R
mArf-F
mArf-R
mINK4a-F
mINK4a-R
mCip1_F
mCip1_R

Oligo sequence
TCCTTTTCGTCCAACCTTCCA
TACTCAACCGGCAGAAGATTCG
CTTTCCCTCCGCATTGACA
GCTCCAGAAGGCCCTCAGA
GTTCATCTCGGAGCCTGTAGTG
TGGACCTTCCAGGATGAGGACA
TAGCCCACGTCGTAGCAAAC
GCAGCCTTGTCCCTTGAAGA
GCCTTCTTGGGACTGATGCT
TGCCATTGCACAACTCTTTTC
GGAGGAACTGGCAAAAGGATGG
ATGTTGTTGCTGATGGCCTGA
ACTCCACTCACGGCAAATTC
TCTCCATGGTGGTGAAGACA
GCCGCACCGGAATCCT
TTGAGCAGAAGAGCTGCTACGT
CCCAACGCCCCGAACT
GCAGAAGAGCTGCTACGTGAA
CGAGAACGGTGGAACTTTGAC
CAGGGCTCAGGTAGACCTTG

4.3.11 Western Blot Analysis
Cells were lysed with NP-40 lysis buffer (1% NP-40, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM
EDTA, 50 mM NaF, 2 mM Na3VO4, and 10 μg/ml each of aprotinin and leupeptin) or with 1× SDS
sample buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% SDS, and 10% glycerol). Proteins were
separated by SDS-PAGE and transferred to nitrocellulose membranes (Millipore, Billerica, MA).
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Membranes were visualized with an enhanced chemiluminescence detection system (Thermo
Fisher Scientific, Waltham, MA). When necessary, the membranes were stripped by incubation in
stripping buffer (Thermo Fisher Scientific, Waltham, MA) for 15 - 30 min with constant agitation,
washed, and then re-probed with various other antibodies.
4.3.12 Lentiviral Transduction
Lentiviral transduction was performed by transfecting HEK 293T cells with pLenti-XI-Neo-GSTConstitutively Active AMPK (addgene#139843), pLenti-XI-Neo-GST, pLenti-XI-Neo-eGFPConstitutively Active AMPK, and pLenti-XI-Neo-eGFP lentiviral vectors along with packaging
plasmids. For the transduction of CD4+ T cells, purified CD4+ T cells were activated with antiCD3/CD28 beads for 24 hours and then transduced with lentivirus in the presence of 10μg/ml
polybrene by spinning at 900g for 120 min. Cells were harvested 2 days after transduction and
then treated with cholesterol for aging marker analysis. For Treg transduction, sorted CD4+CD25+
Tregs were activated with anti-CD3/CD28 beads supplemented with IL-2 (200U/ml) for 24 hours
and then transduced with pLenti-XI-Neo-eGFP or pLenti-XI-Neo-eGFP-Constitutively Active
AMPK in the presence of 10 μg/ml polybrene by spinning at 900g for 120 min. Cells were
harvested for 2 more days after transduction and GFP+ cells were then sorted to perform adoptive
Treg transfer experiments.
4.3.12 Quantification and Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 8 (GraphPad Software,
CA). Student’s t test was used for analysis comparing two samples. One-way ANOVA tested
differences among multiple samples. Two-way ANOVA was applied to study the effect of two
parameters (i.e., time and treatment) and their interaction. P < 0.05 was considered statistically
significant.
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4.4 Results
4.4.1 Tregs are More Likely to be Senescence Under Hyperlipidemia Condition
To determine the role of senescent Tregs in the development of atherosclerosis, we performed
an atherosclerosis mouse model by feeding ApoE-/- mice with 16-weeks western diet. After
treatment, we comprehensively analyzed the cellular senescence of Tconv (conventional T cell)
cells and Treg cells by detecting the expression of senescence-associated β-galactosidase (SAβ-gal) activity, a key marker of cellular senescence. We found that both Tconv cells and Treg cells
from splenocytes of western diet-fed ApoE-/- mice displayed a higher expression of SA-β-gal
activity compared to those from the chow diet-fed group (Figure 23A and 23B). In addition,
compared with Tconv cells, the senescence marker was preferentially upregulated in Tregs
(Figure 23A and 23B).

Figure 23 Preferential Treg senescence during atherogenesis.
8-week-old ApoE-/- mouse were treated with chow diet or western diet for 16 weeks. Senescent cells were
assessed by flow cytometry with the fluorescent β-gal substrate C12FDG. A, Percentage of senescent Treg
(CD4+Foxp3+C12FDGhigh) and Tconv(CD4+Foxp3-C12FDGhigh) cells in the splenocytes of chow diet or
western diet-feed ApoE-/- mice (n=5/group). B, Quantification analysis of relative C12FDG MFI in Tconv
(CD4+Foxp3-C12FDGhigh) and Treg (CD4+Foxp3+C12FDGhigh) cells in the splenocytes of chow diet or western
diet-feed ApoE-/- mice (n=5/group). Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by
Student t test.

Next, we investigated the frequency of senescent Tregs in both para-aorta lymph nodes and
single cells from whole aorta tissues. Compared to chow diet fed ApoE-/- mice, the SA-β-gal
activity was found to be a significant increase in Tregs from western diet fed ApoE-/- mice (Figure
24A-24D). Consistent with the increased SA-β-gal activity, both the mRNA and protein level of
senescence signature genes, including p16lnk4a and p21cip1, were also increased in Tregs from the
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western diet-treated ApoE-/- mice (Figure 24E-24F). When analyzing the expression of senescent
Tregs in different part of the aorta, we found compared to thoracic aorta (low atherosclerosis
plaque formation area), the activity of SA-β-gal was increased in Tregs from aorta arch (high
atherosclerosis plaque formation area) (Figure 24G).

Figure 24 Senescent Tregs are increased during atherogenesis.
A-B, Percentage of senescent Treg cells (A) and mean fluorescence intensity (MFI) of C 12FDG in Treg cells
(B) from para-aorta lymph nodes of ApoE-/- mice feed with chow diet or western diet (n=4/group). C-D,
Percentage of senescent Treg cells (C) and mean fluorescence intensity (MFI) of C 12FDG in Treg cells (D)
from aorta single cells of ApoE-/- mice feed with chow diet or western diet (each sample contains 4 pooled
aortas, n=4/group). E, Relative mRNA expression of p16lnk4a, p19Art, p21Cip1 in Treg cells (CD4+CD25+)
isolated from ApoE-/- mice feeding with chow diet or western diet (n=4/group). F, Mean fluorescence intensity
(MFIs) of p16lnk4a and p21Cip1 in Treg cells (n=4/group). G, Quantification of relative C12FDG MFIs in Treg
cells from aorta arch, Thoracic aorta, and abdominal aorta of ApoE-/- mice feed with 16 weeks western diet
(each sample contains 8 pooled aortas, n=3/group). Data are presented as mean±SD, ns p>0.05, *p<0.05,
and **p<0.01 by Student t test (A-F) and one way ANOVA (G).
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4.4.2 Western Diets Disrupt Immune Homeostasis in ApoE-/- Mice
During the development of aging, the increased senescent Tregs promotes the progression of
immunological aging, with the hallmarks of decreased naïve T cells, increased effector T cells,
and increased production of IFNγ in both CD4+ and CD8+ T cells(Guo et al., 2020). Analyzing the
T cell function in chow diet or western diet feed ApoE-/- mice, we found both CD4+ and CD8+ T
cells in western diet feed ApoE-/- mice adopted effector memory phenotypes, as well as higher
production of IFNγ compared to chow diet feed mice (Figure 25A-25D). However, the frequency
of Tregs in spleen, para-aorta lymph nodes, and aorta tissues was significant increase in western
diet feed ApoE-/- mice (Figure 26A-26C), which may due to the chronic inflammation caused by
western diet treatment. These data suggest that western diet disrupts the immunosuppressive
function of Tregs and leads to immunological aging.

Figure 25 Hypercholesterolemias disturb T cell homeostasis in ApoE-/- mice.
A-B, Representative flow images and quantification of naïve (CD44lowCD62Lhigh) and effector/memory
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(CD44highCD62Llow) CD4+ (A) and CD8+ (B) T cells in peripheral lymph nodes (PLN) and spleens of 16
weeks chow diet or western diet treated ApoE-/- mice (n=4 per group). C-D, Representative flow images and
quantification of IFNγ and IL-4 production CD4+ (C) and CD8+ (D) T cells in peripheral lymph nodes (PLN)
and spleens of 16 weeks chow diet or western diet treated ApoE-/- mice (n=4 per group). Data are presented
as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by Student t test.

Figure 26 Increased Treg frequency in western diet feed ApoE-/- mice.
A-C, Representative flow images and quantification of CD4+Foxp3+ Treg cells in spleens (A), para-aorta
lymph nodes (B), and aorta tissues (C) of 16 weeks chow diet or western diet treated ApoE -/- mice (n=4 per
group). Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by Student t test.

4.4.3 Senescent Tregs Possess Less Protective Effect on Atherosclerosis Development
To directly test the role of Tregs senescence on atherosclerosis development, we performed in
vivo adoptive Tregs transfer experiments following the previously described(Bonacina et al.,
2021). 8-week-old ApoE-/- mice were fed with the western diet for four weeks and then received
senescent Tregs (C12FDGhigh-Treg), and non-senescent Tregs (C12FDGlow-Treg), which were
sorted from ApoE-/- mice fed 20 weeks western diet (Figure 27A). The recipient mice were fed
the western diet for four additional weeks. At the end of the treatment, we observed that the donor
Tregs could be detected within the aorta tissue of the recipient ApoE-/- mice (Figure 28A).
Interestingly, compared to ApoE-/- mice received medium alone, non-senescent-Treg recipients
displayed a 4-fold reduction of plaque size, while senescence-Treg recipients presented a similar
plaque size (Figure 27B and 27C). The serum cholesterol and triglycerides levels were
comparable among different groups (Figure 28B and 28C). These data indicate an impaired
protective role of senescence-Treg on atherosclerosis plaque formation.
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Figure 27. Senescence Treg cells show less protective effect on atherosclerosis development.
A, Experiment design and schematic diagram of adoptive Treg transfer experiment. Western diet feeding
8-week-old ApoE-/- mice received medium alone (non-Treg), senescence (C12FDGhigh) or non-senescence
(C12FDGlow) Tregs. B, Representative oil red staining aorta root figures of ApoE -/- recipients in indicated
groups. C, Quantification of plaque size and plaque area ratio of ApoE-/- recipients in indicated groups (n=12
in non-Treg and C12FDGlow–Treg group and n=11 in C12FDGhigh–Treg group). Data are presented as
mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by one way ANOVA.

Figure 28 Adoptive transfer senescence Tregs show mild effect on serum lipid level.
A, Representative flow images and quantification of CSFE+ Treg (donor Treg) in aortas of indicated groups
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(each sample is pooled by three mice aortas, n=3/group). B-C, Quantification of serum cholesterol (B) and
triglycerides (C) level of indicated groups (n=12 in each group, data are presented as mean±SD, ns p>0.05
by one way ANOVA). D, Gating strategy of CD45+ cells, CD3+ T cells, CD4+ T cells, and CD8+ T cells from
aorta single cells. Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by one way ANOVA.

To further analysis the immune cells’ situation on the recipient mice. Flow cytometry analysis
was performed on different groups' aorta tissues to investigate the impact of senescent-Treg and
non-senescent-Treg on arterial inflammation (Figure 28D). Compared with medium alone,
transfer both senescent and non-senescent-Tregs significant decreased the proportion and
number of CD45+ cells among aorta tissues. However, senescent-Tregs recipients showed higher
frequency and numbers of CD45+ cells compared to non-senescent Tregs (Figure 29A). For CD3+
T cells, both senescent-Tregs and non-senescent Tregs transfer decreased the frequency and
numbers of CD3+ T cells, but senescent-Treg recipients showed higher numbers of CD3+ T cells
than non-senescent Treg recipients (Figure 29B). For CD8+ T cells, transfer non-senescent Tregs
but not senescent Tregs significant decreased the frequency and numbers of CD8+ T cells (Figure
29C and 29D). Importantly, non-senescent Treg recipients but not senescent Treg recipients
attenuated the macrophage content in the plaque area (Figure 29E and 29F). All these suggest
compared to non-senescent Tregs, senescent Tregs are dysfunctional in suppressing arterial
inflammation.
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Figure 29 Senescent Tregs show fewer protective effects on arterial inflammation.
A, Quantification of the percentage and the number of CD45+ cells among aorta single cells (n=4/group,
each group pooled by three mice aorta). B, Quantification of the percentage of CD3+ T cells, CD4+CD8- T
cells, and CD4-CD8+ T cells among CD45+ cells from aorta single cells (n=4/group, each group pooled by
three mice aorta). C, Expression of CD45+CD3+CD4+ T cells and CD45+CD3+CD8+ T cells among aorta
single cells were analyzed by flow cytometry. D, Quantification of the percentage and numbers of CD8+ T
cells among CD45+ cells from aorta single cells (n=4/group, each group pooled by three mice aorta). E,
Representative CD68 immunofluorescence staining figures of aorta root from indicated groups. F,
Quantification of the CD68 content among plaque area (n=6 in each group). Data are presented as
mean±SD, ns p>0.05, and **p<0.01 one way ANOVA.

4.4.4 Senescent Tregs are More Likely to be Dysfunctional and Plasticity
Next, we were trying to investigate the mechanism of how senescent Tregs become
dysfunctional during atherogenesis. Analysis of the expression of several Tregs suppressive
activity related to cell surface molecules such as CD25, GITR, ICOS, LAG3, Nrp1, and PD1, we
found most of them were dramatically decreased in senescent Tregs compared to non-senescent
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Tregs. Significantly, the expression of Foxp3, the critical transcriptional factor of Tregs, was also
decreased in senescent Tregs (Figure 30A and 30B).

Figure 30 Senescent Tregs have decreased suppression markers.
A, Representative histograms of CD25, GITR, iCOS, LAG3, Nrp1, PD1, and Foxp3 expression on
senescence (C12FDGhigh) and non-senescence (C12FDGlow) Treg cells from the spleen of 20 weeks western
diet feed ApoE-/- mice. B, Relative mean fluorescence intensities (MFIs) of surface CD25, GITR, iCOS,
LAG3, Nrp1, PD1, Foxp3 on senescence (C12FDGhigh) and non-senescence (C12FDGlow) Treg cells from
the spleen of 20 weeks western diet feed ApoE-/- mice (n=6 in each group). Data are presented as mean±SD,
ns p>0.05, *p<0.05, and **p<0.01 by Student t test.

Furthermore, the frequency of IL-10+ Tregs and expression of IL-10, an essential
immunosuppressive cytokine secreted by Tregs, were significantly decreased in senescence
Tregs (Figure 31A and 31B). Atherosclerosis was shown to drive Treg plasticity and form IFNγproducing Th1-like Tregs(Butcher et al., 2016). We then hypothesized whether senescent Tregs
are more likely to be plasticity and form IFNγ-producing Tregs. Compared to non-senescent Tregs,
we found a significantly increased frequency of IFNγ+ cells and IFNγ expression in senescent
Tregs (Figure 31C and 31D). Thus, all these data suggest that decreased immunosuppressive
markers and increased proinflammatory cytokine in senescent Tregs promote its plasticity and
cause impaired protective function on arterial inflammation and atherosclerosis development.
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Figure 31 Senescent Tregs are more likely to be plasticity.
A, Representative flow cytometry figure and quantification of IL10 expression in senescence (C 12FDGhigh)
and non-senescence (C12FDGlow) Treg cells from the spleen of 20 weeks western diet feed ApoE -/- mice
(n=6 in each group). B, Relative MFI of IL10 on senescence (C12FDGhigh) and non-senescence (C12FDGlow)
Treg cells from the spleen of 20 weeks western diet feed ApoE -/- mice (n=6 in each group). C,
Representative flow cytometry figure and quantification of IFNγ expression in senescence (C12FDGhigh) and
non-senescence (C12FDGlow) Treg cells from the spleen of 20 weeks western diet feed ApoE-/- mice (n=7 in
each group). D, Relative MFI of IFNγ on senescence (C12FDGhigh) and non-senescence (C12FDGlow) Treg
cells from the spleen of 20 weeks western diet feed ApoE-/- mice (n=7 in each group). Data are presented
as mean±SD, ns p>0.05, and **p<0.01 Student t test.

4.4.5 Cholesterol Accumulation Leads to Treg Senescence
To investigate the role of Cholesterol in the induction of Treg senescence, we firstly analyzed the
cholesterol content in both Tconv cells and Treg cells from young (2 months) and aged (24 months)
mice. We found both Tconv cells and Treg cells from aged mice showed higher cholesterol content
in both their cell membrane and intracellular (Figure 32A and 32B). More interestingly, when we
compared the cholesterol content between aged Tconv cells and aged Treg cells, we found aged
Treg cells even showed higher cholesterol content in both their cell membrane and intracellular
(Figure 32A and 32B). To further test the role of cholesterol in Treg senescence, we treated
isolated CD4+ T cells with different lipid components. We found compared to other lipid
components, CD-CHO(Cholesterol-methyl-β-cyclodextrin), the most efficient manner to load
cholesterol into cells in vitro, treatment shows the strongest effects on the induction of Treg
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senescence (Figure 32C). CD-CHO complexes are the most efficient manner to load cholesterol
into cells in vitro in T cells(Li et al., 2020b). Also, under different dose of CD-CHO treatment, Treg
cells showed more sensitive to be senescence than Tconv cells (Figure 32D). Meanwhile, CDCHO in vitro treatment dramatically increased the mRNA expression of p16Ink4a, p19Arf, and p21Cip1
(Figure 32E). Furthermore, the protein expression of p16Ink4a and p21Cip1 were also increased
under CD-CHO treated Treg cells but not in Tconv cells (Figure 32F and 32G).

Figure 32. High cholesterol leads to Treg senescence
The cholesterol content in both Tconvs and Tregs from young (2 months) and aged (24 months) wild-type
mice were analyzed by filipin staining. A, Representative flow cytometry plots and quantification of cell
membrane filipin staining on Tconvs and Tregs (n=4/group). B, Representative flow cytometry plots and
quantification of intracellular filipin staining on Tconvs and Tregs (n=4/group). C, Isolated CD4+ T cells were
treated with normal LDL, saline, oxLDL, 27-OH cholesterol, and CD-CHO in vitro and quantification of
senescent Treg cells were analysis by flow cytometry (n=4/group). D, Quantification of senescent Tconvs
and Tregs under indicated dose of CD-CHO treatment (n=4/group/dose). E, Relative mRNA expression of
p16lnk4a, p19Art, p21Cip1 in sorted Treg cells (CD4+CD25+) treated with saline or cholesterol (n=4/group). FG, Relative protein expression of p16lnk4a and p21Cip1 in Tconvs and Tregs treated with saline or cholesterol
(n=5/group). Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by Student t test.
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4.4.6 Decreased AMPKα1 Leads to Treg Senescence Under Hyperlipidemia Condition
Next, we explored the potential factor contributing to Treg senescence during atherogenesis
and found the expression of AMPKα1, an essential factor to restrain cellular senescence(Ido et
al., 2012; Inata et al., 2018), was decreased among aged Tregs (Figure 33A). Notably, decreased
AMPKα1 protein expression was also observed in isolated Tregs from 16 weeks western diet fed
ApoE-/- mice (Figure 33B-33D), or in Tregs after in vitro cholesterol and 7KC treatment (Figure
33E). However, the mRNA level of AMPKα1 was comparable between Tregs from chow diet or
western diet feed ApoE-/- mice (Figure 33F), which indicate a posttranslational regulation of
AMPKα1 by hypercholesterolemia. In contrast, the expression of AMPKα1 showed no reduction
in Tconv (CD4+CD25-) cells after western diet treatment (Figure 33G). Therefore, these data
suggest that AMPKα1 may involve in the progression of Treg senescence.

Figure 33. Decreased AMPKα1 protein level in aged and hypercholesterolemia-treated Tregs.
A, Western bolt analysis of AMPKα1 expression in Treg cells isolated from the spleen of 2-month-old and
24-month-old C57 BL/6J mice. B-C, Representative western blot (B) and quantification (C) of relative
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AMPKα1 expression in sorted Treg cells from splenocytes of 16 weeks chow diet or western diet treated
ApoE-/- mice (n=4 in each group). D, Representative histogram and quantification of relative AMPKα1
expression in Tregs from splenocytes of 16 weeks chow diet or western diet treated ApoE-/- mice (n=4 in
each group). E, Quantification of relative AMPKα1 expression in Treg cells treated with cholesterol and 7KC
(n=4 in each group). F, Quantification of relative AMPKα1 mRNA level in sorted Treg cells from splenocytes
of 16 weeks chow diet or western diet treated ApoE-/- mice (n=4 in each group). G, Western blot analysis of
AMPKα1 expression in Tconv (CD4+CD25-) cells isolated from 16 weeks western diet or chow diet feed
ApoE-/- mice. Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by Student t test.

We next analyzed the role of AMPKα1 on Treg senescence and found both Tregs from AMPKα1
global knockout mice (Prkaa1-/-) (Figure 34A and 34B) and Treg-specific AMPKα1 knockout mice
(AMPKα1Treg-/-) displayed a higher SA-β-gal activity (Figure 34C and 34D). Meanwhile, Tregs
from AMPKα1Treg-/- mice showed higher mRNA levels of p16lnk4a, p19Arf, and p21Cip1than those
from AMPKα1Treg+/+ mice, which presented a senescence phenotype (Figure 34E). In addition,
mice with Treg-specific AMPKα1 deletion developed aging-related autoimmunity (Figure 35A
and 35B). All these data indicate AMPKα1 is required to prevent Treg senescence, and deficiency
of AMPKα1 may be responsible for the Treg senescence under cholesterol treatment. Indeed, we
found that overexpression of CA-AMPK (constitutively active AMPK) (Figure 35C) prevented
cholesterol-induced Treg senescence (Figure 34F and 34G). These findings collectively suggest
that hyperlipidemia induces Treg senescence via downregulating AMPKα1 expression.
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Figure 34. Selective activation of AMPK prevents Treg senescence.
A, Representative flow figures and quantification of percentage of C12FDG high Treg cells among Treg cells
from the splenocytes of 7-week-old Prkaa1+/+ and Prkaa1-/- mice (n=4 in each group). B, Relative MFIs of
C12FDG in Tregs from Prkaa1+/+ and Prkaa1-/- mice (n=4 in each group).C, Representative flow figures and
quantification of percentage of C 12FDG high Treg cells among isolated Treg cells from 8-10-week-old
AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n=4 in each group). D, Relative MFIs of C12FDG in Tregs from
AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n=4 in each group). E, Quantification of relative p16, p19, and p21
mRNA level in Treg cells isolated from 8-10-week-old AMPKα1Treg+/+ and AMPKα1Treg-/- mice (n=4 in each
group). F, Isolated CD4+ T cells from C57 BL/6J mice were transfected with lentivirus-GST control or
lentivirus-GST-CA-AMPK, and then treated with cholesterol and saline for 24 hours. Percentage of C12FDG
high Treg cells in indicated groups were analyzed by flow cytometry (n=4 in each group). G, Relative MFIs
of C12FDG in Tregs of indicated groups (n=4 in each group). Data are presented as mean±SD, ns p>0.05,
*p<0.05, and **p<0.01 by Student t test (A-E) and one way ANOVA (F and G).
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Figure 35. Deficiency of AMPKα1 in Tregs causes inflammaging.
A, Quantification of serum total IgG level in 2-month-old and 24-month-old AMPKα1Treg+/+ and AMPKα1Treg/- mice (n=8 in each group). B, Representative H&E staining images for heart, liver, lung, and kidney from
2-month-old and 15-month-old AMPKα1Treg+/+ and AMPKα1Treg-/- mice (arrow indicate immune cell infiltration,
scar bar=100μm). C, Western blot analysis of GST expression in CD4+ T cells transfected with lentivirusGST or lentivirus-GST-CA-AMPK. Data are presented as mean±SD, ns p>0.05 and **p<0.01 by student t
test.

4.4.7 AMPKα1 Attenuates Treg Senescence via Restraining ROS Levels
Following the above findings, we further explored how AMPK regulates Treg senescence.
Aberrant accumulation of ROS was shown as a predominant contributor to Treg senescence(Guo
et al., 2020). Even though AMPK has been widely reported as an essential ROS regulator in
different types of cells(Ren and Shen, 2019; Zhao et al., 2017), its role in ROS production of Tregs
is still unknown. Here we found that Tregs from both AMPKα1Treg-/- and Prkaa1-/- mice displayed a
significantly upregulated ROS level than those from their littermate control mice (Figure 36A and
36B). Meanwhile, the expression of mitochondria ROS was also significant increase in AMPKα1deficient Tregs (Figure 36C). Furthermore, downregulation of ROS levels by its scavengers GSH
and Mito TEMPO can effectively recover the senescence phenotype caused by AMPKα1 deletion
in Treg cells (Figure 36D-36E). Thus, the excessive ROS production is a critical mechanism
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underlying Treg senescence caused by AMPKα1 deletion.

Figure 36. AMPK prevents Treg senescence via inhibition of ROS production.
A, Representative histogram and quantification of relative ROS expression in expression in Treg cells from
splenocytes of Prkaa1+/+ and Prkaa1-/- mice (blank, no DCFDA, n=4 in each group). B, Representative
histogram and quantification of relative ROS expression in Treg cells from splenocytes of AMPKα1Treg+/+
and AMPKα1Treg-/- mice (blank, no DCFDA, n=4 in each group). C, Representative histogram and
quantification of relative Mitochondria ROS expression in Treg cells from splenocytes of AMPKα1Treg+/+ and
AMPKα1Treg-/- mice (blank, no MitoSox, n=4 in each group). D, Representative histogram and quantification
of ROS expression in Treg cells from splenocytes of Prkaa1+/+ and Prkaa1-/- mice in the absence or
presence of Mito TEMPO(10 μM) or GSH (10 mM) (blank, no DCFDA, n=4 in each group).E, Representative
flow figures and quantification of C12FDG high Treg cells from splenocytes of Prkaa1+/+ and Prkaa1-/- mice
in the absence or presence of Mito TEMPO(10 μM) or GSH (10 mM) (n=4 in each group). , data are
presented as mean±SD, ns p>0.05 and **p<0.01 by student t test (A and B) and one way ANOVA (C and
D).

4.4.7 AMPKα1 Deficiency in Tregs Causes Disturbed Immune Homeostasis in ApoE-/- Mice
Intrigued by the essential role of AMPKα1 on the senescence of Tregs, we further explored the
role of AMPKα1 in Tregs on atherosclerosis. We constructed the ApoE-/- Treg-specific AMPKα1
deletion (ApoE-/-AMPKα1Treg-/-) mice via breeding ApoE-/- mice with our previous AMPKα1Treg-/mice, and their littermate was used as control (ApoE-/-AMPKα1Treg+/+). We found that ApoE-/AMPKα1Treg-/- mice displayed disturbed T cell homeostasis at six months old under chow diet
conditions, with upregulated effector/memory and downregulated naïve CD4+ and CD8+ T cells

ROLES OF AMP-ACTIVATED PROTEIN KINASE IN THE CONTROL OF TREG-CELLS

103

(Figure 37A and 37B). Additionally, both CD4+ and CD8+ T cells from ApoE-/-AMPKα1Treg-/- mice
showed higher expression of IFNγ but not IL-4 (Figure 37C-3F).

Figure 37 Deficiency of AMPKα1 disrupts T cell homeostasis in ApoE-/- mice.
A-B, Representative flow images and quantification of naïve (CD44lowCD62Lhigh) and effector/memory
(CD44highCD62Llow) CD4+ (A) and CD8+ (B) T cells in spleens of 6-month-old ApoE-/-AMPKα1Treg+/+ and
ApoE-/-AMPKα1Treg-/- mice under chow diet condition (n=4 per group). C-D, Representative flow images and
quantification of IFNγ production CD4+ (C) and CD8+ (D) T cells in spleens of 6-month-old ApoE-/AMPKα1Treg+/+ and ApoE-/-AMPKα1Treg-/- mice under chow diet condition (n=4 per group). E-F,
Representative flow images and quantification of IL4 production CD4+ (E) and CD8+ (F) T cells in spleens
of 6-month-old ApoE-/-AMPKα1Treg+/+ and ApoE-/-AMPKα1Treg-/- mice under chow diet condition (n=4 per
group). Data are presented as mean±SD, ns p>0.05, **p<0.01, by Student’s t test

Even though the frequency of CD4+YFP+ Tregs were comparable, the expression of Foxp3 was
decreased in Tregs from ApoE-/-AMPKα1Treg-/- mice (Figure 38A). Moreover, compared to ApoE-/AMPKα1Treg+/+ mice, Tregs from ApoE-/-AMPKα1Treg-/- mice displayed less frequency of IL10+ cells
while higher IFNγ+ cells (Figure 38B and 38C). These data suggest that AMPKα1 deletion
induces Treg plasticity and disturbed immune homeostasis, which are similar to that of senescent
Tregs caused by hyperlipidemia.
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Figure 38 AMPKα1 is required to maintain Treg stability in ApoE-/- mice.
A, Frequency of CD4+YFP+ Tregs in spleen and relative Foxp3 MFI in Tregs of 6-month-old ApoE-/AMPKα1Treg+/+ and ApoE-/-AMPKα1Treg-/- mice under chow diet condition (n=4 per group). B-C,
Representative flow images and quantification of IL-10 production (B) and IFNγ (C) production Treg cells
in spleens of 6-month-old ApoE-/-AMPKα1Treg+/+ and ApoE-/-AMPKα1Treg-/- mice under chow diet condition
(n=4 per group). Data are presented as mean±SD, ns p>0.05, **p<0.01, by Student’s t test

4.4.8 Deficiency of AMPKα1 in Tregs Promotes Immune Cell Infiltration in the Aortas of
ApoE-/- Mice
We next performed flow cytometry to analyze the immune cell infiltration in the aorta of 6-monthold ApoE-/-AMPKα1Treg+/+ and ApoE-/-AMPKα1Treg-/- mice under chow diet condition (Figure 39A).
Compared to ApoE-/-AMPKα1Treg+/+ mice, the immune cell infiltration was significant increase in
the aorta of ApoE-/-AMPKα1Treg-/- mice, including higher frequency and numbers of CD45+ cells
(Figure 39B and 39C) and CD3+ T cells (Figure 39D and 39E). Further analysis showed that
both the frequency and numbers of CD4+CD8- and CD4-CD8+ T cells were significant increase in
the aorta of ApoE-/-AMPKα1Treg-/- mice (Figure 39F-39H). However, even though the frequency of
Treg cells in aorta was comparable the total numbers of Tregs were increased in the arterials of
ApoE-/-AMPKα1Treg-/- mice, which could be due to the increased total numbers of T cells (Figure
39I-39K). These data suggest that AMPKα1 is required for Treg function but has mild effect on
Treg survival in the aorta.
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Figure 39. Deficiency of AMPKα1 in Tregs promotes immune cell infiltration in aorta of ApoE-/- mice.
A, Gating strategy of CD45+ cells, CD3+, CD4+, CD8+ T cells, and CD4+YFP+ Treg cells from aorta single
cells. B-C, Quantification of percentage (B) and number (C) of CD45 + cells among aorta single cells from
6-month-old ApoE-/-TregAMPKα1+/+ and ApoE-/-TregAMPKα1-/- mice under chow diet condition (each sample is
pooled by four mice aorta, n=5 in each group). D-E, Quantification of percentage (D) and number (E) of
CD3+ cells among aorta single cells from 6-month-old ApoE-/-TregAMPKα1+/+ and ApoE-/-TregAMPKα1-/- mice
under chow diet condition (each sample is pooled by four mice aorta, n=5 in each group). F, Representative
flow figures of CD45+CD3+CD4+ T cells and CD45+CD3+CD8+ T cells among aorta single cells were
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analyzed by flow cytometry. G-H, Quantification of percentage (G) and number (H) of CD4+CD8- T cells and
CD4-CD8+ T cells among aorta single cells from 6-month-old ApoE-/-TregAMPKα1+/+ and ApoE-/-TregAMPKα1-/mice under chow diet condition (each sample is pooled by four mice aorta, n=5 in each group). I,
Representative flow figures of CD45+CD3+CD4+ YFP+ Treg cells among aorta single cells were analyzed
by flow cytometry. J-K, Quantification of percentage (J) and number (K) of Treg cells among aorta single
cells from 6-month-old ApoE-/-TregAMPKα1+/+ and ApoE-/-TregAMPKα1-/- mice under chow diet condition (each
sample is pooled by four mice aorta, n=5 in each group). Data are presented as mean±SD, ns p>0.05,
*p<0.05, and **p<0.01 by Student t test.

4.4.9 Deficiency of AMPKα1 in Tregs Promotes Arterial Inflammation and Atherosclerosis
We next aimed to investigate the effects of AMPK in Tregs on arterial inflammation and
atherosclerosis. ApoE-/-AMPKα1Treg-/- mice and their littermate controls (ApoE-/-AMPKα1Treg+/+)
were fed chow diet and sacrificed at 6-month-old to detect the cytokine expression in aorta tissues
and plaque formation. As shown in Figure 41A and 41B, no difference in serum cholesterol and
triglyceride levels was observed in the two groups of mice, whereas ApoE-/-AMPKα1Treg-/- mice
displayed significant increased mRNA level of IFN-γ, IL-1β， IL-17， and TNF-α in the aorta
(Figure 40A).Moreover, ApoE-/-AMPKα1Treg-/- mice developed much more lesions area in whole
aorta and aortic root area compared with ApoE-/-AMPKα1Treg+/+ mice (Figure 40B and 40C).
Similar changes were also observed in the female mice of these two groups (Figure 41C).
Furthermore, the expression of macrophage, which was detrimental for plaque stability(Colin et
al., 2014), were significant increase in the plaque area of ApoE-/-AMPKα1Treg-/- mice (Figure 40D).
Thus, all these data demonstrated AMPKα1 in Tregs is required to prevent atherosclerosis plaque
formation and vulnerability.
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Figure 40. AMPKα1 in Tregs is required to prevent arterial inflammation and atherosclerosis.
A, Relative mRNA level of indicated cytokines in the aorta tissues of 6-month-old ApoE-/-TregAMPKα1+/+ and
ApoE-/-TregAMPKα1-/- mice under chow diet condition (each sample is pooled by four mice aorta, n=4 in each
group). B, Representative images and quantification of atherosclerotic plaque area by en face analysis of
the aorta (n=8 in male ApoE-/-AMPKα1Treg+/+ mice, n=9 in male ApoE-/-AMPKα1Treg-/- mice, n=7 in both female
ApoE-/-AMPKα1Treg+/+ mice and ApoE-/-AMPKα1Treg-/- mice). C, Representative images and quantification of
atherosclerotic plaque size and % plaque is to lumen area by cross-sectional analysis of the aortic root
(n=10 in ApoE-/-AMPKα1Treg+/+ group, n=9 ApoE-/-AMPKα1Treg-/- group, Scale bar=500μm). D, Representative
images and quantification of CD68 content among atherosclerotic plaque (n=5 in each group, Scale
bar=200μm). Data are presented as mean±SD, ns p>0.05, *p<0.05, and **p<0.01 by Student t test.
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Figure 41. Deficiency of AMPKα1 in Tregs aggravates atherosclerosis in female ApoE-/- mice.
A-B, Quantification of serum cholesterol (A) and triglycerides (B) level from 6-month-old ApoE-/-TregAMPKα1+/+
and ApoE-/-TregAMPKα1-/- mice under chow diet condition (n=18 in each group). C, Representative oil red
staining images and quantification of atherosclerotic plaque size and lesion area by cross-sectional analysis
of the aortic root of female mice (n=5 in each group). Data are presented as mean±SD, ns p>0.05 and
**p<0.01 by Students’ t test.

4.4.10 Adoptive Transfer CA-AMPK Treg Ablates Atherosclerosis and Atherosclerotic
Plaque Vulnerability
Given the essential role of AMPK in Treg in the development of atherosclerosis. We next
investigated whether adoptive transfer CA-AMPK (constitutive active AMPK) Treg can prevent
atherosclerosis development. We treated 8-week-old ApoE-/- mice with 12 weeks western diet and
transferred GFP-Treg and GFP-CA AMPK Treg at the 8-week and the 10-week (Figure 42A). At
the end of the treatment, GFP+ cells were still detected in the atherosclerotic aorta of recipient
mice (Figure 42B), paralleled by a few cells detectable in the spleen (Figure 42C). Analyzed the
T cells in the aorta, we found compared to non-Treg transfer group, adoptive transfer CA AMPKTregs but not GFP-Tregs significantly decreased the frequency of CD8+ T cells in the aorta
(Figure 42D and 42E).
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Figure 42. Adoptive transfer CA AMPK Treg prevent the infiltration of CD8+ T cells in aorta.

A, Experiment designs and schematic diagram of adoptive Treg transfer experiment. Western diet
feeding 8-week-old ApoE-/- mice received medium alone (non-Treg), GFP-Tregs or GFP-CA
AMPK Tregs. B-C, The expression of donor Tregs in the aorta (B) (n=4/group) and spleen (C)
(n=6/group) of recipient mice.D-E, Representative flow cytometry images (D) and quantification
of CD4+CD8- T cells and CD4-CD8+ T cells frequency (E) (n=4/group). Data are presented as
mean±SD, ns p>0.05, *p<0.05 and **p<0.01 by Students’ t test (B and C) and one-way ANOVA
(E).
Further analysis showed that treatment with CA AMPK-Tregs but not GFP-Tregs significant
reduced macrophage content among the plaque areas (Figure 43A and 43B). Most importantly,
adoptive transfer with CA AMPK-Tregs but not GFP-Tregs significantly decreased the plaque area
at the aortic root compared to GFP-Tregs (Figure 43C and 43D). Furthermore, treatment with CA
AMPK-Tregs also resulted in a significant increase in collagen content and reduced necrotic core
compared to mice treated with GFP-Tregs. Of note, even though mice treated with GFP-Tregs
also showed reduced necrotic core compared to untreated mice, the reduced fold was much less
than that treated with CA AMPK Tregs (Figure 43E and 43F).
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Figure 43. CA AMPK Treg treatment prevents atherosclerosis development and plaque vulnerability.

A-B Representative IF images and quantification of CD68 content in plaque area (n=7/group).CD, Representative oil red staining images and quantification of plaque size and plaque area
(n=12/group). E-F, Representative Masson and H&E staining images and quantification of
collagen content and necrotic core size (n=11/group). Data are presented as mean±SD, ns p>0.05,
*p<0.05 and **p<0.01 by one-way ANOVA.
4.4.11 Adoptive Transfer of CA AMPK-Tregs Partially Restores the Immune Homeostasis in
Western Diet-treated ApoE-/- Mice
Further analysis the T cell function in the spleen and peripheral lymph nodes, we found adoptive
transfer of CA AMPK-Tregs can partially restores the disturbed immune homeostasis in western
diet-fed ApoE-/- mice. Treatment with CA AMPK-Tregs, but not GFP-Tregs, increased naïve T cells
(CD44lowCD62Lhigh) expression in both CD4+ T cells and CD8+ T cells in both peripheral lymph
nodes and spleen. Meanwhile, treatment with CA AMPK-Tregs can also reduce the frequency of
effector T cells (CD44highCD62Llow) in CD8+ T cells (Figure 44A-44D). For IFNγ production,
treatment with CA AMPK-Tregs showed mild effects on the production of IFNγ in CD4+ T cells
(Figure 44E-44F). However, both GFP-Tregs and CA AMPK-Tregs treatment reduced the
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production of IFNγ in CD8+ T cells. Compared to GFP-Tregs, CA AMPK-Tregs treatment showed
stronger negative effects on IFNγ production in CD8+ T cells (Figure 44G-44H).

Figure 44. Adoptive transfer CA AMPK-Tregs partially restores immune homeostasis in western diet
feed ApoE-/- mice.

A-D, Representative flow cytometry figures and quantification of naïve T cells and effector T cells
in CD4+ T cells (A and B) and CD8+ T cells (C and D) in both peripheral lymph nodes (n=5/group)
and spleen (n=6/group). E-H, Representative flow cytometry figures and quantification of IFNγ
expression in CD4+ T cells (E and F) and CD8+ T cells (G and H) in both peripheral lymph nodes
(n=5/group) and spleen (n=6/group). Data are presented as mean±SD, ns p>0.05, *p<0.05 and
**p<0.01 by one-way ANOVA.
4.5 Discussion
In this study, we report that hypocholesterolemia-driven AMPK reduction promotes Tregs
senescence with accentuated atherosclerosis in vivo. We first found spleen Tregs displayed
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preferential upregulation of senescence-related markers than Tconv cells under hyperlipidemia
conditions. In addition to splenocytes, we also observed significant induction of senescent Tregs
in para-aorta lymph nodes and aorta tissues of ApoE-/- mice that received 16 weeks of western
diet feeding. Compared with non-senescent Tregs, senescent Tregs were less efficient in
suppressing arterial inflammation and atherosclerosis development. Mechanistically, senescent
Tregs showed reduced functional suppression molecules and became more plasticity with
upregulation of IFNγ. Furthermore, we discovered that AMPKα1 is required to restrain Treg
senescence via suppressing ROS production, and deficiency of AMPKα1 is responsible for Treg
senescence under hyperlipidemia conditions. Besides, deletion of AMPKα1 promoted Treg
plasticity and disrupted immune homeostasis in ApoE-/- mice. Consequently, ApoE-/- mice with
AMPKα1 deletion in Tregs displayed an upregulated arterial inflammation and aggregated
atherosclerosis development within chow diet feeding. Our results indicate that AMPKα1 is the
key molecular in Tregs in preventing senescence and Tregs plasticity.
Convention of physiological Tregs into pathological Tregs under hyperlipidemia conditions has
been demonstrated to impair Tregs function and aggravate atherosclerosis progression(Ali et al.,
2020; Butcher et al., 2016). However, the factors that mediate Tregs phenotype switching and
dysfunctional during atherogenesis are still unclear. A recent study showed that Tregs became
senescent with age and lost their immunosuppressive functions but produced inflammatory
cytokines (Guo et al., 2020). However, whether and how senescent Tregs play their role in
atherosclerosis is fully unknown. We discovered that hyperlipidemia promoted Tregs senescence
in peripheral lymph organs and aorta tissues. Senescent Tregs were shown to be plastic and
displayed less efficiency in suppressing vascular inflammation and atherosclerosis progression.
By combining comprehensive in vitro and in vivo studies, we observed that AMPKα1 is required
to prevent Tregs senescence via regulating ROS production both in age and hyperlipidemia
conditions, and deficiency of AMPKα1 in Tregs promotes atherosclerosis development. Our
findings suggest that hyperlipidemia skew Tregs into a dysfunctional senescent phenotype and
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activation of AMPK prevents the formation of senescent Tregs, which restrain atherosclerosis
progression.
Advanced atherosclerotic plaques contain senescent cells, which show deleterious effects at
all stages of atherosclerosis via acquiring the senescence-associated secretory phenotype
(SASP) (Gorenne et al., 2006; Minamino et al., 2002). Immunosenescence (immune cell
senescence) plays an essential role in the initiation and progression of atherosclerosis (Childs et
al., 2018; Song et al., 2020). Selective clearance of senescent cells via genetic or
pharmacological methods reverses atherosclerosis progression (Childs et al., 2016). Tregs are
also equally senescent during aging, but their roles in atherosclerosis are still unknown. Here, we
demonstrated that Tregs are susceptible to hyperlipidemia to become senescent. These
senescent Tregs displayed a less protective effect on arterial inflammation and atherosclerosis
via downregulating Tregs function-related markers (CD25, GITR, ICOS, LAG3, Nrp1, PD1, Foxp3,
and IL-10). An early study showed that gene expression of these Tregs function-related markers
was normal in aged Tregs(Guo et al., 2020), which seems to contradict our observations. The
reason could be due to the different stress conditions. Moreover, the comparison only happened
on Tregs from young and aged mice, not the exact senescent Tregs (C12FDGhigh) and nonsenescent Tregs (C12FDGlow) in their study may be another reason caused this discrepancy. Our
data suggest senescent Tregs can influence the proatherogenic processes through controlling
Tregs function, which provides a novel immunotherapy target for atherosclerosis.
The plasticity of Tregs was defined by retaining Foxp3 expression but acquiring inflammatory
factors of effector T cells, which are called Th-like Tregs (Shi and Chi, 2019). In response to
pathological environments, Tregs may partially or fully assume plastic phenotypes and lose their
immunosuppressive function (Sakaguchi et al., 2013; Smigiel et al., 2014). Hyperlipidemia-driven
Treg plasticity is one of the primary reasons that leads to Tregs dysfunction during atherogenesis
(Butcher et al., 2016; Gaddis et al., 2018). However, how hyperlipidemia leads to Treg plasticity
and dysfunction is still unknown. Here, we uncovered hypercholesterolemia-induced senescent
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Tregs acquired higher expression of IFNγ and were more likely to the convention to IFNγ+Tregs.
IFNγ-producing Th1/Tregs were generated within the atherosclerotic aorta and are known as the
significant phenotype of plastic Tregs (Butcher et al., 2016; Li et al., 2016a). Our data suggest
that hypercholesterolemia-induced Tregs senescence is a potential mechanism for Tregs
plasticity during atherosclerosis progression.
Besides Tregs plasticity, we also observed a significantly decreased Foxp3 expression in
senescent Tregs, which means senescence may induce Tregs plasticity and disrupt Tregs stability.
The plasticity and stability of Tregs are closely associated with each other. Unstable Tregs were
shown to easily attain a Th1-like phenotype under pathological environments in islets (Zhou et al.,
2009). Stable expression of Foxp3 inhibited the conversion of Tregs to IFNγ/TNFα-producing
effector T cells(Oldenhove et al., 2009). Plasticity-promoting factors and plastic Tregs-related
markers have also been known to participate in the stability regulation (Koch et al., 2012; Wang
et al., 2011). In atherosclerosis, Tregs were reported to undergo both plasticity and instability(Ali
et al., 2020). Therefore, further in-depth studies may shed new light on investigating whether
senescence promotes Tregs instability during atherosclerosis via measuring the methylation
status and mRNA level of the Foxp3 (Toker et al., 2013).
AMPK has been reported to control the differentiation of Tregs by regulating lipid oxidation
(Michalek et al., 2011). AMPK activation promotes the shift of Th17 cells to Tregs cells and
stabilizes atherosclerotic plaque (Tian et al., 2017). Not only for Tregs differentiation, but we also
observed that AMPKα1 is required to maintain Foxp3 protein stability and Tregs function (An et
al., 2022; Zhu et al., 2021). Here we presented that a deficiency of AMPKα1 leads to Tregs
senescence in young mice, identifying a novel role of AMPK in Tregs. The essential role of
AMPKα1 in anti-Tregs senescence may explain why specific deletion of AMPKα1 in Tregs induced
autoimmunity only in aged mice while not in young mice (Yang et al., 2017; Zhu et al., 2021).
Finally, we also demonstrated that AMPKα1 reduction is responsible for high cholesterolinduced Tregs senescence via gain- and loss- of function assay, suggesting the essential role of
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AMPKα1 in Tregs senescence both in physiological and pathological conditions. Like senescent
Tregs, AMPKα1-deficient Treg also showed decreased Foxp3 expression and increased plasticity,
which impaired its protective effect on arterial inflammation and atherosclerosis progression.
These findings offer AMPK a potential molecular target for atherosclerosis immunotherapy via
modulating Tregs senescence.
In sum, we conclude that hyperlipidemia promotes Treg senescence to form plasticity and
dysfunctional Tregs, which fails to prevent arterial inflammation and atherosclerosis. Degradation
of AMPKα1 by hyperlipidemia leads to Tregs senescence and promotes atherosclerosis
development. These findings identify the activation of AMPK as a novel method to prevent Tregs
senescence, which is a novel immunotherapy target for atherosclerosis.
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5 Conclusions and Perspectives
5.1 AMPK Maintains Tregs Function
Regulatory T cells (Tregs) are an indispensable constituent of the immune system, which are
required to maintain immunological self-tolerance and tissue homeostasis (Josefowicz et al.,
2012). Recent studies have witnessed Tregs-based immunotherapies to control physiological and
pathological immune responses in clinical settings. In clinical trials, improved Treg numbers or
their immunosuppressive activity have been used to treat autoimmune and other inflammatory
diseases. (Ferreira et al., 2019). Moreover, reducing Tregs or their suppressive activity can be
effective for evoking antitumor immune responses or enhancing antimicrobial immunity in chronic
infection (Sakaguchi et al., 2020). Thus, a better understanding of the molecular mechanisms
underlying Tregs survival and immunosuppressive function may benefit the development of novel
immunotherapy strategies to modulate Treg function on inflammatory diseases and antitumor
immunity.
In the first part of this dissertation, we found AMPK as a novel kinase which is required to the
immunosuppressive function of Tregs in both in vitro and in vivo Treg function assays. The
required role of AMPK in the regulation of Treg function prevent an age-dependent increase in
autoinflammation. The role of AMPK in autoimmune disease has been demonstrated before as is
shown that global deletion of AMPKα1 exacerbated experimental autoimmune encephalomyelitis
(EAE) disease severity (Nath et al., 2009b). Moreover, activating AMPK can prevent autoimmune
disease in animal models (Nath et al., 2009a; Zhang et al., 2022). In this dissertation, we found
that mice with AMPKα1 global knockout spontaneously developed an autoimmune liver disease
which can be recovered by adoptive Treg transfer from WT (Prkaa1+/+). This data indicates an
essential role of AMPKα1 in Tregs in developing autoimmune liver disease. Indeed, we observed
that the Treg-specific AMPKα1 deletion mice developed the autoimmune liver disease after 1year-old, which means not only in Tregs but deficiency of AMPKα1 in other cells also contributes
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to the development of autoimmune liver disease. Previous studies showed that activating AMPK
by berberine in liver tissues could efficiently prevent autoimmune hepatitis (Wang et al., 2017).
However, the hepatocyte specific AMPKα1 deficiency mice showed no obvious autoimmune
phenotypes. Further experiments still need to investigate whether deletion of AMPKα1 in any
other cell types such as conventional T cells, dendritic cells, or macrophages plays any role in
developing autoimmune liver disease.
Multiple mechanisms have been proposed to mediate the immunosuppressive function of Tregs,
such

as

expression

of

suppression-related

cell

surface

molecules,

production

of

immunosuppressive cytokines, and production of immune-suppressive metabolites. Cytotoxic Tlymphocyte antigen-4 (CTLA-4) is one of the essential cell surface molecules that controls the
suppressive activity of Treg cells. CTLA-4 on the cell surface of Tregs impairs the maturation of
APC via binding to CD80/CD86 (Walker and Sansom, 2011). CTLA-4 can not only compete
CD80/CD86 binding with CD28 but also induce the deletion of CD80/86 via trans-endocytosis
(Qureshi et al., 2011). In addition to CTLA-4, other immune checkpoint molecules, including ICOS,
PD1, and LAG-3, are also highly expressed in activated Treg cells and inhibit the proliferation of
effector T cells (Sasidharan Nair and Elkord, 2018).The expression of CD25 (high-affinity IL-2
receptor α-chain) on Tregs cells competes the IL-2 with effector T cells, limiting the proliferation
or activation of IL-2. Foxp3+ Treg cells also utilize a wide range of inhibitory cytokines, such as
TGF-β, IL-10, and IL-35, to perform inhibitory function (Collison et al., 2007; Huber and Schramm,
2006; Rubtsov et al., 2008). Moreover, Tregs cells can also produce perforin and granzyme to kill
effector T cells (Cao et al., 2007). In tumor microenvironment (TME), we identified AMPK is
required to maintain the expression of these function related molecules in Tregs, which is further
support the indispensable role of AMPK in the regulation of Tregs function.
5.2 AMPK Controls Tregs Plasticity but not Stability
It is well established that Treg cells express the transcriptional factor Foxp3 and are stable
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and long-lasting under physiological conditions. However, under some disease conditions, Tregs
cells respond to environmental signals and display plastic differentiation and instability. Plasticity
of Treg is characterized by retaining Foxp3 expression but gaining some features of helper T(Th)
cells, including secretion of Th-related cytokines and expression of specific transcription factors
in Th cells (Qiu et al., 2020). Instability of Tregs was described by loss of Foxp3 expression and
becoming so-called ex-Tregs (Ali et al., 2020). Both plasticity and instability of Treg impair the
suppressive capacity of these cells.
Th1-like Treg is the most widely reported subset of plastic Tregs due to the high expression
of IFNγ, T-bet, and CXCR3 in Tregs cells(Zheng et al., 2011). Deficiency of deubiquitinase USP21
and E3 ligase VHL induced the reduction of FOXP3 protein level and the promotion of IFNγ in
Treg cells in vivo(Lee et al., 2015a; Li et al., 2016b). Deficiency of IL-33 promotes the production
of

IFNγ

in

tumor

infiltrated

Tregs

which

promotes

Tregs

plasticity

and

tumor

regression(Hatzioannou et al., 2020). Atherosclerosis environment drives Treg plasticity with
accumulation of IFNγ+ Tregs in plaque area which impairs the protective effect of Tregs on arterial
inflammation and atherosclerosis development. Though the plastic changes of Tregs have been
widely reported, the mechanism behind this is still not clear. Our studies showed that activation
of AMPK is required to restrain the plasticity of Tregs in both TME and atherosclerosis
environments. And we also identified a novel mechanism that AMPK controls Treg plasticity via
inhibiting the senescence of Tregs. Further studies working on the relationship between
senescent Tregs and plastic Tregs in different animal models would achieve a comprehensive
understanding of these plastic Treg subtypes.
As a specific transcription factor, stable expression of Foxp3 is required for the stability of
Tregs(Nie et al., 2015). However, the reduction of Foxp3 under disease conditions promotes the
expression of ex-Tregs. Several Foxp3 tracking mice have been generated to investigate the
stability of Tregs(Miyao et al., 2012; Rubtsov et al., 2010; Zhou et al., 2009). Among them, the
most widely used was the Foxp3-IRES-YFP-Cre-loxp-td-RFP-loxp mice model. In this mouse
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model, Treg expresses both YFP and Cre recombinase under the control of the IRES element,
which follows the Foxp3 gene expression. The deletion of loxp sites that flank RFP by Cre
recombinase mark Treg as red. The "current Tregs" display both yellow and red in this model. If
Tregs become "ex Tregs," they lose YFP expression and only express RFP(Miyao et al., 2012). It
has been demonstrated that 10-20% of total Tregs are unstable and switch to ex Tregs, and this
ratio would increase in response to chronic inflammation(Zhou et al., 2009).
The stability of Tregs is tightly regulated by cellular metabolism. Different from conventional T
cells (Tconv), Tregs are more likely to use oxidative phosphorylation (OXPHOS) but less reliant
on glycolysis for energy production, which has a high expression of AMPK (Michalek et al., 2011).
Glucose uptake impaires the function and stability of Tregs in the tumor microenvironment (TME),
while lactate treatment prevents these destabilizing effects of high-glucose conditions(Kumagai
et al., 2022). Inhibition of glycolysis promoted the induction of Foxp3 in response to TGF-β and
IL-2 stimulation(Eleftheriadis et al., 2013). However, previous study indicates increased glycolysis
promoted PI3K/Akt signaling and Treg proliferation(Gerriets et al., 2016). Thus, it is reasonable
to speculate that high glycolysis promotes the proliferation of Treg cells. However, Tregs' stability
and suppressive activity need to be balanced by other metabolic programs. Recent studies show
great interest in regulating Treg stability by mitochondrial metabolism and OXPHOS. Deleting
mitochondrial transcription factor A (Tfam) promoted the methylation in the TSDR of the
Foxp3 locus, which destabilized Foxp3 expression and impaired Treg suppressive function under
inflammation conditions(Fu et al., 2019). Fatty acid oxidation (FAO) can degrade fatty acids to
produce acetyl-CoA, which is involved in the mitochondrial tricarboxylic acid (TCA) cycle to
regulate mitochondrial OXPHOS. Both short-chain fatty acids and acetyl-CoA can regulate Foxp3
protein acetylation and Treg stability(Smith et al., 2013; van Loosdregt et al., 2010). All these data
suggest an indispensable role of OXPHOS for Treg stability and suppressive activity. As an
essential energy modulator, AMPK has been widely demonstrated to regulate mitochondrial
metabolism and OXPHOS(Rodriguez et al., 2021). However, our data showed that AMPK only
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controls Foxp3 protein level while not affecting its mRNA expression. In both TME and normal
conditions, deficiency of AMPK doesn’t affect YFP expression. These data suggest that AMPK is
essential to Treg plasticity but not stability. Further studies using Prkaa1fl/fl Foxp3-IRES-YFP-Creloxp-td-RFP-loxp mice can better understand the role of AMPK in the regulation of Treg stability
in other disease model.
5.3 Stabilization of Foxp3 by AMPK
Foxp3 belongs to the Forkhead box (Fox) family, well conserved among mammals(Lam et al.,
2013). In humans, the Foxp3 gene locates on the X-chromosome at Xp11.23-Xq13.3, and
mutation of Foxp3 leads to the immune dysregulation polyendocrinopathy enteropathy X-linked
syndrome (IPEX)(Bennett et al., 2000; d'Hennezel et al., 2012). Foxp3 protein is about 431 amino
acids and contains four functional domains, including a proline-rich N-terminal domain, zinc finger,
leucine zipper, and Fork-head domain(Deng et al., 2020). The N-terminal region functions to
suppress NFAT-mediated transcriptional signaling, the zinc finger and leucine zipper domain are
required for the transcriptional functions of Foxp3, and the forkhead domain is essential for DNA
binding and nuclear import(Lopes et al., 2006).
The expression and function of Foxp3 can be regulated in both transcriptional and posttranscriptional level. Transcriptionally, Foxp3 can be regulated by DNA methylation, histone
modification, nucleosome positioning, and a series of cis-acting elements located on the promoter
and the enhancer regions of the Foxp3 locus (Ohkura and Sakaguchi, 2020). Besides
transcriptional regulation, Foxp3 expression is also highly regulated by post-translational
modification (PTM), including phosphorylation, acetylation, methylation, O-GlcNAcylation, and
ubiquitination.
Phosphorylation is a mechanism by which protein kinase binds to the serine (S), threonine (T),
or tyrosine (Y) residue of a protein and controls protein stability and function. Several protein
kinases have been documented to control Foxp3 expression via phosphorylation and
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dephosphorylation mechanisms. Phosphorylation of Ser-19 and Thr-175 of Foxp3 by CDK2
decreased its protein stability and Treg function(Morawski et al., 2013). Under inflammation
conditions, phosphorylation of Foxp3 at Ser-422 by PIM1 reduced its DNA binding activity while
not affecting its protein stability(Li et al., 2014). Activation of NLK under TCR stimulation promoted
the phosphorylation of Foxp3 at seven different sites and prevented its ubiquitination(Fleskens et
al., 2019). Dephosphorylation of Foxp3 at Ser418 leads to impaired Treg function under TNFα
treatment(Nie et al., 2013). Here, we identified AMPK as a novel kinase which can direct
phosphorylates Foxp3 from the in vitro kinase assay. However, the phosphorylation site of Foxp3
by AMPK is still unclear. Further studies to determine the specific phosphorylate site of Foxp3 by
AMPK can help us to better understand the relationship between AMPK and Foxp3.
In Treg cells, STUB1 (CHIP) is one of the major E3 ligases that directly ubiquitinate Foxp3.
Under LPS or proinflammation stimulation, the expression of STUB1 was increased, leading to
K48 polyubiquitination on Foxp3 at Lys-227, Lys-250, Lys-263, and Lys-268(Chen et al., 2013).
Such ubiquitination decreased Foxp3 expression in a proteasome-dependent degradation and
impaired Treg function(Chen et al., 2013).The ubiquitination process can be reversed by
deubiquitinases (DUB), which remove ubiquitin tags from the substrate protein(Nijman et al.,
2005). USP7 is the most well-known DUBs of Foxp3, which preserved Foxp3 homeostasis by
removing K48-type polyubiquitination tags at Lys-249, Lys-251, Lys-263, Lys-267, and Lys393(van Loosdregt et al., 2013). In this dissertation, we found deficiency of AMPKα1 increase
STUB1 expression while not affecting the expression of USP7 in Tregs, which further promotes
Foxp3 ubiquitination and degradation. Silencing STUB1 can partially reverse the Foxp3 protein
level in AMPKα1-deficient Tregs, indicating an indenpensable function of STUB1 in the regulation
of Foxp3 by AMPK. As an E3 ligase, STUB1 is known to regulate several proteins involved in
multiple physiological and pathological processes, but mechanisms operating on the activity of
STUB1 is still far more known(Paul and Ghosh, 2014). Therefore, further studies are still
interesting to investigate the detail mechanisms on how AMPK regulate STUB1 in Tregs.
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5.4 AMPK Controls the Function of Immunosuppressive Cells in TME
With the discovery of immune checkpoint inhibitors, immunotherapy has succeeded in clinical
cancer treatment. Accumulation of large numbers of Tregs in tumor tissues hinders the efficacy
of cancer immunotherapy due to their ability to suppress antitumor immune responses. A high
ratio of Tregs cells to CD8+ T cells in the tumor microenvironment (TME) is correlated with poor
prognosis(Fridman et al., 2012). Therefore, deletion of Tregs and suppression of Treg cell function
are recognized as promising immunotherapy strategies.
An arduous task in the success of cancer immunotherapy is the selective depletion of tumor
infiltrated Tregs or suppression of their immunosuppressive function. Thus, the identification of
cell-intrinsic molecules that control Tregs' suppressive program could provide unique therapeutic
strategies for tumor eradication. In the second part of the dissertation, we demonstrated that
AMPK is also indispensable for the suppressive function of tumor infiltrated Tregs. Tumor exposed,
AMPKα1-deficient Tregs are more plastic and reprogrammed to upregulate IFN-γ expression,
thus preventing tumor development. Activation of AMPK has been shown to activate both
antitumor and pro-tumor responses. Activation of AMPK by aerobic glycolysis in breast tumors
promoted myeloid-derived suppressor cells (MDSC) expansion, promoting tumor progression (Li
et al., 2018). Activation of AMPK has also been shown to promote cancer metastasis by adapting
cancer cells to metabolic and oxidative stresses (Cai et al., 2020). In contrast to the
immunosuppressive effects, stimulation of AMPK through Metformin induced phosphorylation and
degradation of PD-L1, thereby promoting protective T-cell immunity (Cha et al., 2018). These
studies suggest that the role of AMPK in tumor cells is dependent on the context.
For tumor-infiltrating immune cells, the role of AMPK is still controversial. The deficiency of
AMPK in CD8+ T cells suppresses their antitumor function, while conditional deletion of Prkaa1 in
MDSCs potentiated the antitumor T cell immunity (Rao et al., 2015a; Trillo-Tinoco et al., 2019).
Not only for the MDSCs but AMPK has also been shown to regulate the immunosuppressive
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phenotypes in macrophages and the restriction of effector T-cell expansion in tumors (Sag et al.,
2008; Zhu et al., 2015). Our data showed an essential role of AMPK in tumor infiltrated Tregs; we
hypothesize that condition deletion of AMPK in immunosuppressive cells could be a promising
strategy for cancer immunotherapy.
5.5 Activation of AMPK as a Potential Therapeutic Target for Immunological Aging and
Atherosclerosis
Age-associated diseases have become a health burden worldwide(Partridge et al., 2018). The
immune system is greatly affected by aging, chronic inflammation (inflammaging), and
immunosenescence. Aging is also one of the most substantial risk factors for the development of
atherosclerosis. The immune cell senescence plays a pivotal role in the initiation and progression
of atherosclerosis (Childs et al., 2016). As an important immune modulator, Tregs are also
involved in the progression of atherosclerosis. However, whether and how the function of
senescent Tregs is regulated during atherosclerosis is not known. In the third part of the
dissertation, we found that hypercholesterolemia promotes Treg senescence via downregulation
of the expression of AMPKα1. Senescent Tregs showed a minimal protective effect in
atherosclerosis. This work revealed cellular senescence as a novel mechanism that controls Treg
function during atherogenesis. Future studies to test if selectively removing senescent Treg cells
by genetic or pharmacological means could be potential therapeutic strategies to treat
atherosclerosis are warranted.
In the third part of the dissertation, we also observed a novel role of AMPK in regulating Treg
senescence. The critical role of AMPK in the senescence of Tregs may explain why the Tregspecific AMPKα1 deletion mice develop autoimmune hepatitis only after 1-year-old. Tregs have
been shown to senesce more severely than conventional T (Tconv) cells during aging. Aged Tregs
have less protective efficiency in suppressing the Tconv cell aging phenotype and immunological
aging(Guo et al., 2020). Further studies are needed to investigate whether constitutive activation
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of AMPK in Tregs can be an effective way to treat immunological aging.
Finally, we found that AMPK regulates Treg senescence via maintaining ROS production. The
cellular level of ROS is subject to tight regulation of cellular senescence and aging (Colavitti and
Finkel, 2005). It has been shown that compared to Tconv cells, the ROS level is preferentially
increased in Tregs regardless of age. This excessive ROS production impaired the proliferative
capacity and function of aged Tregs (Guo et al., 2020). However, the specific mechanism of AMPK
regulates ROS levels in Treg cells is still unclear. Given the essential role of the DCAF1/GSTP1
axis in regulating ROS and cellular senescence in Tregs cells, future studies on whether and how
AMPK regulates DCAF1 expression in Tregs cells will provide valuable insights into the
progression of Treg senescence. In addition, several other pathway, including PI3K/Akt/mTOR,
DNA damage/p53 response, and inflammation, have also been shown to regulate cellular ROS
generation (Ray et al., 2012). Therefore, it is of interest to investigate whether AMPK ameliorates
Treg senescence and inflammation through these pathways.
5.6 Significance and Impacts
This dissertation has systemically established the essential roles of AMPK in regulatory T cells
and AMPK downregulation in Tregs led to autoimmune diseases, cancer progression, and
accelerated atherosclerosis. The main findings are as follow:
1. I discovered AMPK as a novel molecular required for Tregs' immunosuppressive
function in vitro and in vivo experiments.
2. I determined the essential role of AMPK in tumor infiltrated Tregs and the potential
therapeutic target of conditional deletion of AMPK in Tregs for cancer therapy.
3. I identified a novel role of AMPK in controlling Treg senescence and its therapeutic
effects in atherosclerosis.
4. Overall, this dissertation has established a novel concept that the metabolic homeostasis
plays an essential role in Tregs' stability, plasticity, and function.
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